The mevalonate pathway, also referred to as the isoprenoid pathway or HMG-CoA reductase pathway, is a metabolic pathway that can play a role in multiple cellular processes. Cholesterol is an energy-rich, waxy hydrophobic compound synthesized by animals through the mevalonate pathway. Accumulations of excessive levels of serum cholesterol from dietary consumption or biosynthesis over long periods of time can be correlated with cardiovascular diseases.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
Compared to normal cells, many cancer cells have evolved differential metabolic and nutritional demands for survival, proliferation, and metastases. Current therapies for the treatment for cancer or other pathologies can be ineffective due to patient-specific factors. Personalized methods and formulations can be developed for therapy of various diseases, including cancer.
In view of the foregoing, provided herein, in some embodiments, is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an inhibitor of a mevalonate pathway; and b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids. In some embodiments, disclosed herein is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an inhibitor of a mevalonate pathway; and b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol.
In some embodiments, provided herein is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an HMG-CoA reductase inhibitor; and b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids. In some embodiments, disclosed herein is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an HMG-CoA reductase inhibitor; and b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol.
In some embodiments, provided herein is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of a cholesterol lowering agent; and b) administering to the subject a diet, wherein the diet is formulated to reduce a level of fat in the subject. In some embodiments, disclosed herein is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of a cholesterol lowering agent; and b) administering to the subject a diet, wherein the diet is formulated to reduce a level of cholesterol in the subject.
In some embodiments, provided herein is a composition comprising: a) a cholesterol lowering agent; and b) a dietary product, wherein the dietary product is formulated to reduce a level of fat in a subject. In some embodiments, provided herein is a composition comprising: a) a cholesterol lowering agent; and b) a dietary product, wherein the dietary product is formulated to reduce a level of cholesterol in a subject.
In some embodiments, provided herein is a pharmaceutical composition comprising: a) a therapeutically effective amount of a cholesterol lowering agent; and b) a therapeutically effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of fat in a subject. In some embodiments, provided herein is a pharmaceutical composition comprising: a) a therapeutically effective amount of a cholesterol lowering agent; and b) a therapeutically effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of cholesterol in a subject.
In some embodiments, provided herein is a kit comprising: a) an effective amount of a cholesterol lowering agent; and b) an effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of fat in a subject. In some embodiments, provided herein is a kit comprising: a) an effective amount of a cholesterol lowering agent; and b) an effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of cholesterol in a subject.
The mevalonate pathway, also referred to as the isoprenoid pathway or HMG-CoA reductase pathway, is a metabolic pathway that plays a key role in multiple cellular processes. The mevalonate pathway begins with acetyl-CoA and converts mevalonate into sterol isoprenoids, such as cholesterol, the indispensable precursor of bile acids, lipoproteins, and steroid hormones; and into nonsterol isoprenoids, such as dolichol, heme-A, isopentenyl-tRNA, and ubiquinone. The mevalonate-isoprenoid pathway involves first the synthesis of 3-hydroxy-3-methylglutaryl-CoA (HMG)-CoA from acetyl-CoA through acetoacetyl-CoA. HMG-CoA reductase (HMGR), a highly regulated enzyme, catalyzes the conversion of HMG-CoA to mevalonic acid. HMGR is the rate-limiting enzyme of the mevalonate pathway. Mevalonate kinase (MK) is the second essential enzyme of the isoprenoid/cholesterol biosynthesis pathway, after HMGR, catalyzing the phosphorylation of mevalonic acid into phosphomevalonate. MK activity is regulated via feedback inhibition by intermediates in the isoprenoid/cholesterol pathway, including geranylpyrophosphate, farnesylpyrophosphate, and geranylgeranylpyrophosphate. The intermediates of the mevalonate biosynthetic pathway play important roles in the post-translational modification of a multitude of proteins involved in intracellular signaling and are essential in cell growth and differentiation, gene expression, protein glycosylation, and cytoskeletal assembly.
Cholesterol is an energy-rich, waxy hydrophobic compound synthesized by animals through the mevalonate pathway. Cholesterol functions as a source of energy, a precursor of steroid hormones and vitamin D, a structural component of cells, and is involved in multiple signaling pathways. Because the human body is able to synthesize cholesterol, cholesterol is classified as a non-essential nutrient. Accumulations of excessive levels of serum cholesterol from dietary consumption or biosynthesis over long periods of time can be positively correlated with cardiovascular diseases. Cholesterol synthesis as well as cholesterol uptake is shown to be upregulated in many cancer cells. Fast dividing cancer cells may depend on cholesterol as a source of high energy to sustain rapid proliferation.
Tumors comprise both cancer cells and non-cancer cells. Non-cancer cells can be recruited into tumors and can form up to 90% of a tumor volume. The non-cancerous cells, or tumor-stroma (“stromal”) cells, can develop with tumor growth and are considered cancer-associated cells. A main type of stromal cell population is fibroblasts, or cancer-associated fibroblasts (CAFs). The stroma can also comprise immune cells and non-cellular components like collagen. Tumors can comprise cancer cells, stromal cells, and other stromal components. Effective cancer therapies of the disclosure can affect one or more of the cell populations in a tumor. The methods disclosed herein can influence at least one group of cells selected from: 1) cancer cells; 2) stromal cells, such as CAFs and tumor infiltrating immune cells; and (3) other stromal components, such as collagen.
In some embodiments, disclosed herein is a method of treating a condition, the method comprising: a) administering to a subject in need thereof a therapeutically effective amount of an inhibitor of a mevalonate pathway; and b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids. In some embodiments, disclosed herein is a method of treating a condition, the method comprising: a) administering to a subject in need thereof a therapeutically effective amount of an inhibitor of a mevalonate pathway; and b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol.
In some embodiments, disclosed herein is a method of treating a condition, the method comprising: a) administering to a subject in need thereof a therapeutically effective amount of an HMG-CoA reductase inhibitor; and b) administering to the subject a diet, wherein the diet composes less than about 40 g/day of lipids. In some embodiments, disclosed herein is a method of treating a condition, the method comprising: a) administering to a subject in need thereof a therapeutically effective amount of an HMG-CoA reductase inhibitor; and b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol.
In some embodiments, provided herein is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of a cholesterol lowering agent; and b) administering to the subject a diet, wherein the diet is formulated to reduce a level of fat in the subject. In some embodiments, disclosed herein is a method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of a cholesterol lowering agent; and b) administering to the subject a diet, wherein the diet is formulated to reduce a level of cholesterol in the subject.
Disclosed herein are methods of treating a condition comprising administering a therapeutic agent. In some embodiments, the therapeutic agent is an inhibitor of a mevalonate pathway. In some embodiments, the therapeutic agent is an HMG-CoA reductase inhibitor. In some embodiments, the therapeutic agent is a statin.
Statins are inhibitors of HMG-CoA reductase (HMGR), the rate-limiting enzyme of the mevalonate pathway. Statins block the conversion of HMG-CoA to mevalonic acid by occupying the catalytic portion of HMGR, specifically the binding site of HMG-CoA, thus blocking access of the HMG-CoA substrate to the active site. By interrupting cholesterol synthesis in the liver, statins can activate the production of microsomal HMGR and cell surface low-density lipoprotein (LDL) receptors. This process can result in increased clearance of LDL from the blood stream and decreased blood LDL cholesterol levels.
HMGR inhibitors can be presecribed to patients with hyperlipidemia to reduce serum cholesterol by decreasing cholesterol biosynthesis. Further reduction in cholesterol levels can be achieved through reduced dietary intake of cholesterol, e.g., by following a plant-based diet. In a similar manner, cholesterol-dependent cancer cells can be therapeutically targeted by using statins to inhibit cholesterol biosynthesis along with a diet lacking in cholesterol.
In some embodiments, the therapeutic agent is a lipid lowering agent, a cholesterol lowering agent, or a triglyceride lowering agent. In some embodiments, the methods disclosed herein comprise administering a lipid lowering agent, a cholesterol lowering agent, or a triglyceride lowering agent. A cholesterol lowering agent can reduce serum cholesterol levels by inhibiting cholesterol biosynthesis, reducing cholesterol reabsorption, or increasing cholesterol metabolism. In some embodiments, the methods disclosed herein comprise administering two or more lipid lowering agents or cholesterol lowering agents.
In some embodiments, the methods disclosed herein comprise administering a statin. In some embodiments, the statin is atorvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is atorvastatin calcium. In some embodiments, the statin is fluvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is fluvastatin sodium. In some embodiments, the statin is pravastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is pravastatin sodium. In some embodiments, the statin is rosuvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is rosuvastatin calcium. In some embodiments, the statin is simvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is simvastatin sodium. In some embodiments, the statin is lovastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is lovastatin sodium. In some embodiments, the statin is pitavastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is pitavastatin calcium. In some embodiments, the statin is pitavastatin magnesium.
In some embodiments, a therapeutic agent of the disclosure can be a cholesteryl ester transfer protein (CETP) inhibitor. In some embodiments, the CETP inhibitor is torcetrapib, dalcetrapib, evacetrapib, obicetrapib, or anacetrapib. In some embodiments, the CETP inhibitor is anacetrapib. In some embodiments, a therapeutic agent of the disclosure can be a lecithin-cholesterol acyltransferase (LCAT) inhibitor.
In some embodiments, a therapeutic agent of the disclosure can be a bile acid-binding resin or a bile acid sequestrant. The agents bind to bile acids and prevent their reabsorption in the gastrointestinal system, promoting bile acid excretion. Disruption of bile acid reabsorption can have the effect of reducing cholesterol levels, e.g., low density lipoprotein (LDL) cholesterol levels.
In some embodiments, a therapeutic agent of the disclosure can be a cholesterol absorption inhibitor. In some embodiments, the cholesterol absorption inhibitor is ezetimibe. In some embodiments, a therapeutic agent of the disclosure can be a fixed combination of a statin and a cholesterol absorption inhibitor. In some embodiments, the combination cholesterol absorption inhibitor and statin is ezetimibe/simvastatin, ezetimibe/atorvastatin, or ezetimibe/rosuvastatin. In some embodiments, the combination cholesterol absorption inhibitor and statin is ezetimibe/simvastatin. In some embodiments, the combination cholesterol absorption inhibitor and statin is ezetimibe/atorvastatin. In some embodiments, the combination cholesterol absorption inhibitor and statin is ezetimibe/rosuvastatin.
Provided herein is the use of pharmaceutically-acceptable salts of any therapeutic agent or compound described herein. Pharmaceutically-acceptable salts include, for example, acid-addition salts and base-addition salts. The acid that is added to the compound to form an acid-addition salt can be an organic acid or an inorganic acid. A base that is added to the compound to form a base-addition salt can be an organic base or an inorganic base. In some embodiments, a pharmaceutically-acceptable salt is a metal salt. In some embodiments, a pharmaceutically-acceptable salt is an ammonium salt.
Metal salts can arise from the addition of an inorganic base to a compound provided herein. The inorganic base comprises a metal cation paired with a basic counterion, such as, for example, hydroxide, carbonate, bicarbonate, or phosphate. The metal can be an alkali metal, alkaline earth metal, transition metal, or main group metal. In some embodiments, the metal is lithium, sodium, potassium, cesium, cerium, magnesium, manganese, iron, calcium, strontium, cobalt, titanium, aluminum, copper, cadmium, or zinc.
In some embodiments, a metal salt is a lithium salt, a sodium salt, a potassium salt, a cesium salt, a cerium salt, a magnesium salt, a manganese salt, an iron salt, a calcium salt, a strontium salt, a cobalt salt, a titanium salt, an aluminum salt, a copper salt, a cadmium salt, or a zinc salt.
Ammonium salts can arise from the addition of ammonia or an organic amine to a compound provided herein. In some embodiments, the organic amine is triethyl amine, diisopropyl amine, ethanol amine, diethanol amine, triethanol amine, morpholine, N-methylmorpholine, piperidine, N-methylpiperidine, N-ethylpiperidine, dibenzylamine, piperazine, pyridine, pyrrazole, pipyrrazole, imidazole, pyrazine, or pipyrazine.
In some embodiments, an ammonium salt is a triethyl amine salt, a diisopropyl amine salt, an ethanol amine salt, a diethanol amine salt, a triethanol amine salt, a morpholine salt, an N-methylmorpholine salt, a piperidine salt, an N-methylpiperidine salt, an N-ethylpiperidine salt, a dibenzylamine salt, a piperazine salt, a pyridine salt, a pyrrazole salt, a pipyrrazole salt, an imidazole salt, a pyrazine salt, or a pipyrazine salt.
Acid addition salts can arise from the addition of an acid to a compound of provided herein. In some embodiments, the acid is organic. In some embodiments, the acid is inorganic. In some embodiments, the acid is hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, nitrous acid, sulfuric acid, sulfurous acid, a phosphoric acid, isonicotinic acid, lactic acid, salicylic acid, tartaric acid, ascorbic acid, gentisinic acid, gluconic acid, glucaronic acid, saccaric acid, formic acid, benzoic acid, glutamic acid, pantothenic acid, acetic acid, propionic acid, butyric acid, fumaric acid, succinic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, oxalic acid, or maleic acid.
In some embodiments, the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a nitrate salt, a nitrite salt, a sulfate salt, a sulfite salt, a phosphate salt, isonicotinate salt, a lactate salt, a salicylate salt, a tartrate salt, an ascorbate salt, a gentisinate salt, a gluconate salt, a glucaronate salt, a saccarate salt, a formate salt, a benzoate salt, a glutamate salt, a pantothenate salt, an acetate salt, a propionate salt, a butyrate salt, a fumarate salt, a succinate salt, a methanesulfonate (mesylate) salt, an ethanesulfonate salt, a benzenesulfonate salt, a p-toluenesulfonate salt, a citrate salt, an oxalate salt, or a maleate salt.
A pharmaceutical composition of the disclosure can be used or administered, for example, before, during, or after treatment of a subject with, for example, another pharmaceutical agent.
In some embodiments, a subject is a human. Subjects can be, for example, elderly adults, adults, adolescents, pre-adolescents, children, toddlers, infants, neonates, and non-human animals. In some embodiments, a subject is a patient.
A pharmaceutical composition provided herein can be a combination of any pharmaceutical compounds or therapeutic agents described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, thickening agents, and/or excipients. The pharmaceutical composition facilitates administration of the compound to an organism. Pharmaceutical compositions can be administered in therapeutically effective amounts as pharmaceutical compositions by various forms and routes including, for example, intravenous, subcutaneous, intramuscular, oral, parenteral, ophthalmic, subcutaneous, transdermal, nasal, vaginal, and topical administration. In some embodiments, a compound or pharmaceutical composition of the disclosure is administered orally. In some embodiments, a compound or pharmaceutical composition of the disclosure is administered intravenously.
A pharmaceutical composition can be administered in a local manner, for example, via injection of the compound directly into an organ, optionally in a depot or sustained release formulation or implant. Pharmaceutical compositions can be provided in the form of a rapid release formulation, in the form of an extended release formulation, or in the form of an intermediate release formulation. A rapid release form can provide an immediate release. An extended release formulation can provide a controlled release or a sustained delayed release.
For oral administration, pharmaceutical compositions can be formulated by combining the active compounds with pharmaceutically-acceptable carriers or excipients. Such carriers can be used to formulate liquids, gels, syrups, elixirs, slurries, or suspensions, for oral ingestion by a subject. Non-limiting examples of solvents used in an oral dissolvable formulation can include water, ethanol, isopropanol, saline, physiological saline, DMSO, dimethylformamide, potassium phosphate buffer, phosphate buffer saline (PBS), sodium phosphate buffer, 4-2-hydroxyethyl-1-piperazineethanesulfonic acid buffer (HEPES), 3-(N-morpholino) propanesulfonic acid buffer (MOPS), piperazine-N,N′-bis(2-ethanesulfonic acid) buffer (PIPES), and saline sodium citrate buffer (SSC). Non-limiting examples of co-solvents used in an oral dissolvable formulation can include sucrose, urea, cremaphor, DMSO, and potassium phosphate buffer.
Pharmaceutical preparations can be formulated for intravenous administration. The pharmaceutical compositions can be in a form suitable for parenteral injection as a sterile suspension, solution or emulsion in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Suspensions of the active compounds can be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. The suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
In practicing the methods of treatment or use provided herein, therapeutically-effective amounts of the compounds described herein are administered in pharmaceutical compositions to a subject having a disease or condition to be treated. In some embodiments, the subject is a mammal such as a human. A therapeutically-effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compounds used, and other factors. The compounds can be used singly or in combination with one or more therapeutic agents as components of mixtures.
Pharmaceutical compositions can be formulated using one or more physiologically-acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations that can be used pharmaceutically. Formulations can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a compound described herein can be manufactured, for example, by mixing, dissolving, emulsifying, encapsulating, entrapping, or compression processes.
The pharmaceutical compositions can include at least one pharmaceutically-acceptable carrier, diluent, or excipient and compounds described herein as free-base or pharmaceutically-acceptable salt form. Pharmaceutical compositions can contain solubilizers, stabilizers, tonicity enhancing agents, buffers and preservatives.
Methods for the preparation of compositions comprising the compounds described herein include formulating the compounds with one or more inert, pharmaceutically-acceptable excipients or carriers to form a solid, semi-solid, or liquid composition. Solid compositions include, for example, powders, tablets, dispersible granules, capsules, and cachets. Liquid compositions include, for example, solutions in which a compound is dissolved, emulsions comprising a compound, or a solution containing liposomes, micelles, or nanoparticles comprising a compound as disclosed herein. Semi-solid compositions include, for example, gels, suspensions and creams. The compositions can be in liquid solutions or suspensions, solid forms suitable for solution or suspension in a liquid prior to use, or as emulsions. These compositions can also contain minor amounts of nontoxic, auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and other pharmaceutically-acceptable additives.
Non-limiting examples of dosage forms suitable for use as described herein include liquid, powder, gel, nanosuspension, nanoparticle, microgel, aqueous or oily suspensions, emulsion, and any combination thereof.
Non-limiting examples of pharmaceutically-acceptable excipients suitable for use herein include binding agents, disintegrating agents, anti-adherents, anti-static agents, surfactants, anti-oxidants, coating agents, coloring agents, plasticizers, preservatives, suspending agents, emulsifying agents, anti-microbial agents, spheronization agents, and any combination thereof.
A composition can be, for example, an immediate release form or a controlled release formulation. An immediate release formulation can be formulated to allow the compounds to act rapidly. Non-limiting examples of immediate release formulations include readily dissolvable formulations. A controlled release formulation can be a pharmaceutical formulation that has been adapted such that release rates and release profiles of the active agent can be matched to physiological and chronotherapeutic requirements or, alternatively, has been formulated to effect release of an active agent at a programmed rate. Non-limiting examples of controlled release formulations include granules, delayed release granules, hydrogels (e.g., of synthetic or natural origin), other gelling agents (e.g., gel-forming dietary fibers), matrix-based formulations (e.g., formulations comprising a polymeric material having at least one active ingredient dispersed through), granules within a matrix, polymeric mixtures, and granular masses.
In some, a controlled release formulation is a delayed release form. A delayed release form can be formulated to delay a compound's action for an extended period of time. A delayed release form can be formulated to delay the release of an effective dose of one or more compounds, for example, for about 4, about 8, about 12, about 16, or about 24 h.
A controlled release formulation can be a sustained release form. A sustained release form can be formulated to sustain, for example, the compound's action over an extended period of time. A sustained release form can be formulated to provide an effective dose of any compound described herein (e.g., provide a physiologically-effective blood profile) over about 4, about 8, about 12, about 16, or about 24 h.
Non-limiting examples of pharmaceutically-acceptable excipients can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, H. A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated by reference in its entirety.
Pharmaceutical compositions described herein can be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compounds. The unit dosage can be in the form of a package containing discrete quantities of the formulation. Non-limiting examples are packaged injectables, vials, or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multiple-dose reclosable containers can be used, for example, in combination with or without a preservative. Formulations for injection can be presented in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.
Pharmaceutical compositions provided herein, can be administered in conjunction with other therapies, for example, chemotherapy, radiation, surgery, anti-inflammatory agents, and selected vitamins. The other agents can be administered prior to, after, or concomitantly with the pharmaceutical compositions.
Depending on the intended mode of administration, the pharmaceutical compositions can be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, lotions, creams, or gels, for example, in unit dosage form suitable for single administration of a precise dosage.
For solid compositions, nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talc, cellulose, glucose, sucrose, and magnesium carbonate.
Non-limiting examples of pharmaceutically active agents suitable for combination with compositions of the disclosure include anti-infectives, i.e., aminoglycosides, antiviral agents, antimicrobials, anticholinergics/antispasmotics, antidiabetic agents, antihypertensive agents, antineoplastics, cardiovascular agents, central nervous system agents, coagulation modifiers, hormones, immunologic agents, immunosuppressive agents, and ophthalmic preparations.
Non-limiting examples of dosage forms suitable for use in the disclosure include liquid, elixir, nanosuspension, aqueous or oily suspensions, drops, syrups, and any combination thereof. Non-limiting examples of pharmaceutically-acceptable excipients suitable for use in the disclosure include granulating agents, binding agents, lubricating agents, disintegrating agents, sweetening agents, glidants, anti-adherents, anti-static agents, surfactants, anti-oxidants, gums, coating agents, coloring agents, flavoring agents, coating agents, plasticizers, preservatives, suspending agents, emulsifying agents, plant cellulosic material and spheronization agents, and any combination thereof.
In some embodiments, provided herein dietary product is formulated to reduce a level of lipid, fat, or cholesterol in a subject. Dietary products described herein can be formulated as a powder, a gel, a solution, a suspension, a paste, a solid, a liquid, a liquid concentrate, a powder which may be reconstituted, a shake, a concentrate, a pill, a bar, a tablet, a capsule or a ready-to-use product. The dietary product can be formulated for oral, parenteral, intravenous, or enteral administration. A dietary product can also be a pharmaceutical composition when the supplement is in the form of a tablet, pill, capsule, liquid, aerosol, injectable solution, or other pharmaceutically acceptable formulation. In some embodiments, the dietary product is a beverage. In some embodiments, the dietary product is administered once, twice, three, four, five, six, seven eight, nine, or ten times a day.
In some embodiments, provided herein is a composition comprising: a) a cholesterol lowering agent; and b) a dietary product, wherein the dietary product is formulated to reduce a level of fat, a level of cholesterol, or both in a subject. In some embodiments, provided herein is a composition comprising: a) a cholesterol lowering agent; and b) a dietary product, wherein the dietary product is formulated to reduce a level of fat in a subject. In some embodiments, provided herein is a composition comprising: a) a cholesterol lowering agent; and b) a dietary product, wherein the dietary product is formulated to reduce a level of cholesterol in a subject.
In some embodiments, provided herein is a pharmaceutical composition comprising: a) a therapeutically effective amount of a cholesterol lowering agent; and b) a therapeutically effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of fat, a level of cholesterol, or both in a subject. In some embodiments, provided herein is a pharmaceutical composition comprising: a) a therapeutically effective amount of a cholesterol lowering agent; and b) a therapeutically effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of fat in a subject. In some embodiments, provided herein is a pharmaceutical composition comprising: a) a therapeutically effective amount of a cholesterol lowering agent; and b) a therapeutically effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of cholesterol in a subject.
Compositions of the invention can be packaged as a kit. In some embodiments, a kit includes written instructions on the administration/use of the composition. The written material can be, for example, a label. The written material can suggest conditions methods of administration. The instructions provide the subject and the supervising physician with the best guidance for achieving the optimal clinical outcome from the administration of the therapy. The written material can be a label. In some embodiments, the label can be approved by a regulatory agency, for example the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other regulatory agencies.
In some embodiments, provided herein is a kit comprising: a) an effective amount of a cholesterol lowering agent; b) an effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of fat in the subject; and optionally, c) written instructions for use of the kit. In some embodiments, provided herein is a kit comprising: a) an effective amount of a cholesterol lowering agent; b) an effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of cholesterol in the subject; and optionally, c) written instructions for use of the kit.
Therapeutic agents described herein can be administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing a therapeutic agent can vary. For example, the compositions can be used as a prophylactic and can be administered continuously to subjects with a propensity to conditions or diseases in order to lessen a likelihood of the occurrence of the disease or condition. The compositions can be administered to a subject during or as soon as possible after the onset of the symptoms. The administration of the therapeutic agents can be initiated within the first 48 h of the onset of the symptoms, within the first 24 h of the onset of the symptoms, within the first 6 h of the onset of the symptoms, or within 3 h of the onset of the symptoms. The initial administration can be via any route practical, such as by any route described herein using any formulation described herein.
A compound can be administered as soon as is practical after the onset of a disease or condition is detected or suspected, and for a length of time necessary for the treatment of the disease, such as, for example, from about 1 month to about 3 months. In some embodiments, the length of time a compound can be administered can be about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, about 6 days, about 1 week, about 2 weeks, about 3 weeks, about 4 weeks, about 1 month, about 5 weeks, about 6 weeks, about 7 weeks, about 8 weeks, about 2 months, about 9 weeks, about 10 weeks, about 11 weeks, about 12 weeks, about 3 months, about 13 weeks, about 14 weeks, about 15 weeks, about 16 weeks, about 4 months, about 17 weeks, about 18 weeks, about 19 weeks, about 20 weeks, about 5 months, about 21 weeks, about 22 weeks, about 23 weeks, about 24 weeks, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 1 year, about 13 months, about 14 months, about 15 months, about 16 months, about 17 months, about 18 months, about 19 months, about 20 months, about 21 months, about 22 months about 23 months, about 2 years, about 2.5 years, about 3 years, about 3.5 years, about 4 years, about 4.5 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, or about 10 years. The length of treatment can vary for each subject.
Multiple therapeutic agents can be administered in any order or simultaneously. In some embodiments, a compound of the invention is administered in combination with, before, or after treatment with another therapeutic agent. If simultaneously, the multiple therapeutic agents can be provided in a single, unified form, or in multiple forms, for example, as multiple separate pills. The agents can be packed together or separately, in a single package or in a plurality of packages. One or all of the therapeutic agents can be given in multiple doses. If not simultaneous, the timing between the multiple doses can vary to as much as about a month.
In some embodiments, a method of the disclosure can comprise administering an additional therapeutic agent. In some embodiments, the additional therapeutic agent is a chemotherapy. In some embodiments, the additional therapeutic agent is a radiotherapy. In some embodiments, the additional therapeutic agent is an immunotherapy.
In some embodiments, the additional therapeutic agent is a chemotherapy. In some embodiments, the chemotherapy comprises administering an antimetabolite. In some embodiments, the antimetabolite is an antifolate, pyrimidine antagonist, purine antagonist, or a ribonucleotide reductase inhibitor. In some embodiments, the chemotherapy is an alkylating agent. In some embodiments, the alkylating agent is an oxazaphosphorine, nitrogen mustard, imidazotetrazine, nitrosourea, alkyl sulfonate, hydrazine, or platinum-based agent. In some embodiments, the chemotherapy is a topoisomerase inhibitor. In some embodiments, the topoisomerase inhibitor is a topoisomerase I inhibitor or a topoisomerase II inhibitor. In some embodiments, the chemotherapy is a mitotic inhibitor. In some embodiments, the mitotic inhibitor is a vinca alkaloid, taxane, or nontaxane microtubule inhibitor. In some embodiments, the chemotherapy is an antitumor antibiotic. In some embodiments, the antitumor antibiotic is bleomycin, actinomycin D, an anthracycline, or mitomycin. In some embodiments, the chemotherapy is a protein kinase inhibitor. In some embodiments, the protein kinase inhibitor is a BCR-ABL and c-KIT tyrosine kinase inhibitor; EGFR tyrosine kinase inhibitor, ALK tyrosine kinase inhibitor, V600E mutated-BRAF oncogene inhibitor, MEK inhibitor, Bruton kinase inhibitor, Janus kinase inhibitor, or CDK inhibitor. In some embodiments, the chemotherapy is a selective estrogen receptor modulator (SERM).
In some embodiments, the chemotherapy is one or more of drugs listed in TABLE 1 or TABLE 2.
In some embodiments, the chemotherapy can include one or more of the following categories of anti-cancer agents:
The therapeutic agents used in the methods of the disclosure can be a single agent or a combination of agents. In some embodiments, such combinations include agents that have different mechanisms of action. Such combinations can be administered simultaneously, separately, or sequentially. In some embodiments, a combination therapy provided herein is simultaneously administered. In some embodiments, a combination therapy provided herein is separately administered. In some embodiments, a combination therapy provided herein is sequentially administered.
In some embodiments, the additional therapeutic agent is an immunotherapy. In some embodiments, the immunotherapy is a cancer treatment vaccine. In some embodiments, the immunotherapy is a checkpoint inhibitor. In some embodiments, the checkpoint inhibitor blocks CTLA-4, PD-1, or PD-L1. In some embodiments, the checkpoint inhibitor is ipilimumab, nivolumab, or pembrolizumab. In some embodiments, the immunotherapy is an immune system modulator. In some embodiments, the immunotherapy is a monoclonal antibody. In some embodiments, the immunotherapy is a T-cell transfer therapy.
In some embodiments, disclosed herein is a method of treating a condition by 1) administering a therapeutically effective amount of an inhibitor of a mevalonate pathway; b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids, wherein the subject consumes a 2000 kcal/day diet; and c) an anticancer agent. In some embodiments, disclosed herein is a method of treating a condition by 1) administering a therapeutically effective amount of an inhibitor of a mevalonate pathway; b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol, wherein the subject consumes a 2000 kcal/day; and c) an anticancer agent. In some embodiments, the anticancer agent is a SERM inhibitor.
In some embodiments, disclosed herein is a method of treating a condition by 1) administering a therapeutically effective amount of an inhibitor of a mevalonate pathway; b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids, wherein the subject consumes a 2000 kcal/day diet; and c) an anticancer agent. In some embodiments, disclosed herein is a method of treating a condition by 1) administering a therapeutically effective amount of an inhibitor of a mevalonate pathway; b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol, wherein the subject consumes a 2000 kcal/day diet; and c) an anticancer agent. In some embodiments, the anticancer agent is a SERM inhibitor.
In some embodiments, disclosed herein is a method of treating a condition by 1) administering a therapeutically effective amount of a first inhibitor of a mevalonate pathway; b) a therapeutically effective amount of a second inhibitor of the mevalonate pathway; and c) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids, wherein the subject consumes a 2000 kcal/day diet. In some embodiments, disclosed herein is a method of treating a condition by 1) administering a therapeutically effective amount of a first inhibitor of a mevalonate pathway; b) a therapeutically effective amount of a second inhibitor of the mevalonate pathway; and c) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol, wherein the subject consumes a 2000 kcal/day diet.
Pharmaceutical compositions described herein can be in unit dosage forms suitable for single administration of precise dosages. In unit dosage form, the formulation is divided into unit doses containing appropriate quantities of one or more compounds. The unit dosage can be in the form of a package containing discrete quantities of the formulation. Non-limiting examples are liquids in vials or ampoules. Aqueous suspension compositions can be packaged in single-dose non-reclosable containers. Multiple-dose reclosable containers can be used, for example, in combination with a preservative. Formulations for parenteral injection can be presented in unit dosage form, for example, in ampoules, or in multi-dose containers with a preservative.
A compound described herein can be administered or present in a composition in a range of from about 1 mg to about 2000 mg; from about 100 mg to about 2000 mg; from about 10 mg to about 2000 mg; from about 5 mg to about 1000 mg, from about 10 mg to about 500 mg, from about 50 mg to about 250 mg, from about 100 mg to about 200 mg, from about 1 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about 350 mg, from about 350 mg to about 400 mg, from about 400 mg to about 450 mg, from about 450 mg to about 500 mg, from about 500 mg to about 550 mg, from about 550 mg to about 600 mg, from about 600 mg to about 650 mg, from about 650 mg to about 700 mg, from about 700 mg to about 750 mg, from about 750 mg to about 800 mg, from about 800 mg to about 850 mg, from about 850 mg to about 900 mg, from about 900 mg to about 950 mg, or from about 950 mg to about 1000 mg.
A compound described herein can be administered or present in a composition in an amount of about 1 mg, about 2 mg, about 3 mg, about 4 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, about 1500 mg, about 1550 mg, about 1600 mg, about 1650 mg, about 1700 mg, about 1750 mg, about 1800 mg, about 1850 mg, about 1900 mg, about 1950 mg, or about 2000 mg.
In some embodiments, a dose can be expressed in terms of an amount of the drug divided by the mass of the subject, for example, milligrams of drug per kilograms of subject body mass. In some embodiments, a compound is administered in an amount ranging from about 5 mg/kg to about 50 mg/kg, about 250 mg/kg to about 2000 mg/kg, about 10 mg/kg to about 800 mg/kg, about 50 mg/kg to about 400 mg/kg, about 100 mg/kg to about 300 mg/kg, or about 150 mg/kg to about 200 mg/kg.
In some embodiments, an inhibitor of a mevalonate pathway, a HMG-CoA reductase inhibitor, or a statin of the disclosure can be administered in an amount of from about 5 mg to about 10 mg, about 10 mg to about 20 mg, about 20 mg to about 30 mg, about 30 mg to about 40 mg, about 40 mg to about 50 mg, about 50 mg to about 60 mg, about 60 mg to about 70 mg, about 70 mg to about 80 mg, about 80 mg to about 90 mg, or about 90 mg to about 100 mg.
In some embodiments, the inhibitor of a mevalonate pathway is an HMG-CoA reductase inhibitor. In some embodiments, an HMG-CoA reductase inhibitor used in the methods disclosed herein is a statin.
In some embodiments, the statin is simvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is simvastatin sodium. In some embodiments, a method of the disclosure comprises administering simvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 45 mg/day. In some embodiments, a method of the disclosure comprises administering simvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 10 mg/day, from about 10 mg/day to about 15 mg/day, from about 15 mg/day to about 20 mg/day, from about 20 mg/day to about 25 mg/day, from about 25 mg/day to about 30 mg/day, from about 30 mg/day to about 35 mg/day, from about 35 mg/day to about 40 mg/day, or from about 40 mg/day to about 45 mg/day. In some embodiments, a method of the disclosure comprises administering simvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 10 mg/day to about 20 mg/day. In some embodiments, a method of the disclosure comprises administering simvastatin or a pharmaceutically acceptable salt thereof in an amount of about 5 mg/day, about 10 mg/day, about 15 mg/day, about 20 mg/day, about 25 mg/day, about 30 mg/day, about 35 mg/day, about 40 mg/day, or about 45 mg/day. In some embodiments, a method of the disclosure comprises administering simvastatin or a pharmaceutically acceptable salt thereof in an amount of about 10 mg/day. In some embodiments, a method of the disclosure comprises administering simvastatin or a pharmaceutically acceptable salt thereof in an amount of about 15 mg/day. In some embodiments, a method of the disclosure comprises administering simvastatin or a pharmaceutically acceptable salt thereof in an amount of about 20 mg/day.
In some embodiments, the statin is fluvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is fluvastatin sodium. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 80 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 10 mg/day, from about 10 mg/day to about 15 mg/day, from about 15 mg/day to about 20 mg/day, from about 20 mg/day to about 25 mg/day, from about 25 mg/day to about 30 mg/day, from about 30 mg/day to about 35 mg/day, from about 35 mg/day to about 40 mg/day, from about 40 mg/day to about 45 mg/day, from about 45 mg/day to about 50 mg/day, from about 50 mg/day to about 55 mg/day, from about 55 mg/day to about 60 mg/day, from about 60 mg/day to about 65 mg/day, from about 65 mg/day to about 70 mg/day, from about 70 mg/day to about 75 mg/day, or from about 75 mg/day to about 80 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 10 mg/day to about 20 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 20 mg/day to about 30 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 30 mg/day to about 40 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of about 5 mg/day, about 10 mg/day, about 15 mg/day, about 20 mg/day, about 25 mg/day, about 30 mg/day, about 35 mg/day, about 40 mg/day, about 45 mg/day, about 50 mg/day, about 55 mg/day, about 60 mg/day, about 65 mg/day, about 70 mg/day, about 75 mg/day, or about 80 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of about 10 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of about 15 mg/day. In some embodiments, a method of the disclosure comprises administering fluvastatin or a pharmaceutically acceptable salt thereof in an amount of about 20 mg/day. In some embodiments, fluvastatin or a pharmaceutically acceptable salt thereof can be administered once or twice a day.
In some embodiments, the statin is atorvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is atorvastatin calcium. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 80 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 10 mg/day, from about 10 mg/day to about 15 mg/day, from about 15 mg/day to about 20 mg/day, from about 20 mg/day to about 25 mg/day, from about 25 mg/day to about 30 mg/day, from about 30 mg/day to about 35 mg/day, from about 35 mg/day to about 40 mg/day, from about 40 mg/day to about 45 mg/day, from about 45 mg/day to about 50 mg/day, from about 50 mg/day to about 55 mg/day, from about 55 mg/day to about 60 mg/day, from about 60 mg/day to about 65 mg/day, from about 65 mg/day to about 70 mg/day, from about 70 mg/day to about 75 mg/day, or from about 75 mg/day to about 80 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 10 mg/day to about 20 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 20 mg/day to about 30 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 30 mg/day to about 40 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of about 5 mg/day, about 10 mg/day, about 15 mg/day, about 20 mg/day, about 25 mg/day, about 30 mg/day, about 35 mg/day, about 40 mg/day, about 45 mg/day, about 50 mg/day, about 55 mg/day, about 60 mg/day, about 65 mg/day, about 70 mg/day, about 75 mg/day, or about 80 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of about 10 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of about 15 mg/day. In some embodiments, a method of the disclosure comprises administering atorvastatin or a pharmaceutically acceptable salt thereof in an amount of about 20 mg/day.
In some embodiments, the statin is rosuvastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is rosuvastatin calcium. In some embodiments, a method of the disclosure comprises administering rosuvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 45 mg/day. In some embodiments, a method of the disclosure comprises administering rosuvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 10 mg/day, from about 10 mg/day to about 15 mg/day, from about 15 mg/day to about 20 mg/day, from about 20 mg/day to about 25 mg/day, from about 25 mg/day to about 30 mg/day, from about 30 mg/day to about 35 mg/day, from about 35 mg/day to about 40 mg/day, or from about 40 mg/day to about 45 mg/day. In some embodiments, a method of the disclosure comprises administering rosuvastatin or a pharmaceutically acceptable salt thereof in an amount of from about 10 mg/day to about 20 mg/day. In some embodiments, a method of the disclosure comprises administering rosuvastatin or a pharmaceutically acceptable salt thereof in an amount of about 5 mg/day, about 10 mg/day, about 15 mg/day, about 20 mg/day, about 25 mg/day, about 30 mg/day, about 35 mg/day, about 40 mg/day, or about 45 mg/day. In some embodiments, a method of the disclosure comprises administering rosuvastatin or a pharmaceutically acceptable salt thereof in an amount of about 10 mg/day. In some embodiments, a method of the disclosure comprises administering rosuvastatin or a pharmaceutically acceptable salt thereof in an amount of about 15 mg/day. In some embodiments, a method of the disclosure comprises administering rosuvastatin or a pharmaceutically acceptable salt thereof in an amount of about 20 mg/day.
In some embodiments, the statin is lovastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is lovastatin sodium. In some embodiments, a method of the disclosure comprises administering lovastatin or a pharmaceutically acceptable salt thereof in an amount of from about 15 mg/day to about 20 mg/day, from about 20 mg/day to about 25 mg/day, from about 25 mg/day to about 30 mg/day, from about 30 mg/day to about 35 mg/day, from about 35 mg/day to about 40 mg/day, from about 40 mg/day to about 45 mg/day, from about 45 mg/day to about 50 mg/day, from about 50 mg/day to about 55 mg/day, from about 55 mg/day to about 60 mg/day, or from about 60 mg/day to about 65 mg/day. In some embodiments, a method of the disclosure comprises administering lovastatin or a pharmaceutically acceptable salt thereof in an amount of from about 20 mg/day to about 30 mg/day. In some embodiments, a method of the disclosure comprises administering lovastatin or a pharmaceutically acceptable salt thereof in an amount of from about 30 mg/day to about 40 mg/day. In some embodiments, a method of the disclosure comprises administering lovastatin or a pharmaceutically acceptable salt thereof in an amount of from about 40 mg/day to about 50 mg/day. In some embodiments, a method of the disclosure comprises administering lovastatin or a pharmaceutically acceptable salt thereof in an amount of from about 50 to about 60 mg/day.
In some embodiments, the statin is pravastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is pravastatin sodium. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 80 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of from about 5 mg/day to about 10 mg/day, from about 10 mg/day to about 15 mg/day, from about 15 mg/day to about 20 mg/day, from about 20 mg/day to about 25 mg/day, from about 25 mg/day to about 30 mg/day, from about 30 mg/day to about 35 mg/day, from about 35 mg/day to about 40 mg/day, from about 40 mg/day to about 45 mg/day, from about 45 mg/day to about 50 mg/day, from about 50 mg/day to about 55 mg/day, from about 55 mg/day to about 60 mg/day, from about 60 mg/day to about 65 mg/day, from about 65 mg/day to about 70 mg/day, from about 70 mg/day to about 75 mg/day, or from about 75 mg/day to about 80 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of from about 10 mg/day to about 20 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of from about 20 mg/day to about 30 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of from about 30 mg/day to about 40 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of about 5 mg/day, about 10 mg/day, about 15 mg/day, about 20 mg/day, about 25 mg/day, about 30 mg/day, about 35 mg/day, about 40 mg/day, about 45 mg/day, about 50 mg/day, about 55 mg/day, about 60 mg/day, about 65 mg/day, about 70 mg/day, about 75 mg/day, or about 80 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of about 10 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of about 15 mg/day. In some embodiments, a method of the disclosure comprises administering pravastatin or a pharmaceutically acceptable salt thereof in an amount of about 20 mg/day.
In some embodiments, the statin is pitavastatin or a pharmaceutically acceptable salt thereof. In some embodiments, the statin is pitavastatin calcium. In some embodiments, the statin is pitavastatin magnesium. In some embodiments, pitavastatin or a pharmaceutically acceptable salt thereof can be administered in an amount of about 0.5 mg/day, about 1 mg/day, about 1.5 mg/day, about 2 mg/day, about 2.5 mg/day, about 3 mg/day, about 3.5 mg/day, about 4 mg/day, or about 4.5 mg/day. In some embodiments, pitavastatin or a pharmaceutically acceptable salt thereof can be administered in an amount of about 1 mg/day. In some embodiments, pitavastatin or a pharmaceutically acceptable salt thereof can be administered in an amount of about 2 mg/day. In some embodiments, pitavastatin or a pharmaceutically acceptable salt thereof can be administered in an amount of about 4 mg/day.
A method of the disclosure can comprise administering a diet. In some embodiments, a method of the disclosure can comprise administering a vegetarian diet. In some embodiments, a method of the disclosure can comprise administering a vegan diet. In some embodiments, a method of the disclosure can comprise administering a diet substantially devoid of animal-based fats, e.g., no more than 1%, no more than 0.5%, or no more than 0.1% of total fat in the diet. In some embodiments, a method of the disclosure can comprise administering a diet that does not comprise animal-based fats. In some embodiments, a method of the disclosure can comprise administering a diet devoid of animal-based fats. In some embodiments, a method of the disclosure can comprise replacing animal-based fats in a diet with plant-based fats. In some embodiments, a method of the disclosure can comprise administering a diet that does not comprise animal-based fat. In some embodiments, a method of the disclosure can comprise administering a diet where greater than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the animal-based fat is replaced with plant-based fats. In some embodiments, a method of the disclosure can comprise administering a diet devoid of or restricted in lipids. In some embodiments, a method of the disclosure can comprise administering a diet devoid of or restricted in cholesterol. In some embodiments, a method of the disclosure can comprise administering a diet devoid of or restricted in fat.
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in total lipid intake, e.g., a daily total lipid intake. In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in a daily recommended dietary lipid intake. In some embodiments, a diet comprises no more than 80%, no more than 70%, no more than 75%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 25%, no more than 20%, no more than 10%, no more than 5%, no more than 4%, no more than 3%, no more than 2%, no more than 1%, or no more than 0.5% of a subject's average daily lipid intake prior to start of the diet. In some embodiments, a diet comprises less than 90%, less than 80%, less than 70%, less than 75%, less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, or less than 0.5% of a subject's average daily lipid intake prior to start of the diet. In some embodiments, a method of the disclosure can comprise administering a diet that does not comprise lipids. A subject's lipid intake can be according to a dietary guideline published by a federal government agency, e.g., the United States Departments of Agriculture and Health and Human Services or the National Health and Nutrition Examination Survey (NHANES). A subject's average daily lipid intake can be according to the Dietary Guidelines for Americans published by the United States Departments of Agriculture and Health and Human Services. A subject's average daily recommended lipid intake can be according to the Dietary Guidelines for Americans published by the United States Departments of Agriculture and Health and Human Services.
In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 100 g/day, no more than 90 g/day, no more than 80 g/day, no more than 70 g/day, no more than 60 g/day, no more than 50 g/day, no more than 40 g/day, no more than 30 g/day, no more than 20 g/day, no more than 10 g/day, no more than 5 g/day, or no more than 1 g/day of total lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising a restricted amount of lipids, e.g., less than about 40% of total calories from lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, or less than about 5% of total daily calories from lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 30% of total daily calories from lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 25% of total daily calories from lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 20% of total daily calories from lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15% of total daily calories from lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 10% of total daily calories from lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 5% of total daily calories from lipids, e.g., based on a 2000 kcal/day diet. The amount of lipids in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet.
In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 80 g/day, less than about 75 g/day, less than about 70 g/day, less than about 65 g/day, less than about 60 g/day, less than about 55 g/day, less than about 50 g/day, less than about 45 g/day, less than about 40 g/day, less than about 35 g/day, less than about 30 g/day, less than about 25 g/day, less than about 20 g/day, less than about 15 g/day, less than about 10 g/day, or less than about 5 g/day of lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering diet comprising less than about 70 g/day of lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 60 g/day of lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 50 g/day of lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 40 g/day of lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 30 g/day of lipids, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 20 g/day of lipids, e.g., based on a 2000 kcal/day diet. The amount of lipids in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet.
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in total dietary cholesterol intake, e.g., a daily total cholesterol intake. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 500 mg/day, no more than 450 mg/day, no more than 400 mg/day, no more than 350 mg/day, no more than 300 mg/day, no more than 250 mg/day, no more than 200 mg/day, no more than 150 mg/day, no more than 100 mg/day, no more than 75 mg/day, or no more than 50 mg/day of cholesterol, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet devoid of cholesterol. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 250 mg/day of cholesterol, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 200 mg/day of cholesterol, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 150 mg/day of cholesterol, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 100 mg/day of cholesterol, e.g., based on a 2000 kcal/day diet. Diets low in or devoid of cholesterol can exclude food products containing high levels of cholesterol, such as animal fat, egg yolks, shrimp, whole milk dairy, butter, cream, and cheese.
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in cholesterol intake, e.g., a daily cholesterol intake. Cholesterol dietary intake by men can average by about 350 mg/day; cholesterol dietary intake by women can average by about 240 mg/day. In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in a daily recommended dietary cholesterol intake. In some embodiments, a diet comprises no more than 80%, no more than 70%, no more than 75%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 25%, no more than 20%, no more than 10%, no more than 5%, no more than 4%, no more than 3%, no more than 2%, no more than 1%, or no more than 0.5% of a subject's average daily cholesterol intake prior to start of the diet. In some embodiments, a diet comprises less than 90%, less than 80%, less than 70%, less than 75%, less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, or less than 0.5% of a subject's average daily cholesterol intake prior to start of the diet. A subject's cholesterol intake can be according to a dietary guideline published by a federal government agency, e.g., the United States Departments of Agriculture and Health and Human Services or the National Health and Nutrition Examination Survey (NHANES). A subject's average daily cholesterol intake can be according to the Dietary Guidelines for Americans published by the United States Departments of Agriculture and Health and Human Services. A subject's average daily recommended cholesterol intake can be according to the Dietary Guidelines for Americans published by the United States Departments of Agriculture and Health and Human Services. For example, a daily recommended cholesterol intake is about 300 mg/day according to the 2010 Dietary Guidelines for Americans published by the United States Departments of Agriculture and Health and Human Services.
In some cases, a subject's typical cholesterol intake exceeds a recommended cholesterol intake amount. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 170%, no more than 160%, no more than 150%, no more than 140%, no more than 130%, no more than 120%, no more than 110%, no more than 100%, no more than 90%, no more than 80%, no more than 70%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 20%, no more than 10% of a daily recommended cholesterol intake amount. In some embodiments, a method of the disclosure can comprise administering a diet that does not comprise cholesterol. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 70% of a daily recommend daily cholesterol intake value. In some embodiments, a method of the disclosure comprise administering a diet comprising no more than 50% of a daily recommended cholesterol intake value. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 30% of a daily recommended cholesterol intake value. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 25% of a daily recommended cholesterol intake value.
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in total fat intake, e.g., a daily total fat intake. In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in total fat intake, e.g., a daily total fat intake. In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in a daily recommended dietary fat intake. In some embodiments, a diet comprises no more than 80%, no more than 70%, no more than 75%, no more than 60%, no more than 50%, no more than 40%, no more than 30%, no more than 25%, no more than 20%, no more than 10%, no more than 5%, no more than 4%, no more than 3%, no more than 2%, no more than 1%, or no more than 0.5% of a subject's average daily fat intake prior to start of the diet. In some embodiments, a diet comprises less than 90%, less than 80%, less than 70%, less than 75%, less than 60%, less than 50%, less than 40%, less than 30%, less than 25%, less than 20%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, or less than 0.5% of a subject's average daily fat intake prior to start of the diet. In some embodiments, a method of the disclosure can comprise administering a diet that does not comprise fat. A subject's fat intake can be according to a dietary guideline published by a federal government agency, e.g., the United States Department of Agriculture and Health and Human Services or the National Health and Nutrition Examination Survey (NHANES). A subject's average daily fat intake can be according to the Dietary Guidelines for Americans published by the United States Departments of Agriculture and Health and Human Services. A subject's average daily recommended fat intake can be according to the Dietary Guidelines for Americans published by the United States Departments of Agriculture and Health and Human Services.
In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 100 g/day, no more than 90 g/day, no more than 80 g/day, no more than 70 g/day, no more than 60 g/day, no more than 50 g/day, no more than 40 g/day, no more than 30 g/day, no more than 20 g/day, no more than 10 g/day, no more than 5 g/day, or no more than 1 g/day of total fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising a restricted amount of fat, e.g., less than about 40% of total calories from fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 40%, less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, or less than about 5% of total daily calories from fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 30% of total daily calories from fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 25% of total daily calories from fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 20% of total daily calories from fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15% of total daily calories from fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 10% of total daily calories from fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 5% of total daily calories from fat, e.g., based on a 2000 kcal/day diet. The amount of fat in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet.
In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 80 g/day, less than about 75 g/day, less than about 70 g/day, less than about 65 g/day, less than about 60 g/day, less than about 55 g/day, less than about 50 g/day, less than about 45 g/day, less than about 40 g/day, less than about 35 g/day, less than about 30 g/day, less than about 25 g/day, less than about 20 g/day, less than about 15 g/day, less than about 10 g/day, or less than about 5 g/day of fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering diet comprising less than about 70 g/day of fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 60 g/day of fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 50 g/day of fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 40 g/day of fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 30 g/day of fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 20 g/day of fat, e.g., based on a 2000 kcal/day diet. The amount of fat in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet.
The amount of fat in the diet can be based on the weight of a subject, e.g., a weight in kilograms (kg). In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 1500 mg/kg/day, less than about 1400 mg/kg/day, less than about 1300 mg/kg/day, less than about 1200 mg/kg/day, less than about 1100 mg/kg/day, less than about 1000 mg/kg/day, less than about 900 mg/kg/day, less than about 800 mg/kg/day, less than about 700 mg/kg/day, less than about 600 mg/kg/day, less than about 500 mg/kg/day, less than about 400 mg/kg/day, less than about 300 mg/kg/day, less than about 200 mg/kg/day, or less than about 100 mg/kg/day of fat based on a subject's weight.
In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 110%, less than 100%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% of a recommended daily fat intake, e.g., based on a 2000 kcal/day diet. A daily recommended intake for fat can be based on the United States Food and Drug Administration Rules and Regulations-Revision of the Nutrition and Supplemental Facts Label. For example, a daily recommended intake is about 78 g/day of fat, based on the United States Food and Drug Administration Rules and Regulations-Revision of the Nutrition and Supplemental Facts Label dated May 27, 2016. In some embodiments, a method of the disclosure can comprise administering diet comprising less than 90% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 80% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 70% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 60% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 50% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 40% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 30% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 20% of a daily recommended fat intake, e.g., based on a 2000 kcal/day diet. The amount of fat in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet.
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in saturated fat intake, e.g., a daily saturated fat intake. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 100 g/day, no more than 90 g/day, no more than 80 g/day, no more than 70 g/day, no more than 60 g/day, no more than 50 g/day, no more than 40 g/day, no more than 30 g/day, no more than 20 g/day, no more than 10 g/day, no more than 5 g/day, or no more than 1 g/day of saturated fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15% of total kcals/day in saturated fat. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15%, less than about 14%, less than about 13%, less than about 12%, less than about 11%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1% of total kcals/day in saturated fat, e.g. based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15% of total kcals/day in saturated fat, e.g. based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 10% of total kcals/day in saturated fat, e.g. based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 7% of total kcals/day in saturated fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 5% of total kcals/day in saturated fat, e.g. based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than a daily recommend intake value of saturated fat. For example, a daily recommended saturated fat intake value is 20 g/day based on the United States Food and Drug Administration Rules and Regulations-Revision of the Nutrition and Supplemental Facts Label dated May 27, 2016. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 20 g/day, less than 15 g/day, less than 10 g/day, less than 5 g/day, less than 4 g/day, less than 3 g/day, less than 2 g/day, less than 1 g/day, or less than 500 mg/day in saturated fat, e.g., based on a 2000 kcal/day diet. The amount of fat in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet. A diet low in saturated fats can exclude foods of animal origin (e.g., liver and other organ meats) and oils (e.g., coconut oil, palm oil, palm kernel oil).
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in trans fat intake, e.g., a daily trans fat intake. In some embodiments, a method of the disclosure can comprise administering a diet comprising no more than 100 g/day, no more than 90 g/day, no more than 80 g/day, no more than 70 g/day, no more than 60 g/day, no more than 50 g/day, no more than 40 g/day, no more than 30 g/day, no more than 20 g/day, no more than 10 g/day, no more than 5 g/day, or no more than 1 g/day of trans fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 5% of total kcals/day in trans fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, or less than about 0.5% of total kcals/day in trans fat, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than 20 g/day, less than 15 g/day, less than 10 g/day, less than 5 g/day, less than 4 g/day, less than 3 g/day, less than 2 g/day, less than 1 g/day, or less than 500 mg/day in trans fat, e.g., based on 2000 kcal/day diet. The amount of fat in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet. Diets low in trans fat can exclude foods such as margarine, baked products (e.g., crackers, cookies, doughnuts, breads), and fried foods.
In some embodiments, a method of the disclosure can comprise administering a diet high in stanols or sterols. A diet high in stanols and sterols can include fruits, vegetables, and supplements, such as benecol (3-4 grams/day).
In some embodiments, a method of the disclosure can comprise administering a diet comprising from about 10 g to about 40 g of fiber/day. In some embodiments, a method of the disclosure can comprise administering a diet comprising from about 10 g to about 20 g, from about 20 g to about 30 g, or from about 30 g to about 40 g of fiber/day. In some embodiments, a method of the disclosure can comprise administering a diet comprising from about 10 g to about 20 g of fiber/day. In some embodiments, a method of the disclosure can comprise administering a diet comprising from about 20 g to about 30 g of fiber/day. In some embodiments, a method of the disclosure can comprise administering a diet comprising from about 30 g to about 40 g of fiber/day. In some embodiments, a method of the disclosure can comprise administering a diet high in high-fiber carbohydrates comprising, for example, oats, bran, barley, nuts and seeds, beans, lentils, peas, and vegetables.
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in polyunsaturated fat intake. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15% in total kcals/day in polyunsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15%, less than about 14%, less than about 13%, less than about 12%, less than about 11%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1% in total kcals/day in polyunsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15% in total kcals/day in polyunsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 10% in total kcals/day in polyunsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 8% in total kcals/day in polyunsaturated fats, e.g., based on a 2000 kcal/day diet. The amount of fat in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet.
In some embodiments, a method of the disclosure can comprise administering a diet that is restricted in monounsaturated fat intake. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 25% total kcals/day in monounsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 25%, less than about 24%, less than about 23%, less than about 22%, less than about 21%, less than about 20%, less than about 19%, less than about 18%, less than about 17%, less than about 16%, less than about 15%, less than about 14%, less than about 13%, less than about 12%, less than about 11%, less than about 10%, less than about 9%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1% in total kcals/day in monounsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 25% in total kcals/day in monounsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 20% in total kcals/day in monounsaturated fats, e.g., based on a 2000 kcal/day diet. In some embodiments, a method of the disclosure can comprise administering a diet comprising less than about 15% in total kcals/day in monounsaturated fats, e.g., based on a 2000 kcal/day diet. The amount of fat in the diet can vary in a proportionate amount for subjects who consume less than 2000 kcal/day diet or more than 2000 kcal/day diet.
In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of fat in a subject. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of fat in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of fat in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of fat in a subject by about 20%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of fat in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of fat in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet formulated to reduce a level of fat in a subject by about 75%.
In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject by about 20%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject by about 75%.
In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of fat in a subject. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of fat in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of fat in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of fat in a subject by about 20%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of fat in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of fat in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet that reduces a level of fat in a subject by about 75%.
In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of fat in a subject. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of fat in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of fat in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of fat in a subject by about 20%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of fat in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of fat in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet formulated to reduce a blood level of fat in a subject by about 75%.
In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of cholesterol in a subject. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of cholesterol in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of cholesterol in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of cholesterol in a subject by about 20%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of cholesterol in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a level of cholesterol in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet formulated to reduce a level of cholesterol in a subject by about 75%.
In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of cholesterol in a subject. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of cholesterol in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of cholesterol in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of cholesterol in a subject by about 20%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of cholesterol in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet formulated to reduce a blood level of cholesterol in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet formulated to reduce a blood level of cholesterol in a subject by about 75%.
In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of cholesterol in a subject. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of cholesterol in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of cholesterol in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of cholesterol in a subject by about 20%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of cholesterol in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a level of cholesterol in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet that reduces a level of cholesterol in a subject by about 75%.
In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of cholesterol in a subject. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of cholesterol in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of cholesterol in a subject by about 10%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of cholesterol in a subject by about 20%. In some embodiments, a method of the disclosure c can comprise administering a diet that reduces a blood level of cholesterol in a subject by about 30%. In some embodiments, a method of the disclosure can comprise administering a diet that reduces a blood level of cholesterol in a subject by about 50%. In some embodiments a method of the disclosure can comprise administering a diet that reduces a blood level of cholesterol in a subject by about 75%.
A nutrient amount disclosed herein can be based on a recommended amount of the nutrient for an adult subject consuming on average a 2000 kcal/day diet. Any nutrient amount disclosed herein can be scaled appropriately based on the dietary intake of the subject. For example, a subject consuming on average a 2500 kcal/day diet can have a 25% increase in the amount of a nutrient amount or percentage disclosed herein. In another example, a subject consuming on average a 1500 kcal/day diet can have a 25% decrease in the amount of a nutrient amount or percentage disclosed herein.
In some embodiments, a method of the disclosure comprises a subject participating in physical activity. In some embodiments, a method of the disclosure comprises a subject including from about 30 min to about 200 min per week of moderate exercise. In some embodiments, a method of the disclosure comprises a subject including from about 30 min to about 60 min, from about 60 min to about 90 min, from about 90 min to about 120 min, from about 120 min to about 150 min, or from about 150 min to about 200 min per week of moderate exercise. In some embodiments, a method of the disclosure comprises a subject including from about 60 min to about 90 min per week of moderate exercise. In some embodiments, a method of the disclosure comprises a subject including from about 90 min to about 120 min per week of moderate exercise. In some embodiments, a method of the disclosure comprises a subject including from about 120 min to about 150 min per week of moderate exercise.
A method of the disclosure can be used to treat a condition. In some embodiments, the condition is a cholesterol-dependent condition. In some embodiments, the condition is a cancer.
In some embodiments, the condition is a cholesterol-dependent cancer. In some embodiments, the condition is a cancer that consumes exogenous cholesterol.
A method of the disclosure can slow the proliferation of cancer cell lines, or kill cancer cells. Non-limiting examples of cancer that can be treated by methods disclosed herein include: acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, AIDS-related cancers, AIDS-related lymphoma, anal cancer, appendix cancer, astrocytomas, basal cell carcinoma, bile duct cancer, bladder cancer, blood cancer, bone cancers, brain tumors, such as cerebellar astrocytoma, cerebral astrocytoma/malignant glioma, ependymoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic glioma, breast cancer, bronchial adenomas, Burkitt lymphoma, carcinoma of unknown primary origin, central nervous system lymphoma, cerebellar astrocytoma, cervical cancer, childhood cancers, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative disorders, colon cancer, cutaneous T-cell lymphoma, desmoplastic small round cell tumor, endometrial cancer, ependymoma, esophageal cancer, Ewing's sarcoma, germ cell tumors, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor, gliomas, hairy cell leukemia, head and neck cancer, heart cancer, hepatocellular (liver) cancer, Hodgkin lymphoma, Hypopharyngeal cancer, intraocular melanoma, islet cell carcinoma, Kaposi sarcoma, kidney cancer, laryngeal cancer, lip and oral cavity cancer, liposarcoma, liver cancer, lung cancers, such as non-small cell and small cell lung cancer, lymphomas, leukemias, macroglobulinemia, malignant fibrous histiocytoma of bone/osteosarcoma, medulloblastoma, melanomas, mesothelioma, metastatic squamous neck cancer with occult primary, mouth cancer, multiple endocrine neoplasia syndrome, myelodysplastic syndromes, myeloid leukemia, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cancer, oropharyngeal cancer, osteosarcoma/malignant fibrous histiocytoma of bone, ovarian cancer, ovarian epithelial cancer, ovarian germ cell tumor, pancreatic cancer, pancreatic cancer islet cell, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal astrocytoma, pineal germinoma, pituitary adenoma, pleuropulmonary blastoma, plasma cell neoplasia, primary central nervous system lymphoma, prostate cancer, rectal cancer, renal cell carcinoma, clear renal cell carcinoma, renal pelvis and ureter transitional cell cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, sarcomas, skin cancers, skin carcinoma merkel cell, small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, T-cell lymphoma, throat cancer, thymoma, thymic carcinoma, thyroid cancer, trophoblastic tumor (gestational), cancers of unknown primary site, urethral cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenström macroglobulinemia, and Wilms tumor.
A method of the disclosure can decrease cancer cell proliferation in a subject. In some embodiments, a therapeutic agent or composition of the disclosure can decrease cancer cell proliferation in a subject by from about 5% to about 10%, from about 10% to about 15%, from about 15% to about 20%, from about 20% to about 25%, from about 25% to about 30%, from about 35% to about 40%, from about 40% to about 45%, from about 45% to about 50%, from about 50% to about 75%, from about 75% to about 100%, from about 100% to about 125%, from about 125% to about 150%, from about 150% to about 175%, or from about 175% to about 200% compared to a subject that is not administered the therapeutic agent or composition of the disclosure. In some embodiments, a therapeutic agent or composition of the disclosure can decrease cancer cell proliferation in a subject by from about 20% to about 25% compared to a subject that is not administered the therapeutic agent or composition of the disclosure. In some embodiments, a therapeutic agent or composition of the disclosure can decrease cancer cell proliferation in a subject by from about 50% to about 75% compared to a subject that is not administered the therapeutic agent or composition of the disclosure.
In some embodiments, a method of the disclosure can decrease cancer cell proliferation in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200% compared to a subject that is not administered the method. In some embodiments, a method of the disclosure can decrease cancer cell proliferation in a subject by about 20% compared to a subject that is not administered the method. In some embodiments, a method of the disclosure can decrease cancer cell proliferation in a subject by about 30% compared to a subject that is not administered the method. In some embodiments, a method of the disclosure can decrease cancer cell proliferation in a subject by about 50% compared to a subject that is not administered the method. In some embodiments, a method of the disclosure can decrease cancer cell proliferation in a subject by about 70% compared to a subject that is not administered the method.
In some embodiments, a method of the disclosure can decrease a tumor size in a subject by from about 5% to about 10%, from about 10% to about 15%, from about 15% to about 20%, from about 20% to about 25%, from about 25% to about 30%, from about 35% to about 40%, from about 40% to about 45%, from about 45% to about 50%, from about 50% to about 75%, from about 75% to about 100%, from about 100% to about 125%, from about 125% to about 150%, from about 150% to about 175%, or from about 175% to about 200%. In some embodiments, a method of the disclosure can decrease a tumor size in a subject by from about 20% to about 25%. In some embodiments, a method of the disclosure can decrease a tumor size in a subject by from about 45% to about 50%.
In some embodiments, a method of the disclosure can decrease a tumor size in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can decrease a tumor size in a subject by about 20%. In some embodiments, a method of the disclosure can decrease a tumor size in a subject by about 30%. In some embodiments, a method of the disclosure can decrease a tumor size in a subject by about 50%.
A method of the disclosure can reduce low-density lipoprotein-cholesterol (LDL-C) levels in a subject's blood. In some embodiments, a method of the disclosure can reduce LDL-C levels in a subject's blood by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can reduce LDL-C levels in a subject's blood by about 10%. In some embodiments, a method of the disclosure can reduce LDL-C levels in a subject's blood by about 20%. In some embodiments, a method of the disclosure can reduce LDL-C levels in a subject's blood by about 30%. In some embodiments, a method of the disclosure can reduce LDL-C levels in a subject's blood by about 50%. In some embodiments, a method of the disclosure can reduce LDL-C levels in a subject's blood by about 75%.
A method of the disclosure can reduce triglyceride levels in a subject's blood. In some embodiments, a method of the disclosure can reduce triglyceride levels in a subject's blood by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can reduce triglyceride levels in a subject's blood by about 10%. In some embodiments, a method of the disclosure can reduce triglyceride levels in a subject's blood by about 20%. In some embodiments, a method of the disclosure can reduce triglyceride levels in a subject's blood by about 30%. In some embodiments, a method of the disclosure can reduce triglyceride levels in a subject's blood by about 50%. In some embodiments, a method of the disclosure can reduce triglyceride levels in a subject's blood by about 75%.
A method of the disclosure can reduce a level of fat in a subject. In some embodiments, a method of the disclosure can reduce a level of fat in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can reduce a level of fat in a subject by about 10%. In some embodiments, a method of the disclosure can reduce a level of fat in a subject by about 20%. In some embodiments, a method of the disclosure can reduce a level of fat in a subject by about 30%. In some embodiments, a method of the disclosure can reduce a level of fat in a subject by about 50%. In some embodiments, a method of the disclosure can reduce a level of fat in a subject by about 75%.
A method of the disclosure can reduce a level of cholesterol in a subject. In some embodiments, a method of the disclosure can reduce a level of cholesterol in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can reduce a level of cholesterol in a subject by about 10%. In some embodiments, a method of the disclosure can reduce a level of cholesterol in a subject by about 20%. In some embodiments, a method of the disclosure can reduce a level of cholesterol in a subject by about 30%. In some embodiments, a method of the disclosure can reduce a level of cholesterol in a subject by about 50%. In some embodiments, a method of the disclosure can reduce a level of cholesterol in a subject by about 75%.
A method of the disclosure can reduce a blood level of fat in a subject. In some embodiments, a method of the disclosure can reduce a blood level of fat in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can reduce a blood level of fat in a subject by about 10%. In some embodiments, a method of the disclosure can reduce a blood level of fat in a subject by about 20%. In some embodiments, a method of the disclosure can reduce a blood level of fat in a subject by about 30%. In some embodiments, a method of the disclosure can reduce a blood level of fat in a subject by about 50%. In some embodiments, a method of the disclosure can reduce a blood level of fat in a subject by about 75%.
A method of the disclosure can reduce a blood level of cholesterol in a subject. In some embodiments, a method of the disclosure can reduce a blood level of cholesterol in a subject by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can reduce a blood level of cholesterol in a subject by about 10%. In some embodiments, a method of the disclosure can reduce a blood level of cholesterol in a subject by about 20%. In some embodiments, a method of the disclosure can reduce a blood level of cholesterol in a subject by about 30%. In some embodiments, a method of the disclosure can reduce a blood level of cholesterol in a subject by about 50%. In some embodiments, a method of the disclosure can reduce a blood level of cholesterol in a subject by about 75%.
A method of the disclosure can increase high-density lipoprotein-cholesterol (HDL-C) levels in a subject's blood. In some embodiments, a method of the disclosure can increase HDL levels in a subject's blood by about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 75%, about 100%, about 125%, about 150%, about 175%, or about 200%. In some embodiments, a method of the disclosure can increase HDL levels in a subject's blood by about 5%. In some embodiments, a method of the disclosure can increase HDL levels in a subject's blood by about 10%. In some embodiments, a method of the disclosure can increase HDL levels in a subject's blood by about 20%. In some embodiments, a method of the disclosure can increase HDL levels in a subject's blood by about 30%. In some embodiments, a method of the disclosure can increase HDL levels in a subject's blood by about 50%.
A method of the disclosure can increase overall survival of a subject. In some embodiments, a method of the disclosure can increase overall survival of a subject by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%. In some embodiments, a method of the disclosure can increase overall survival of a subject by at least about 10%. In some embodiments, a method of the disclosure can increase overall survival of a subject by at least about 20%. In some embodiments, a method of the disclosure can increase overall survival of a subject by at least about 30%.
A method of the disclosure can increase progression free survival of a subject. In some embodiments, a method of the disclosure can increase progression free survival of a subject by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%. In some embodiments, a method of the disclosure can increase progression free survival of a subject by at least about 10%. In some embodiments, a method of the disclosure can increase progression free survival of a subject by at least about 20%. In some embodiments, a method of the disclosure can increase progression free survival of a subject by at least about 30%.
A method of the disclosure can increase percentage of cancer cell death. In some embodiments, a method of the disclosure can increase percentage of cancer cell death by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%. In some embodiments, a method of the disclosure can increase percentage of cancer cell death by at least about 10%. In some embodiments, a method of the disclosure can increase percentage of cancer cell death by at least about 20%. In some embodiments, a method of the disclosure can increase percentage of cancer cell death by at least about 30%.
A method of the disclosure can increase sensitivity to a cancer therapy in a subject. In some embodiments, a method of the disclosure can increase sensitivity to a cancer therapy in a subject by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%. In some embodiments, a method of the disclosure can increase sensitivity to a cancer therapy in a subject by at least about 10%. In some embodiments, a method of the disclosure can increase sensitivity to a cancer therapy in a subject by at least about 20%. In some embodiments, a method of the disclosure can increase sensitivity to a cancer therapy in a subject by at least about 30%.
A method of the disclosure can increase a treatment response rate of a therapeutic agent. In some embodiments, a method of the disclosure can increase a treatment response rate of a therapeutic agent by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95%. In some embodiments, a method of the disclosure can increase a treatment response rate of a therapeutic agent by at least about 10%. In some embodiments, a method of the disclosure can increase a treatment response rate of a therapeutic agent by at least about 20%. In some embodiments, a method of the disclosure can increase a treatment response rate of a therapeutic agent by at least about 30%.
A method of the disclosure can increase the efficacy of an additional therapeutic agent in a subject compared to a subject treated only with the method of the disclosure. In some embodiments, administering a method of the disclosure with a therapeutic agent can increase the efficacy of the therapeutic agent in a subject by at least about at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% compared to a subject treated only with the method of the disclosure. In some embodiments, administering a method of the disclosure with a therapeutic agent can increase the efficacy of the therapeutic agent in a subject by at least about at least about 10% compared to a subject treated only with the method of the disclosure. In some embodiments, administering a method of the disclosure with a therapeutic agent can increase the efficacy of the therapeutic agent in a subject by at least about at least about 20% compared to a subject treated only with the method of the disclosure. In some embodiments, administering a method of the disclosure can increase the efficacy of the therapeutic agent in a subject by at least about at least about 30% compared to a subject treated only with the method of the disclosure.
Administering a method with a therapeutic agent to a subject can have a decreased dose of the therapeutic agent compared to a subject treated with the method alone to achieve the same outcome. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease the required dose of the therapeutic agent by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% compared to a subject treated with the therapeutic agent alone to achieve the same outcome. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease the required dose of the therapeutic agent by at least about 10% compared to a subject treated with the therapeutic agent alone to achieve the same outcome. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease the required dose of the therapeutic agent by at least about 20% compared to a subject treated with the therapeutic agent alone to achieve the same outcome. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease the required dose of the therapeutic agent by at least about 30% compared to a subject treated with the therapeutic agent alone to achieve the same outcome.
Administering a method of the disclosure with a therapeutic agent to a subject can decrease adverse events associated with an additional therapy compared to a subject treated with the additional therapy alone. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease adverse events associated with an additional therapy by at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, or at least about 95% compared to a subject treated with the additional therapy alone. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease adverse events associated with an additional therapy by at least about 10% compared to a subject treated with the additional therapy alone. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease adverse events associated with an additional therapy by at least about 20% compared to a subject treated with the additional therapy alone. In some embodiments, administering a method of the disclosure with a therapeutic agent to a subject can decrease adverse events associated with an additional therapy by at least about 30% compared to a subject treated with the additional therapy alone.
In some embodiments, disclosed herein is a method of identifying gene-expression signature to predict cells, tumors, or subjects that will be most responsive to a treatment method disclosed herein. In some embodiments, disclosed herein is a method of identifying gene-mutation signature to predict cells, tumors, or subjects that will be most responsive to a treatment method disclosed herein. In some embodiments, a method disclosed herein can comprise assessing the expression of genes in the mevalonate pathway. In some embodiments, a method disclosed herein can comprise assessing genes that regulate the mevalonate pathway. In some embodiments, a method disclosed herein can comprise assessing genes that modulate cholesterol uptake or cholesterol transport. In some embodiments, a method disclosed herein can comprise assessing the assessing genes related to Apolipoproteins.
An experiment was designed to assess the growth of cancer cells in the presence of varying doses of statins. The added role of diet was studied by growing cells with statins in the presence or absence of cholesterol.
In human cell culture, cholesterol is supplied by the supplementation of fetal bovine serum (FBS). The amount of cholesterol supplied by the serum is undefined and subject to batch variation. FBS was replaced by supplementing the growth media. RPMI or DMEM with a defined amount of cholesterol, fatty acids, vitamins, minerals and growth factors were used for cell culture, which allowed for completed defined media. Cancer cell growth was measured in complete media containing 56 μM of cholesterol or cholesterol-free media subjected to varying doses of statins.
On Day 1, cells were seeded at a density of around 7500 cells/well in a Corning 96-well flat bottom culture plate in complete media containing 10% FBS. On Day 2, the plates were washed with PBS and test media, and varying doses of statins were added to the wells (
Growth curves showing absorbance of crystal violet at 595 nm or fluorescence of reosurfin at 590 nM were plotted from test wells against the logarithmic statin concentration.
Cells grown in cholesterol-free media exhibited less cell growth than cells grown in complete media. The difference in cell growth was more pronounced for cell lines such as pancreatic PSN1 and PATU8902; lung H358, HCC287, and H292; colorectal DLD1 and SW480; breast T47D and MCF7; head and neck cancers SCC9 and CAL33, indicating an increased dependence on dietary cholesterol for cell proliferation in the cell lines. A significant left-shift was observed when growth curves of cells grown with statins were compared (shown as arrows). The data demonstrate that cells grown in cholesterol free media required a lower dose of statin to kill cells compared to cells grown in complete media. The data indicate that a lack of dietary cholesterol may require reduced statin doses to induce cancer cell death. The combination effect was highly pronounced for the lung cancer cell line H292, and pancreatic cell lines PSN1 and PATU8902. Responses of the cell lines to simvastatin and fluvastatin were similar. The maximum achievable serum concentration of minimum dose of either statin (20 mg) was 0.39 μM. Cell death in all the cell lines were achieved at concentrations lower than the Cmax value. Cell death was observed at the highest concentration of statins (30 μM) for lung cell line A549 and pancreatic cell line PANC1. Overall, the data demonstrate that modulating dietary cholesterol can alter cholesterol biosynthesis, and cholesterol modulation can be used with administration of statins to control cancer cell growth.
NCI-H292 lung cancer cells derived from a cervical node metastasis of a pulmonary mucoepidermoid carcinoma of a 32 year old African-American female were used for the study. The FDA drug library was purchased from Medchem Express. The cells were cultured in RPMI with 10% FBS to 90-100% confluency. One Day 0, spent media was removed from culture, and cells were dissociated using TrypLE. Viable cells were counted with a haemocytometer using Trypan blue and resuspended in fresh media at a concentration of 75000 cells/mL. Using an Integra Mini 96 channel electronic pipette, 100 μL of the cell suspension was plated into each well of a 96-well plate. The plates were incubated overnight at 37° C. at 5% CO2 in a humidified cell culture incubator. On Day 1, spent media was removed and each plate was washed with PBS. Half the plate (48 wells) had 115 μL of Complete media added to each of the wells, while the wells in the other half had 115 μL of cholesterol-free Media without statin (in screening for drug activity modulated by dietary cholesterol only) or with 0.04 μL of simvastatin (in screening for drug activity modulated by decreasing both cholesterol biosynthesis and dietary cholesterol). The concentration of simvastatin used was the minimum dose at which killing was observed in cholesterol free media. The FDA library was so formatted to include each drug twice so each drug could be tested in both media conditions on the same plate, along with negative controls (vehicle) and positive controls (disulfiram+pemetrexed+paclitaxel). 10 μL of each drug solution was added to both complete and experimental media accounting for a final 2 μM of drug concentration in an experimental volume of 125 μL per well. The plates were placed back at 37° C. at 5% CO2 in a humidified cell culture incubator for 4 additional days. On Day 5, spent media was removed and 100 μL of staining solution containing 0.015% crystal violet, 1% formaldehyde and 1% methanol in PBS. 15 minutes later, the plates were washed with tap water and dried to remove any liquid residue. The wells were then treated with 100 μL of 10% acetic acid, and absorbance was read at 595 nm using a Biotek Powerwave Plate Reader. Absorbance at 595 nm was used as a proxy for cell number.
TABLE 1 shows the list of drugs that were tested for anti-cancer activity when paired with cholesterol-free media. TABLE 2 shows the list of drugs tested for anti-cancer activity when paired with cholesterol-free media and a statin (simvastatin). The drugs are listed from strongest to lowest anti-cancer activity. Bolded drugs indicate drugs that worked better in cholesterol-free or cholesterol-free+statin conditions. Normal text indicates drug that showed no difference between cholesterol-free or cholesterol-free+statin conditions. Italicized drugs indicate drugs that worked better in complete media. Drugs with “difference” values greater than 0 exhibited enhanced anti-cancer activity; drugs with “difference” values of about 0 were considered neutral; and drugs with “difference” values below 0 were considered antagonists.
Baclofen
Gestrinone
Sumatriptan (succinate)
Quinidine
Bedaquiline
Topiroxostat
Nefazodone (hydrochloride)
Cephradine
Clindamycin palmitate (hydrochloride)
D-Mannitol
Rimantadine (hydrochloride)
Abiraterone acetate
Meprednisone
Diosmin
Isocarboxazid
Coumarin
Nateglinide
Fluralaner
Ticarcillin (disodium)
Apremilast
Ethambutol (dihydrochloride)
Buclizine (dihydrochloride)
Oxcarbazepine
Indacaterol
Triamterene
Isoniazid
Proglumide
Amezinium (methylsulfate)
Thiabendazole
Megestrol
Cephalothin (sodium)
Levamisole (hydrochloride)
DL-alpha-Tocopherol
Butylphthalide
Amfenac (Sodium Hydrate)
Levobunolol (hydrochloride)
Latanoprostene bunod
Fesoterodine
Amlodipine
Diflunisal
Iopromide
Imiquimod
Guanfacine (hydrochloride)
Niflumic acid
Vemurafenib
Toceranib
Paromomycin (sulfate)
Nebivolol (hydrochloride)
Lecithin
Fluphenazine decanoate
6-Aminocaproic acid
Felbinac
Vinburnine
Alectinib (Hydrochloride)
Ceftibuten (dihydrate)
Mephenesin
Atropine methyl bromide
Acyclovir
Docosahexaenoic Acid
Talniflumate
Cyproheptadine (hydrochloride)
Trospium (chloride)
Sulfamethizole
Acetophenazine (dimaleate)
Menadione
Bekanamycin
Clioquinol
Troglitazone
Tolmetin (sodium dihydrate)
Cinacalcet
Flubendazole
Abacavir
Cyproheptadine (hydrochloride sesquihydrate)
Proxyphylline
Moguisteine
Desfesoterodine
Lobeline (hydrochloride)
DL-Norepinephrine (hydrochloride)
Cinepazide (Maleate)
Piperidolate (hydrochloride)
Josamycin
Trimethoprim
Nicorandil
Pranoprofen
Fesoterodine (L-mandelate)
Ethynyl Estradiol
Midecamycin
Piribedil
Idoxuridine
Amprenavir
Nicergoline
Imidapril (hydrochloride)
Mirogabalin
Itraconazole
Bendazac L-Lysine
Erythromycin estolate
Benzyl benzoate
Ethylparaben
Vigabatrin
L-Glutamine
Esomeprazole magnesium
Choline (chloride)
Orlistat
Amitriptyline (hydrochloride)
Vincamine
Vitamin K1
L-Leucine
Fadrozole
Cevimeline (hydrochloride hemihydrate)
Sacubitril hemicalcium salt
Deoxycorticosterone acetate
Pyridoxal phosphate
Epristeride
Amantadine (hydrochloride)
D-α-Tocopherol acetate
Febuxostat
γ-Oryzanol
Anisindione
Tafamidis
Chlorothiazide
Danoprevir
Gilteritinib
Saquinavir (Mesylate)
Betrixaban
Imatinib (Mesylate)
Ipriflavone
4-Methylumbelliferone
Clorprenaline hydrochloride
Mezlocillin (sodium)
Enzalutamide
Clonixin
Linaclotide
Amodiaquine (dihydrochloride dihydrate)
Clidinium (bromide)
Ampicillin
Dienestrol
Ornidazole
Flecainide (acetate)
Secnidazole
Linoleic acid
Davercin
Meisoindigo
Sulbenicillin (disodium)
Olmesartan medoxomil
Diethylstilbestrol
Chenodeoxycholic Acid
Nimorazole
4-Deoxypyridoxine 5′-phosphate
Vortioxetine
Acetylcholine (chloride)
Phenindione
Magnolol
Rifampicin
Tenofovir (hydrate)
Brigatinib
Diclazuril
Adefovir
Medrysone
Tobramycin
Acemetacin
Lesinurad (sodium)
N-Acetylprocainamide
Fusidic acid (sodium salt)
Quinapril (hydrochloride)
Camostat (mesylate)
Aniracetam
Nevirapine
Diclofenac (diethylamine)
Loteprednol Etabonate
Mupirocin
Furazolidone
Meropenem (trihydrate)
Erdafitinib
Gilteritinib hemifumarate
Rifaximin
Roxithromycin
Budesonide
Cefmetazole (sodium)
Sodium 4-phenylbutyrate
Adapalene
Axitinib
Ribociclib hydrochloride
Hydroxyzine (pamoate)
Obeticholic acid
Empagliflozin
Rosiglitazone (maleate)
Uridine triacetate
Flurbiprofen
D-Sorbitol
Cefoperazone
Selexipag
Voriconazole
Sinomenine hydrochloride
Chlormezanone
Citalopram (hydrobromide)
Squalene
Rucaparib (phosphate)
Emtricitabine
Citicoline
Carbimazole
Prasugrel
Saralasin (TFA)
Erlotinib (Hydrochloride)
Sodium citrate (dihydrate)
Haloperidol
Raloxifene (hydrochloride)
Minocycline (hydrochloride)
Fructose
Dronedarone (Hydrochloride)
Silibinin
Imiquimod (hydrochloride)
Etoricoxib
Bepotastine
Pioglitazone
Eplerenone
Ziprasidone (hydrochloride monohydrate)
Cefadroxil
Maraviroc
Ertugliflozin L-pyroglutamic acid
Pitolisant (hydrochloride)
Darunavir (Ethanolate)
Abiraterone
Merbromin
Ripasudil
Mosapride (citrate)
Guanidine (hydrochloride)
Acalabrutinib
Droxidopa
Dichlorisone acetate
Vonoprazan (Fumarate)
Olmutinib
Articaine (hydrochloride)
Mebendazole
Avibactam (sodium hydrate)
Bretylium (tosylate)
Crizotinib
Mebhydrolin (napadisylate)
Pyrimethamine
Dabrafenib (Mesylate)
Tyloxapol
Simeprevir
Pyrithioxin (dihydrochloride)
Cefpodoxime Proxetil
Norethindrone
Ospemifene
Angiotensin II 5-valine
Osalmid
Tacrine hydrochloride hydrate
Gefitinib (hydrochloride)
Vesnarinone
Lumefantrine
Reboxetine (mesylate)
Nedocromil
Larotrectinib sulfate
Polyvinylpyrrolidone
Sorafenib
Esmolol (hydrochloride)
Amoxicillin
Midodrine (hydrochloride)
Chloroxine
Lysipressin
Broxyquinoline
Bicyclol
Terbinafine
Biperiden (Hydrochloride)
Tetrandrine
Aceclofenac
Eravacycline (dihydrochloride)
Istradefylline
Menthol
DHEA
S-Adenosyl-L-methionine (tosylate)
Afoxolaner
Nitroxoline
Sulbutiamine
Cyclobenzaprine (hydrochloride)
Cyclosporin A
Cysteamine hydrochloride
Amisulpride
Tenapanor
Casanthranol
Edoxaban (tosylate monohydrate)
Vandetanib
Ferulic acid (sodium)
Cefoperazone (sodium salt)
Apronal
Umeclidinium (bromide)
Sertaconazole (nitrate)
Vilazodone
Suplatast (Tosilate)
Benznidazol
Bethanechol (chloride)
Sonidegib
Imidafenacin
Polidocanol
Succinic acid
Cefoselis (sulfate)
Entacapone
Amiloride hydrochloride dihydrate
Oxytetracycline
Edoxaban
Fenspiride (Hydrochloride)
Agomelatine
Alendronate (sodium hydrate)
Micafungin (sodium)
Revaprazan (hydrochloride)
Deoxycholic acid sodium salt
Cilazapril (monohydrate)
Atovaquone
Benzethonium chloride
Ethacrynic acid
Felbamate
Pirenzepine (dihydrochloride)
Cephapirin (sodium)
Pimavanserin
Vanillin
Hydrocortisone
Deflazacort
Nitrofurazone
Cilnidipine
5-Acetylsalicylic acid
Trioxsalen
L-Arginine
Resveratrol
Gatifloxacin
Abemaciclib
Mianserin (hydrochloride)
Dutasteride
Pyrantel (pamoate)
Tenofovir alafenamide hemifumarate
Bendazol
Acetazolamide
Chlorhexidine (digluconate)
Taurine
Pemirolast (potassium)
Nitazoxanide
Amoxicillin (trihydrate)
Bufexamac
Glycerol
Thymopentin (acetate)
Bambuterol hydrochloride
Pasiniazid
Rofecoxib
Ixazomib citrate
Diphenmanil (methylsulfate)
Terconazole
Prasugrel (hydrochloride)
Duloxetine (hydrochloride)
Quizartinib
Prulifloxacin
Oxybuprocaine hydrochloride
Thiamphenicol
Asenapine (hydrochloride)
Crizotinib (hydrochloride)
Triflusal
Bivalirudin (TFA)
Andrographolide
L-Tryptophan
Etofylline
Spectinomycin (dihydrochloride)
Metformin (hydrochloride)
Calcium dobesilate
Fudosteine
Phenytoin
Almitrine mesylate
Metaproterenol (hemisulfate)
Ozagrel (hydrochloride)
Amoxapine
Deprodone propionate
Rifabutin
Belinostat
Pindolol
Bleomycin (hydrochloride)
Albendazole
Oxprenolol (hydrochloride)
Frovatriptan (succinate hydrate)
Atropine (sulfate monohydrate)
Sorafenib (Tosylate)
Fenticonazole (Nitrate)
Norfloxacin
Tamoxifen (Citrate)
Azelastine (hydrochloride)
Rutin
Thioridazine (hydrochloride)
Colistin (sulfate)
Doxorubicin (hydrochloride)
Trimethobenzamide hydrochloride
Iodixanol
Dirithromycin
Tolterodine
Pemetrexed (disodium hemipenta hydrate)
Cladribine
Clavulanate (lithium)
Homatropine (Bromide)
Busulfan
Ganciclovir
Gimeracil
Ensulizole
Dexamethasone
Gentamicin (sulfate)
Rotigotine
Moxisylyte (hydrochloride)
Hydroxyfasudil
Riboflavin Tetrabutyrate
Tolperisone (hydrochloride)
Ropivacaine (hydrochloride)
Flunarizine (dihydrochloride)
Abacavir (sulfate)
Sulconazole (mononitrate)
Vaborbactam
Rilpivirine
Desogestrel
Hydroquinidine
Midostaurin
Estradiol
Terpin (hydrate)
Cefodizime (sodium)
Neratinib
L-Isoleucine
Doravirine
Erdosteine
Flumazenil
Icotinib (Hydrochloride)
Azithromycin
Pyridostigmine (bromide)
Alimemazine hemitartrate
Zafirlukast
Talazoparib tosylate
Alosetron (Hydrochloride)
Moxonidine
D-Fructose
Domiphen (bromide)
Dihydroartemisinin
Cefixime
Histamine
Metipranolol hydrochloride
Melatonin
Methenamine (hippurate)
Pramipexole (dihydrochloride hydrate)
Oxymatrine
Tamoxifen
Amphotericin B
Bosutinib
Sulconazole (nitrate)
Chlorhexidine
Regorafenib (Hydrochloride)
Gliclazide
Bumetanide
Afloqualone
Daclatasvir
Linezolid
Vinblastine (sulfate)
Docetaxel
Ibudilast
Digitoxin
Cepharanthine
Sulfacarbamide
Sulfacetamide (Sodium)
Chlormethine (hydrochloride)
Pyrazinamide
Alpelisib
Rapacuronium bromide
Ioxilan
Quinine (hydrochloride dihydrate)
Donepezil
Ketanserin (tartrate)
Ramosetron (Hydrochloride)
Spironolactone
Pinaverium bromide
Succinylsulfathiazole
Cetylpyridinium (chloride monohydrate)
Tipiracil (hydrochloride)
Pralatrexate
Dexrazoxane (hydrochloride)
Acamprosate (calcium)
Ornipressin
Tricaprilin
Afatinib (dimaleate)
Atorvastatin
Gemcitabine (elaidate)
Menadione bisulfite (sodium)
Ceftizoxime
Methylbenactyzium Bromide
Candesartan
Metoprolol (Succinate)
6α-Methylprednisolone 21-hemisuccinate (sodium salt)
Fruquintinib
Tigecycline (tetramesylate)
Setiptiline (maleate)
Copanlisib (dihydrochloride)
Propafenone (hydrochloride)
Vincristine (sulfate)
Etofenamate
L-Eflornithine (monohydrochloride)
Daclatasvir (dihydrochloride)
Levocetirizine (dihydrochloride)
Inosine
Pazopanib
Rizatriptan (benzoate)
Valdecoxib
Valrubicin
Tizanidine (hydrochloride)
Emetine (dihydrochloride hydrate)
Ifenprodil (tartrate)
Moexipril (hydrochloride)
Stiripentol
Glycopyrrolate
Irinotecan (hydrochloride)
Riluzole
Nintedanib esylate
Chlorobutanol
Emamectin (Benzoate)
Epinastine
Chlorquinaldol
Auranofin
Saccharin
Gadobutrol
Flavoxate (hydrochloride)
Quinidine hydrochloride monohydrate
10-Undecenoic acid
Octenidine (dihydrochloride)
Fluocinolone (Acetonide)
Binimetinib
Ouabain (Octahydrate)
Dicloxacillin (Sodium hydrate)
Benserazide (hydrochloride)
Levomepromazine
Lafutidine
Caffeic acid
Cobimetinib (hemifumarate)
Dobutamine (hydrochloride)
Rilmenidine (phosphate)
Carcainium (chloride)
Podofilox
Zidovudine
Aclacinomycin A hydrochloride
Daunorubicin (Hydrochloride)
Tedizolid (phosphate)
Plicamycin
Pemetrexed
Cabazitaxel
Zinc Pyrithione
Idarubicin (hydrochloride)
Brimonidine
Selpercatinib
Siponimod
AZD7545
Sulfogaiacol
Exemestane
Camptothecin
Ruxolitinib
Pantoprazole (sodium)
Paclitaxel
Salmeterol
Sunitinib
Ixabepilone
Triptolide
Floxuridine
Selamectin
Harringtonine
Triptonide
Epirubicin (hydrochloride)
i-Inositol
D-Tyrosine
Nicardipine (hydrochloride)
Mycophenolate Mofetil
Azaperone
Phenazine (methylsulfate)
Escitalopram (oxalate)
Ceritinib dihydrochloride
Probenecid
Disulfiram
Guaiacol
Propantheline (bromide)
Inulin
Solriamfetol (hydrochloride)
Faropenem sodium
Prednisolone
Daidzein
Fexofenadine (hydrochloride)
Treprostinil (sodium)
Norepinephrine
Buflomedil (hydrochloride)
17-Hydroxyprogesterone
Betaxolol (hydrochloride)
Oxacillin (sodium monohydrate)
Dexamethasone phosphate disodium
Sulfapyridine
Lanatoside C
Puromycin (dihydrochloride)
Clopidogrel
Homoharringtonine
Rucaparib
Cobimetinib (racemate)
Nelfinavir (Mesylate)
Fipexide
Eslicarbazepine
Panobinostat
Diclofenac (potassium)
Ibandronate (Sodium Monohydrate)
Paritaprevir
Hyperoside
Fursultiamine
Topotecan (Hydrochloride)
Tetrahydrozoline (hydrochloride)
Hydrocortisone 17-butyrate
Medroxyprogesterone
Tafamidis meglumine
Zofenopril (calcium)
Metronidazole
Ozanimod
Ampiroxicam
Abemaciclib (methanesulfonate)
Ledipasvir (D-tartrate)
9-Aminoacridine
D-Pantothenic acid (sodium)
Peficitinib
Gemcitabine
Polymyxin B (Sulfate)
Sulfalene
Nadifloxacin
Telbivudine
Imipenem monohydrate
Cetylpyridinium (chloride)
L-Glutamic acid monosodium salt
Valganciclovir (hydrochloride)
Betamethasone
D-Pantothenic acid (hemicalcium salt)
Trimetrexate
Itopride (hydrochloride)
Hemin
Rolapitant
Cinobufotalin
Triamcinolone (acetonide)
Sisomicin (sulfate)
Octisalate
Cefozopran (hydrochloride)
Carbocisteine
Gemcitabine (hydrochloride)
Sulbactam
Milrinone
Baicalin
Ponatinib
Mitoxantrone
Glecaprevir
Indirubin
Beclometasone
Tavaborole
Morinidazole (R enantiomer)
Solriamfetol
Fluocinonide
Dexamethasone acetate
Verteporfin
Nifuroxazide
L-Cysteine (hydrochloride)
Altretamine
Olanzapine
Saxagliptin
Naftidrofuryl (oxalate)
Colchicine
Sertindole
Adefovir dipivoxil
Desipramine hydrochloride
Bisacodyl
Ozagrel
Ruxolitinib (phosphate)
Ondansetron
Vismodegib
Cefditoren (Pivoxil)
Cinoxacin
Clodronate (disodium tetrahydrate)
Ceritinib
Dexmedetomidine (hydrochloride)
Dexchlorpheniramine (maleate)
Triclocarban
Lappaconitine (hydrobromide)
Hydroxocobalamin (monohydrochloride)
Piroctone olamine
Cytarabine
Docetaxel (Trihydrate)
Bosentan
Levoleucovorin (Calcium)
Ethacridine (lactate monohydrate)
DL-Arginine
Methotrexate (disodium)
Isosorbide
Icotinib
Pramiracetam
Hyaluronidase
Rocuronium (Bromide)
Ceftazidime
Carbenoxolone (disodium)
Entrectinib
Osimertinib (dimesylate)
Bleomycin (sulfate)
Evans Blue
Aspartame
Talazoparib
Blonanserin
DL-Methionine
Benzoic acid
Tafenoquine (Succinate)
Roflumilast
Trametinib
Protirelin (Acetate)
Visomitin
Laurocapram
Grazoprevir potassium salt
Cefodizime
Iloperidone
Aripiprazole Lauroxil
Terazosin (hydrochloride dihydrate)
Rifapentine
Cobimetinib
Artemisinin
D-Glucose
Cimetropium (Bromide)
Tolvaptan
Flunisolide
Gadopentetate (dimeglumine)
Fosamprenavir
Fenofibrate
Sonidegib (diphosphate)
Mycophenolic acid
Clevudine
Kasugamycin (hydrochloride hydrate)
Favipiravir
Methicillin (sodium salt)
Temsirolimus
Phenazopyridine (hydrochloride)
Mestranol
Ixazomib
Levosimendan
Telmisartan
Desoximetasone
Ligustrazine (hydrochloride)
Danazol
Selumetinib (sulfate)
Apixaban
Tofacitinib
Omeprazole (sodium)
Ozagrel (sodium)
L-Thyroxine (sodium)
Azasetron (hydrochloride)
Almonertinib (hydrochloride)
Chloramphenicol succinate (sodium)
Flopropione
Lacidipine
2-Ethoxybenzamide
Lapatinib
Miltefosine
Isosulfan blue
Ibrutinib
Toltrazuril
Benztropine (mesylate)
Carboxin
Desonide
Pitavastatin (Calcium)
Natamycin
Estradiol dipropionate
Norvancomycin (hydrochloride)
Diatrizoic acid
Penicillin G Procaine
DL-Glutamine
Vonoprazan
Famotidine
Pralidoxime (iodide)
Tanshinone I
Sofalcone
Dichlorphenamide
Lanolin
Hesperidin
Lisinopril (dihydrate)
Iodipamide
Vancomycin (hydrochloride)
Argatroban (monohydrate)
Parecoxib (Sodium)
Acitretin
Alogliptin (Benzoate)
Lamotrigine
Fimasartan
Manidipine (dihydrochloride)
Nitisinone
Setiptiline
Amenamevir
Gallic acid
Cabozantinib
Dimemorfan (phosphate)
Sitagliptin
Ertugliflozin
Mildronate
Repaglinide
Clindamycin (hydrochloride)
Benzthiazide
Lenampicillin (hydrochloride)
Larotrectinib
Almotriptan (malate)
Diethyltoluamide
Cytarabine (hydrochloride)
Irbesartan
Sodium diatrizoate
Irinotecan
Plerixafor (octahydrochloride)
Fluorometholone
Fumagillin
Glycyrrhizic acid
Rotigotine (Hydrochloride)
Teniposide
Phenacetin
Gatifloxacin (hydrochloride)
Bithionol
Talipexole dihydrochloride
Berberine (chloride)
Pirarubicin (Hydrochloride)
Allantoin
Amikacin (disulfate)
Eperisone (Hydrochloride)
Proguanil
18β-Glycyrrhetinic acid
Bromhexine (hydrochloride)
Acetylleucine
Quetiapine
Mepivacaine
Asunaprevir
Vinpocetine
Pericyazine
Regorafenib
Panaxatriol
Valsartan
Stavudine
Fenoterol (hydrobromide)
D-Panthenol
Eprazinone (dihydrochloride)
Guacetisal
Dabigatran etexilate
Salicylic acid
Grazoprevir
Tetrahydrobiopterin
Etoposide phosphate
LCZ696
Melitracen (hydrochloride)
Temoporfin
Carglumic Acid
Ioversol
Fondaparinux (sodium)
sn-Glycero-3-phosphocholine
Ciclopirox
Delavirdine (mesylate)
Dasatinib (hydrochloride)
Fludarabine (phosphate)
Oxybutynin
Mizoribine
Pranlukast (hemihydrate)
Medetomidine
Vecuronium (bromide)
Iopanoic acid
Trandolapril
Orphenadrine (citrate)
Diflorasone
Pranlukast
Metyrosine
Eicosapentaenoic Acid
L-5-Hydroxytryptophan
Tazobactam
Ramelteon
Irinotecan (hydrochloride trihydrate)
Betaxolol
ATP
Clopidogrel (hydrogen sulfate)
Betahistine
Tedizolid
Ivacaftor
trans-Tranilast
Lenvatinib (mesylate)
Lenvatinib
Lovastatin
Phenothiazine
L-Ornithine (hydrochloride)
Biapenem
Dorzolamide (hydrochloride)
S-Adenosyl-L-methionine (disulfate tosylate)
Crocin
Roxadustat
Fluvoxamine (maleate)
Lipoic acid
Ceftezole (sodium)
Sugammadex (sodium)
Cefaclor
Doxepin (Hydrochloride)
Enfuvirtide (acetate)
6-Mercaptopurine hydrate
Sertraline (hydrochloride)
Miconazole (nitrate)
Oxyphenbutazone
Darifenacin (hydrobromide)
Pimobendan
Gestodene
Miglitol
Sotagliflozin
Glafenine (hydrochloride)
Fosamprenavir (Calcium Salt)
Clemizole (hydrochloride)
Ribavirin
Pregnenolone monosulfate
L-Carnitine
Tazarotene
Tinoridine hydrochloride
Oxaprozin
Dacarbazine
Ciprofibrate
Omeprazole
Sodium gualenate
Pazopanib (Hydrochloride)
Tasimelteon
Povidone iodine
Glafenine
Tenofovir alafenamide fumarate
Phenformin (hydrochloride)
Clonidine (hydrochloride)
L-Methionine
Metadoxine
Clofibrate
Lesinurad
Voglibose
Taurochenodeoxycholic acid
Flavin adenine dinucleotide (disodium salt)
Fasudil (Hydrochloride)
Novobiocin (Sodium)
Norethindrone acetate
Sulfadiazine (sodium)
Pamidronate (disodium pentahydrate)
Fertirelin
Cefamandole (sodium)
Dacomitinib
Lomerizine dihydrochloride
Bromocriptine (mesylate)
Propyphenazone
Taltirelin (acetate)
Deferoxamine (mesylate)
Folinic acid
Fenoldopam (mesylate)
Tigecycline
Methotrexate
Olopatadine (hydrochloride)
Lodoxamide (tromethamine)
Zaltoprofen
Mebrofenin
Bromperidol
Opicapone
Thonzonium (bromide)
Fedratinib (hydrochloride hydrate)
Florfenicol
Ciclopirox (olamine)
Bosentan (hydrate)
4-Phenylbutyric acid
Dimethyl fumarate
Econazole (nitrate)
Idelalisib
Troxerutin
Trimebutine (maleate)
Salbutamol (hemisulfate)
Cefoxitin
Verapamil (hydrochloride)
Bucladesine (calcium)
Safinamide
Thio-TEPA
5-Fluorouracil
Rapamycin
Acetohexamide
Tinidazole
Triprolidine (hydrochloride monohydrate)
Diacerein
Sulfameter
Sodium nitroprusside
Tripelennamine (hydrochloride)
Ledipasvir (acetone)
Acarbose
Silver sulfadiazine
Ilaprazole
L-Epinephrine (Bitartrate)
Perhexiline maleate
Tamsulosin
Stearic acid
Cariprazine (hydrochloride)
Masitinib (mesylate)
Penfluridol
Alfuzosin
Risperidone
Sulfacetamide
Benzyl alcohol
Esaxerenone
Brimonidine (tartrate)
Palmatine (chloride)
L-Ascorbic acid
Dronedarone
Iohexol
Cangrelor (tetrasodium)
Adenosine
Crisaborole
Dihydroergotoxine (mesylate)
Gramicidin
Loperamide (hydrochloride)
Carboprost (tromethamine)
Alpha-Estradiol
Lomustine
Trifluridine
Aminophylline
Nomegestrol acetate
L-Ascorbic acid (sodium salt)
Osimertinib
Lofexidine
Domperidone
Piperacillin (sodium)
Gabapentin enacarbil
Osimertinib mesylate
Memantine (hydrochloride)
Carbazochrome
Sodium 4-aminosalicylate (dihydrate)
Avatrombopag (hydrochloride)
Levodropropizine
Isoconazole (nitrate)
Dasatinib
Laquinimod
α-Lipoic Acid
Disopyramide
Cisatracurium (besylate)
Bupivacaine (hydrochloride)
Mecillinam
Pirmenol (hydrochloride)
Iopamidol
Omadacycline (hydrochloride)
Racanisodamine
Danthron
Lapatinib (ditosylate)
Azelnidipine
Efonidipine (hydrochloride monoethanolate)
Edrophonium (chloride)
Fludarabine
Gabexate (mesylate)
Methacholine (chloride)
L-Thyroxine (sodium salt pentahydrate)
Trifluridine/tipiracil hydrochloride mixture
Quinagolide (hydrochloride)
Alprenolol (hydrochloride)
Naloxegol (oxalate)
Lifitegrast
Doxycycline (hyclate)
Carbidopa
Torsemide
Rasagiline (mesylate)
Diquafosol (tetrasodium)
Azatadine (dimaleate)
DL-Methionine methylsulfonium (chloride)
Cefetamet pivoxil (hydrochloride)
Pamabrom
4-Aminosalicylic acid
Azlocillin (sodium salt)
Sivelestat
Nitrofurantoin
L-Arginine (hydrochloride)
Lenalidomide
Neticonazole
Paliperidone palmitate
Ambrisentan
Leflunomide
Teriflunomide
Hexythiazox
N-Acetyl-L-tyrosine
Mafenide (Acetate)
Amcinonide
Oclacitinib (maleate)
Candesartan Cilexetil
Oseltamivir (phosphate)
Lactulose
Oxytocin (acetate)
Amoxicillin (sodium)
Aripiprazole
Valbenazine
Ajmaline
Dihydroergocristine (mesylate)
Isocorydine
Erlotinib
Uracil
Ombitasvir
Ledipasvir
Lactitol (monohydrate)
Crotamiton
Glucosamine (hydrochloride)
Naratriptan (hydrochloride)
Bulleyaconitine A
Mirtazapine
Neomycin (sulfate)
Nintedanib
Vorinostat
Mepyramine maleate
Amiloride (hydrochloride)
Nicotinamide
Pyrantel (tartrate)
Glycerol phenylbutyrate
Sulfachloropyridazine
Chloropyramine hydrochloride
Mizolastine
Citric acid
Ivosidenib
Arterolane
Atrasentan (hydrochloride)
Hydrocortisone buteprate
Pentamidine (isethionate)
Amifostine
Nikethamide
Sulfaphenazole
Carvedilol
Dimesna
Milnacipran ((1S-cis)hydrochloride)
Methylene blue (trihydrate)
Arotinolol
Dapagliflozin
Ibuprofen piconol
Methylcobalamin
Promazine (hydrochloride)
Retapamulin
Dimercaprol
Tafluprost
Anethole (trithione)
Nabumetone
Clofibric acid
Monocrotaline
Halobetasol (propionate)
Dabrafenib
Paliperidone
Pamidronic acid
Safinamide (mesylate)
Neostigmine (Bromide)
Clobetasone butyrate
Halcinonide
Lercanidipine (hydrochloride)
Berberine (chloride hydrate)
Cefuroxime axetil
Edaravone
Cabozantinib (S-malate)
Atazanavir (sulfate)
Bacampicillin (hydrochloride)
Selumetinib
Carprofen
Nitroprusside (disodium dihydrate)
Propofol
Raltegravir
Salicylanilide
Beclometasone dipropionate
Carteolol hydrochloride
Teriparatide
Tetrahydropalmatine
Tolcapone
Butoconazole (nitrate)
Triflupromazine (hydrochloride)
10-Undecenoic acid (zinc salt)
Cloxacillin (sodium monohydrate)
Peretinoin
Cytisinicline
Ganciclovir (sodium)
Vilazodone carboxylic acid
Diphenhydramine (hydrochloride)
Masitinib
Uridine
Lumacaftor
Oleanolic Acid
Felypressin
Chloroxylenol
Encorafenib
Almonertinib
Xanthinol Nicotinate
Vitamin B12
Pemetrexed (disodium)
Felodipine
Cefuroxime (sodium)
Bismuth subgallate
Captopril
Protriptyline (hydrochloride)
Bepridil hydrochloride
Lenalidomide (hemihydrate)
Mozavaptan
Acetylspiramycin
Baricitinib (phosphate)
Urea
Sulfasalazine
Amsacrine
Dolutegravir
Azathioprine
Mitotane
Prednisone acetate
Indacaterol (maleate)
Aprepitant
Methimazole
Thiamine (hydrochloride)
Helicid
Dihydroergotamine (mesylate)
Butamben
Hydrocortisone acetate
Noscapine
Tromantadine (hydrochloride)
Minoxidil
Carbazochrome (sodium sulfonate)
Aztreonam
Canrenone
Mexiletine (hydrochloride)
Chlorphenesin
Clobetasol propionate
Citric acid (trilithium salt tetrahydrate)
Adiphenine (hydrochloride)
Vorapaxar
Fostamatinib Disodium
Capecitabine
Darolutamide
Dolutegravir (sodium)
Ropivacaine
Tiopronin
Sapropterin (dihydrochloride)
Parecoxib
Varenicline (Hydrochloride)
Choline theophyllinate
Triamcinolone hexacetonide
Phenoxybenzamine (hydrochloride)
Carbinoxamine maleate salt
Rosiglitazone
20(S)-Ginsenoside Rg3
Pergolide (mesylate)
Guaiazulene
Artemotil
Mivacurium (dichloride)
Carbetapentane (citrate)
Moxidectin
Levonorgestrel
Sulfisomidin
Bendamustine (hydrochloride)
Vitamin K4
Regadenoson
Sodium Salicylate
Alectinib
Difluprednate
Idebenone
Eslicarbazepine acetate
Rotundine
Ribociclib succinate hydrate
Carbasalate calcium
Bergenin
Zileuton
Imipramine (hydrochloride)
L-Cysteine
Atorvastatin (hemicalcium salt)
Glutathione oxidized
Pretomanid
Aprotinin
Decamethonium (Bromide)
Levetiracetam
Chlorthalidone
Paroxetine (hydrochloride)
Droperidol
Zalcitabine
Baricitinib
Fipronil
Finafloxacin
Decloxizine (dihydrochloride)
Levamlodipine besylate
Trelagliptin
Sulfathiazole (sodium)
Fosfomycin (sodium)
Gemifloxacin (mesylate)
Bexarotene
Diphenylpyraline (hydrochloride)
Heparin (Lithium salt)
Heparin (Lithium salt)
Fenitrothion
Methylprednisolone
Ribostamycin (sulfate)
Escin
Homatropine (methylbromide)
Amlodipine (maleate)
Estradiol (cypionate)
Alfuzosin (hydrochloride)
Taurochenodeoxycholic acid (sodium salt)
Lidocaine (hydrochloride)
Lamivudine
Fluvastatin (sodium)
Oxiracetam
Loxoprofen (sodium)
Ambroxol
Quetiapine (hemifumarate)
Delamanid
Eflornithine (hydrochloride hydrate)
Riociguat
Sulpiride
Meclocycline (Sulfosalicylate Salt)
Angiotensin II human (acetate)
Zoledronic acid (monohydrate)
Cyclandelate
Everolimus
Nizatidine
Fenoprofen (Calcium hydrate)
Trometamol (hydrochloride)
Diclofenac (Sodium)
Cytidine
Trimethadione
Histamine (phosphate)
Donepezil (Hydrochloride)
Ranolazine (dihydrochloride)
Levofloxacin
Naproxen
Didanosine
Furagin
Ribociclib succinate
Anagliptin
Dabigatran etexilate (mesylate)
Bentiromide
Linagliptin
Tiotropium (Bromide)
Clozapine
Taurodeoxycholic acid (sodium hydrate)
Bucladesine (sodium)
Nifuratel
Anidulafungin
Lefamulin (acetate)
Rupatadine (Fumarate)
Propylthiouracil
Thiamine monochloride
Trilostane
Ferulic acid
Orotic acid
Antazoline (hydrochloride)
Dehydroandrographolide
Rosuvastatin (Calcium)
Flufenamic acid
Inosine pranobex
L-Lysine
Tamibarotene
Ramipril
Raltitrexed
Eliglustat (hemitartrate)
Losartan (potassium)
Ethosuximide
Antipyrine
Methyclothiazide
Pentagastrin
Lanreotide (acetate)
L-Phenylalanine
Methyl Salicylate
Mometasone furoate
Cefdinir
Fesoterodine (fumarate)
Sulfaguanidine
Ritonavir
Lomitapide
Daidzin
Laropiprant
Tiagabine (hydrochloride)
Nedaplatin
Estramustine (phosphate sodium)
Decitabine
Gastrodenol
Metixene hydrochloride hydrate
Doripenem (monohydrate)
Nelfinavir
Oxolamine (citrate)
Bempedoic acid
Oleic acid
Diclofenac
Alibendol
Dehydrocholic acid
Olsalazine (Disodium)
Tolazoline (hydrochloride)
Carmustine
Reldesemtiv
Galanthamine (hydrobromide)
Tolbutamide
Clomiphene (citrate)
Gefitinib
Perindopril (erbumine)
Ramatroban
Aminohippurate (sodium)
L-Lysine hydrochloride
Meticrane
Tegafur
Bepridil (hydrochloride hydrate)
Palbociclib (isethionate)
Valproic acid (sodium salt)
Tegaserod (maleate)
Mequinol
Anagrelide (hydrochloride)
L-Valine
Hydroxyfasudil (hydrochloride)
Loxapine
Thiamine nitrate
Lodoxamide
Pentoxifylline
Tacrolimus (monohydrate)
Meglumine
Nimesulide
L-Hyoscyamine
Tandospirone
Iproniazid (phosphate)
Granisetron (Hydrochloride)
Pinacidil monohydrate
Atenolol
Megestrol acetate
Palbociclib (hydrochloride)
Xylitol
Gadoxetate (Disodium)
Naphazoline (hydrochloride)
Fomepizole
Solifenacin
Carbetocin
Phenylbutazone
Artemether
Tofacitinib (citrate)
Rucaparib (Camsylate)
Vernakalant (Hydrochloride)
Goserelin (acetate)
Pimecrolimus
Liothyronine
Lusutrombopag
Cefotetan
Aclidinium (Bromide)
Tioconazole
Mirodenafil (dihydrochloride)
Cholesterol
Flutamide
Niacin
Ethylenediaminetetraacetic acid (trisodium salt)
Olprinone (Hydrochloride)
Guanabenz (Acetate)
Phenytoin (sodium)
Moclobemide
Bilastine
Heptaminol (hydrochloride)
Fosfomycin (calcium)
Tipranavir
Fedratinib
Diiodohydroxyquinoline
Valpromide
Famciclovir
Tranilast
Daphnetin
Emedastine
Nilvadipine
Puerarin
Desloratadine
Lodenafil
Lurasidone (Hydrochloride)
L-Asparagine
Oxaceprol
Avanafil
Minoxidil sulfate
Dalbavancin (hydrochloride)
Triamcinolone
Sulfadoxine
Riluzole hydrochloride
Pomalidomide
Ethacridine (lactate)
Rufloxacin hydrochloride
Acetohydroxamic acid
Molindone (hydrochloride)
Irsogladine
Cetirizine (dihydrochloride)
Urapidil (hydrochloride)
Meclofenoxate (hydrochloride)
Udenafil
Chloroprocaine (hydrochloride)
Ciclesonide
Losartan
Toremifene (citrate)
Anastrozole
L-Thyroxine
Suprofen
6-Mercaptopurine
Proglumide (sodium)
Pazufloxacin (mesylate)
Lubiprostone
Gallamine Triethiodide
Reserpine
Capsaicin
Guanethidine (sulfate)
Betamethasone dipropionate
Acenocoumarol
Cloperastine (hydrochloride)
Talaporfin (sodium)
Piperonyl butoxide
Allopurinol
Fostamatinib
Oxybenzone
Terbutaline (sulfate)
Bazedoxifene (acetate)
Clebopride (malate)
Fulvestrant
Mesna
Nalfurafine (hydrochloride)
Etoposide
Epalrestat
Valproic acid
Paeonol
Demecarium Bromide
Iotalamic acid
Methocarbamol
Ingenol
Flucloxacillin sodium
Phthalylsulfacetamide
Heparin (sodium salt) (MW 15 kDa)
Heparin (sodium salt) (MW 15 kDa)
Phensuximide
Cefmenoxime (hydrochloride)
β-Pinene
Desvenlafaxine (succinate hydrate)
Loratadine
Benzamil (hydrochloride)
Risedronate (sodium)
Darunavir
Benzocaine
Velpatasvir
Ribociclib
Metronidazole Benzoate
Cefathiamidine
Doxylamine (succinate)
Trimetazidine (dihydrochloride)
Sivelestat (sodium tetrahydrate)
Phenolphthalein
Fludrocortisone acetate
Niraparib
Pioglitazone (hydrochloride)
Boceprevir
Rivaroxaban
Furosemide
Enasidenib
Eliglustat
Eltrombopag
Nadolol
Diroximel fumarate
Tilorone (dihydrochloride)
Gabapentin
Sulfadimethoxine (sodium)
Pipobroman
Deserpidine
Vortioxetine (hydrobromide)
Tropisetron (Hydrochloride)
Delapril (hydrochloride)
Trapidil
Gastrodin
Sacubitril
Cortisone
Levocarnitine propionate (hydrochloride)
Mebhydrolin
Acefylline
Pralidoxime (chloride)
Malotilate
Solifenacin (hydrochloride)
Cefotaxime (sodium salt)
Kalii Dehydrographolidi Succinas
Ingenol Mebutate
Methylergometrine (maleate)
Chloroquine
Berbamine
Bestatin (hydrochloride)
Tandospirone (citrate)
L-Carnitine (hydrochloride)
Sulfanilamide
Ulipristal acetate
Dapoxetine (hydrochloride)
Cinacalcet (hydrochloride)
Trifarotene
Leuprolide (Acetate)
Chlorphenoxamine
Thymol
Abarelix (Acetate)
Medetomidine (hydrochloride)
Ropinirole (hydrochloride)
Temozolomide
Teprenone
Naproxen (sodium)
Moroxydine (hydrochloride)
Sultamicillin (tosylate)
Liothyronine (sodium)
Alizapride hydrochloride
Venlafaxine (hydrochloride)
Talc
Diltiazem (hydrochloride)
Estrone
Dienogest
Besifovir
Trovafloxacin
Dapagliflozin ((2S)-1,2-propanediol, hydrate)
Ibrutinib (Racemate)
Drospirenone
Furosemide (sodium)
Tocofersolan
Pefloxacin (mesylate)
Flupentixol dihydrochloride
D-(+)-Glucono-1,5-lactone
Vilazodone (Hydrochloride)
Efavirenz
Penciclovir
Reserpine (hydrochloride)
Ozenoxacin
Letrozole
Etomidate
Terfenadine
Dithranol
Telotristat ethyl
Otilonium (bromide)
Riboflavin (phosphate sodium)
Eletriptan (hydrobromide)
Pancuronium (dibromide)
Balsalazide
Umifenovir (hydrochloride)
Amlodipine (besylate)
Nortriptyline (hydrochloride)
Prednisolone acetate
Bacitracin
Homosalate
Cilostazol
Dantrolene (sodium hemiheptahydrate)
Tadalafil
Desvenlafaxine
Norgestrel
Salmeterol (xinafoate)
S-(+)-Ketoprofen
Rivastigmine (tartrate)
Benorilate
Butenafine (Hydrochloride)
Levobupivacaine (hydrochloride)
Baicalein
Dinoprost (tromethamine salt)
Perospirone
Nafamostat (mesylate)
Toceranib (phosphate)
Cephalexin
Etodolac
Niclosamide
5-Aminosalicylic Acid
Isosorbide mononitrate
5-Hydroxytryptophan
Cilastatin
Asenapine
Cefprozil (monohydrate)
Avapritinib
Trelagliptin (succinate)
Morinidazole
Xylose
L-Serine
Amifampridine
Galanthamine
Netupitant
Lincomycin (hydrochloride monohydrate)
Ipratropium (bromide)
Dyclonine (hydrochloride)
6-Acetamidohexanoic acid
Lorlatinib
Bifendate
Trometamol
Canagliflozin
Citicoline (sodium)
Bepotastine (besilate)
Bromfenac (sodium)
Ethoxzolamide
Oxybutynin (chloride)
Enalapril (maleate)
Clinofibrate
Primaquine (Diphosphate)
Nifurtimox
Foscarnet (sodium)
Tosufloxacin (tosylate hydrate)
Teneligliptin
Etidronic acid
Artesunate
Lemborexant
Bifonazole
[Sar1, Ile8]-Angiotensin II (TFA)
Valacyclovir (hydrochloride)
Bictegravir
Dimetridazole
Hydroxyzine (dihydrochloride)
Pizotifen
Acipimox
Prednisolone Tebutate
Methylthiouracil
Maprotiline (hydrochloride)
Cloperastine fendizoate
Iguratimod
Carmofur
Doxofylline
Vidarabine
Pimethixene maleate
Netilmicin (sulfate)
Tranylcypromine (hemisulfate)
Angiotensin III (TFA)
5-Azacytidine
Acetylcholine (iodide)
Brexpiprazole
Pirfenidone
Guaifenesin
Menaquinone-4
Icatibant (acetate)
Clofarabine
Pipemidic acid
Tropisetron
Neticonazole (hydrochloride)
Isradipine
Erythromycin Ethylsuccinate
Metyrapone
Capreomycin (sulfate)
Diazoxide
Mirabegron
Sulfadimethoxine
Methylprednisolone succinate
Bromfenac (sodium hydrate)
Sulfinpyrazone
Benidipine (hydrochloride)
Fumaric acid
Ropivacaine (mesylate)
Plerixafor
Pimavanserin tartrate
Ibuprofen
Dicyclomine (hydrochloride)
Estradiol benzoate
Imatinib
Nalidixic acid
Lornoxicam
Clevidipine
Betahistine (mesylate)
Indomethacin (sodium hydrate)
Ofloxacin
Kanamycin (sulfate)
Tolmetin
Mequitazine
Ropivacaine (hydrochloride monohydrate)
Lomefloxacin (hydrochloride)
Vardenafil (hydrochloride)
Apalutamide
Trazodone (hydrochloride)
Solifenacin (Succinate)
Sarpogrelate (hydrochloride)
Ecabet (sodium)
D-Cysteine
Carbamazepine
D-Cycloserine
Roxatidine (Acetate Hydrochloride)
Pantoprazole (sodium hydrate)
Sodium Picosulfate
Eugenol
Etripamil
Benfotiamine
Pramocaine (hydrochloride)
Tenoxicam
Tropicamide
Oxytocin
Quinine
Palonosetron (Hydrochloride)
Isoxsuprine hydrochloride
Quetiapine sulfoxide (dihydrochloride)
Chlortetracycline (hydrochloride)
Fenofibric acid
Daptomycin
Proparacaine (Hydrochloride)
Nimodipine
Nitrendipine
Diethylcarbamazine (citrate)
L-Proline
Phenylephrine
Berbamine (dihydrochloride)
Tofogliflozin (hydrate)
Brivudine
Atosiban (acetate)
Catechin
Lansoprazole
Ilaprazole (sodium)
Maltitol
Glipizide
Dimenhydrinate
Telaprevir
L-Ornithine
Nestoron
Testosterone propionate
Ketoconazole
Amorolfine (hydrochloride)
Cefsulodin (sodium)
Sulfabenzamide
Betahistine (dihydrochloride)
Saquinavir
Meloxicam
Ketoprofen
6-Thioguanine
Progesterone
Hydroxyprogesterone caproate
Fabomotizole (hydrochloride)
Estriol
Estradiol valerianate
Dasabuvir
Fluconazole
Azilsartan
Fluoxetine (hydrochloride)
Glucosamine
Nilotinib
Regorafenib (monohydrate)
Deferiprone
Flibanserin
Aliskiren (hemifumarate)
Piperaquine (tetraphosphate tetrahydrate)
Tolfenamic Acid
Isopropamide (iodide)
Sitagliptin (phosphate monohydrate)
Flucytosine
Bimatoprost
Permethrin
VAL-083
Racecadotril
Sulfisoxazole
Trichlormethiazide
Prednisolone (hemisuccinate)
EC5026
Apraclonidine (hydrochloride)
Vilanterol (trifenatate)
Hydrocortisone cypionate
DL-Menthol
Rimonabant (Hydrochloride)
Ursodiol
Lopinavir
Amlexanox
Castor oil
Chlorzoxazone
Aceglutamide
Fluorometholone acetate
Dexpramipexole (dihydrochloride)
Nefopam (hydrochloride)
Fluspirilene
Valemetostat (tosylate)
Pidotimod
Raltegravir (potassium salt)
Silodosin
Rauwolscine (hydrochloride)
Glimepiride
Ranolazine
Celecoxib
Glasdegib
Propyl gallate
Pargyline (hydrochloride)
Theophylline
α-Vitamin E
Folic acid
Nonivamide
Atropine
Gadodiamide
Letermovir
Chromocarb
Efloxate
Tenofovir (Disoproxil Fumarate)
Finasteride
Tocainide (hydrochloride)
Dolasetron
Diphenidol (hydrochloride)
Cinnarizine
Delafloxacin (meglumine)
Ketorolac (tromethamine salt)
Prucalopride (succinate)
Azaphen (dihydrochloride monohydrate)
Alendronic acid
Sotalol (hydrochloride)
Bephenium (hydroxynaphthoate)
Chlorprothixene
Tivozanib
Halofantrine hydrochloride
Octreotide (acetate)
Metergoline
Fluticasone furoate
Buspirone (hydrochloride)
Lasofoxifene (Tartrate)
Clofazimine
Taltirelin
Topiramate
Bestatin
Benazepril (hydrochloride)
Benfluorex (hydrochloride)
Sulfamethoxazole
Rifamycin (sodium)
Ciprofloxacin
Neostigmine (methyl sulfate)
Oxaliplatin
Amodiaquine (dihydrochloride)
Sitafloxacin (hydrate)
Phenprocoumon
Minaprine (dihydrochloride)
Pentostatin
Levomefolic acid
Trihexyphenidyl (hydrochloride)
Rilmenidine (hemifumarate)
Zanubrutinib
Liranaftate
Dolasetron (Mesylate hydrate)
Praziquantel
Benzydamine (hydrochloride)
Oseltamivir acid
Tetramisole (hydrochloride)
Cephalexin (monohydrate)
Voxelotor
Prednisolone (disodium phosphate)
Clindamycin (phosphate)
Pixantrone (dimaleate)
Hyodeoxycholic acid
Docusate (Sodium)
Sulfadiazine
Alcaftadine
Propranolol (hydrochloride)
Hydralazine (hydrochloride)
Salsalate
Succimer
Gemfibrozil
Sofosbuvir
Ambroxol (hydrochloride)
Deferasirox
Limaprost
L-Lactic acid
Medroxyprogesterone acetate
Pexidartinib (hydrochloride)
Tetrabenazine
Ampicillin (sodium)
Efinaconazole
Aspirin
Milnacipran (hydrochloride)
Peramivir (trihydrate)
Fluorescein
Tetracycline (hydrochloride)
Tacrine (hydrochloride)
Fingolimod (hydrochloride)
Biotin
Procyclidine (hydrochloride)
Albendazole sulfoxide
Ritodrine (hydrochloride)
Pimozide
Gamithromycin
Olmesartan
Chlorprothixene (hydrochloride)
Sophoridine
Quinestrol
Ivabradine (hydrochloride)
Landiolol (hydrochloride)
Bedaquiline (fumarate)
Garenoxacin (Mesylate hydrate)
Cidofovir
Ronidazole
Rimegepant
Acotiamide (monohydrochloride trihydrate)
Ketanserin
Bromisoval
Detomidine (hydrochloride)
Tazemetostat (hydrobromide)
Chondroitin (sulfate)
Chondroitin (sulfate)
Toloxatone
Pravastatin (sodium)
Ruxolitinib (S enantiomer)
Dapsone
Lactose
Latanoprost
Dofetilide
Amrinone
Macitentan
Avobenzone
Camphor
Sulfamonomethoxine
Niraparib (hydrochloride)
Cefoxitin (sodium)
Estropipate
Fingolimod
Sodium stibogluconate
Primidone
Embelin
Levofloxacin (hydrate)
Sulindac
Pivmecillinam (hydrochloride)
Azilsartan medoxomil
Prilocaine
Mefloquine (hydrochloride)
Tenofovir alafenamide
Enoxacin (hydrate)
Etravirine
Dapiprazole (hydrochloride)
Prucalopride
Sulfamerazine
Pramipexole (dihydrochloride)
Metaxalone
Doxifluridine
Atracurium (besylate)
Tazemetostat
Piracetam
Treosulfan
Perflubron
Etamivan
Ethynodiol diacetate
Treprostinil
Procarbazine (Hydrochloride)
Vildagliptin
Gefarnate
Deracoxib
Tolazamide
Lofexidine (hydrochloride)
Isoprenaline (hydrochloride)
Phentolamine (mesylate)
Deferasirox (Fe3+ chelate)
Dipyridamole
Oxantel (pamoate)
Chlorpheniramine (maleate)
Zonisamide
Piperidolate
Telotristat etiprate
Montelukast (sodium)
Flumethasone
Duvelisib
Chlorpropamide
2-(Phosphonooxy)benzoic acid
Canagliflozin (hemihydrate)
Upadacitinib
Benactyzine hydrochloride
Miglustat (hydrochloride)
Procainamide (hydrochloride)
Tucidinostat
Telithromycin
Trimipramine (maleate)
Gabapentin (hydrochloride)
Fosinopril (sodium)
Varenicline (Tartrate)
Ziprasidone
Entecavir (monohydrate)
Bevantolol (hydrochloride)
Prednisone
Prazosin (hydrochloride)
Bronopol
Cefepime (Dihydrochloride Monohydrate)
Sparfloxacin
Nifedipine
Acrivastine
Calcifediol
Nylidrin (hydrochloride)
Santonin
Tolnaftate
Ethamsylate
Migalastat (hydrochloride)
Desoxycorticosterone pivalate
Epinastine (hydrochloride)
Brompheniramine (maleate)
Penicillin G benzathine (tetrahydrate)
Levosulpiride
Anamorelin
Cefazolin
Varenicline
Levobetaxolol (hydrochloride)
Imrecoxib
Fadrozole hydrochloride
Clomipramine (hydrochloride)
Nilotinib (monohydrochloride monohydrate)
Faropenem daloxate
Eprosartan (mesylate)
Drofenine (hydrochloride)
Ranitidine (hydrochloride)
Batilol
Tiratricol
Penicillamine
Oxeladin (citrate)
Asenapine (maleate)
Allylestrenol
Iproniazid
Aristolochic acid A
Glycine
Dropropizine
Cyclopentolate (hydrochloride)
Mozavaptan (hydrochloride)
Flupirtine (Maleate)
Argipressin
Urapidil
Pregnenolone
Teneligliptin (hydrobromide)
Acebutolol (hydrochloride)
Hydrocortisone hemisuccinate
Cefotaxime
Sodium copper chlorophyllin A
Terbinafine hydrochloride
Methazolamide
Methacycline (hydrochloride)
Mifepristone
Luliconazole
Ornidazole (Levo-)
Enalaprilat (dihydrate)
Latrepirdine (dihydrochloride)
Octocrylene
Salicylamide
Iloprost
Venetoclax
Mefenamic acid
Cabergoline
Nelarabine
Methyl aminolevulinate (hydrochloride)
Demeclocycline (hydrochloride)
Xylometazoline (hydrochloride)
Relebactam
Alverine (citrate)
Meclofenamate (sodium)
Posaconazole
Etomidate (hydrochloride)
Tannic acid
Azelaic acid
Bezafibrate
Ebastine
Molsidomine
Rebamipide
Fluticasone (propionate)
Clemastine (fumarate)
Doxazosin (mesylate)
Mepivacaine (hydrochloride)
Rivastigmine
Pyridoxine (hydrochloride)
Enasidenib (mesylate)
Prostaglandin E2
Phenylephrine (hydrochloride)
Prothionamide
Mephenytoin
Vitamin D2
Tulobuterol (hydrochloride)
Tenofovir
Gluconate (sodium)
Metolazone
Niraparib (tosylate)
Sildenafil
Histamine (dihydrochloride)
Cromolyn (sodium)
Indapamide
Tezacaftor
Griseofulvin
Omarigliptin
Nilutamide
Selenomethionine
Dibucaine
Sildenafil (citrate)
Clonidine
Labetalol (hydrochloride)
Serotonin hydrochloride
Acetylcysteine
Metformin
Oritavancin (diphosphate)
Chloroquine (phosphate)
Relugolix
Glibenclamide
Triclabendazole
Choline Fenofibrate
Pheniramine (Maleate)
Tenofovir (Disoproxil)
Conivaptan (hydrochloride)
Gadodiamide (hydrate)
Revefenacin
Indinavir (sulfate)
Deoxycholic acid
Nifenazone
Ethionamide
Ezetimibe
Retinoic acid
Amiodarone (hydrochloride)
Cefazedone
Aliskiren
β-Carotene
Atomoxetine (hydrochloride)
4-(Aminomethyl)benzoic acid
Dydrogesterone
Pramipexole
Gliquidone
Diphylline
L-(−)-α-Methyldopa (hydrate)
Cimetidine
Elbasvir
Suramin (sodium salt)
Troxipide
DL-Xylose
Rabeprazole (sodium)
Isoxicam
Ketotifen (fumarate)
Ceftaroline fosamil
Alarelin (Acetate)
Piroxicam
Fidaxomicin
Osilodrostat
Etretinate
Dibucaine (hydrochloride)
Nepafenac
Idramantone
Penbutolol (sulfate)
Ticagrelor
Olaparib
Oxytetracycline (hydrochloride)
Hydroxychloroquine sulfate
Methoxsalen
Loxapine (succinate)
D-Gluconic acid
Sucrose
Adenine (hemisulfate)
Avibactam (sodium)
Yohimbine (Hydrochloride)
Gluconate (Calcium)
Chlormadinone acetate
Vigabatrin (hydrochloride)
Clarithromycin
Omidenepag isopropyl
5-Aminolevulinic acid (hydrochloride)
Mangafodipir (trisodium)
Ceforanide
Isosorbide dinitrate
Bemegride
Betaine (hydrochloride)
Clotrimazole
Phillyrin
Sulfamethazine
Tranexamic acid
Promestriene
Danofloxacin (mesylate)
Pexidartinib
Lidocaine
L-Cycloserine
Choline (bitartrate)
Hydroxyurea
Cefazolin (sodium)
Moxalactam (sodium salt)
Potassium guaiacolsulfonate (hemihydrate)
Fidarestat
Mitiglinide (Calcium)
Degarelix
DL-Panthenol
Disodium succinate
Indomethacin
Piperacetazine
Elvitegravir
Isavuconazole
Lumateperone (tosylate)
Clofoctol
Zanamivir
Probucol
Ipragliflozin
Monobenzone
Loxoprofen
L-Histidine
Ticlopidine (hydrochloride)
Naftifine (hydrochloride)
Bremelanotide (Acetate)
Triclosan
Cisapride
Thalidomide
Benzbromarone
Tolterodine (tartrate)
L-SelenoMethionine
Spectinomycin (dihydrochloride pentahydrate)
Elagolix sodium
Anamorelin (hydrochloride)
Dicoumarol
Sodium tauroglycocholate
Creatine
Eltrombopag (Olamine)
Fenbufen
Tirofiban (hydrochloride monohydrate)
Adenine
Cholic acid
Naftopidil
Erythromycin
Betamipron
Nafcillin (sodium monohydrate)
Doxapram (hydrochloride hydrate)
Travoprost
Eptifibatide
Alvimopan (dihydrate)
Streptomycin (sulfate)
Ibutilide (fumarate)
Cetrorelix (Acetate)
Spiramycin
Dehydroandrographolide succinate
Fosphenytoin (disodium)
Cholic acid (sodium)
Cortisone acetate
Oxethazaine
Cyproterone acetate
Triflupromazine
Nikethamide
Cepharanthine
Berbamine
Biperiden (Hydrochloride)
Neticonazole
Citicoline
Econazole (nitrate)
Clomiphene (citrate)
Bromperidol
Ebastine
Sulfapyridine
Buflomedil (hydrochloride)
Alendronate (sodium hydrate)
Nateglinide
Oxeladin (citrate)
Oxiconazole nitrate
Berbamine (dihydrochloride)
Butoconazole (nitrate)
Diphenylpyraline
Flecainide (acetate)
D-Mannitol
Meclofenamate (sodium)
Mecillinam
Cefoperazone
Gestrinone
Pazopanib (Hydrochloride)
Sulconazole (nitrate)
Niclosamide
Milrinone
Oleanolic Acid
Tazemetostat
Alverine (citrate)
Amorolfine (hydrochloride)
Toremifene (citrate)
Donepezil
S-Adenosyl-L-methionine
Benzydamine (hydrochloride)
Ketoconazole
Silver sulfadiazine
Dibucaine (hydrochloride)
Isosorbide
Piperidolate
Tazemetostat (hydrobromide)
Pitolisant (hydrochloride)
Riboflavin Tetrabutyrate
Norethindrone
Ifenprodil (tartrate)
Dexamethasone phosphate
disodium
Bufexamac
Guanfacine (hydrochloride)
Tulobuterol (hydrochloride)
Laropiprant
Flupentixol dihydrochloride
LCZ696
Rupatadine (Fumarate)
Oxybuprocaine hydrochloride
Cefadroxil
Meisoindigo
Iproniazid
Loxoprofen (sodium)
Hydroxyzine (dihydrochloride)
L-Ornithine
6-Aminocaproic acid
Phenazopyridine
Fenticonazole (Nitrate)
Dolasetron (Mesylate hydrate)
Luliconazole
Abarelix (Acetate)
Neostigmine (methyl sulfate)
Efinaconazole
Proparacaine (Hydrochloride)
Sertaconazole (nitrate)
Ciclopirox
Noscapine
Molsidomine
Neticonazole (hydrochloride)
D-(+)-Glucono-1,5-lactone
Linoleic acid
Clotrimazole
Ozagrel
Cefazedone
Procarbazine (Hydrochloride)
Minaprine (dihydrochloride)
Isoconazole (nitrate)
Orlistat
Pranlukast
Hydroxocobalamin
Tiratricol
Sulconazole (mononitrate)
Histamine
Amezinium (methylsulfate)
Ticagrelor
Apremilast
Emamectin (Benzoate)
Diiodohydroxyquinoline
Amikacin (disulfate)
Seratrodast
Posaconazole
Elvitegravir
Dobutamine (hydrochloride)
Isavuconazole
Bazedoxifene (acetate)
Pramocaine (hydrochloride)
Amodiaquine (dihydrochloride
dihydrate)
Amoxicillin
Oxybutynin
Miconazole (nitrate)
Cefepime (Dihydrochloride
Monohydrate)
Carbetapentane (citrate)
Amlexanox
Dronedarone
Orphenadrine (citrate)
Terconazole
DL-Xylose
Minocycline (hydrochloride)
Pizotifen
Grazoprevir potassium salt
Carbinoxamine maleate salt
Gamithromycin
Raloxifene (hydrochloride)
Ronidazole
Rifapentine
Methyl aminolevulinate
Canrenone
Gadodiamide
Netilmicin (sulfate)
Perflubron
Bifonazole
Eicosapentaenoic Acid
Dimesna
Alimemazine hemitartrate
Retinoic acid
Tamoxifen
Indacaterol
Chlormethine (hydrochloride)
Sertindole
Amprenavir
Fluorometholone acetate
Piperidolate (hydrochloride)
Teneligliptin
Cariprazine (hydrochloride)
Umifenovir (hydrochloride)
Vandetanib
Anisindione
Valacyclovir (hydrochloride)
Acalabrutinib
Thonzonium (bromide)
Verteporfin
Valpromide
Isradipine
Acarbose
Mephenesin
Daidzein
Ropinirole (hydrochloride)
Avapritinib
Nafcillin (sodium monohydrate)
Estradiol
Pazopanib
Fesoterodine (fumarate)
Prednisolone (disodium
phosphate)
Lodoxamide (tromethamine)
Tioconazole
Alpha-Estradiol
Ceforanide
Doxepin (Hydrochloride)
Brompheniramine (maleate)
Diflorasone
L-Arginine
Tropisetron
Lasofoxifene (Tartrate)
Kalii Dehydrographolidi
Succinas
Temoporfin
Sertraline (hydrochloride)
Fosinopril (sodium)
Medroxyprogesterone
Tocofersolan
Amlodipine
Lovastatin
Pasiniazid
Trimebutine (maleate)
Tenofovir (hydrate)
AZD7545
Atorvastatin (hemicalcium salt)
Bepridil hydrochloride
Loteprednol Etabonate
Carglumic Acid
Lipoic acid
Diphenidol (hydrochloride)
Fomepizole
Aceglutamide
Cyclobenzaprine
Bendazol
Amcinonide
Ramosetron (Hydrochloride)
Bacitracin
Riluzole
Tegafur
Phenylephrine
Bepridil (hydrochloride
hydrate)
Cisatracurium (besylate)
Melitracen (hydrochloride)
Pimavanserin
Amoxicillin (trihydrate)
Salmeterol (xinafoate)
Melatonin
Sulfacetamide (Sodium)
Atorvastatin
Perphenazine
Clozapine
Rosiglitazone
Guaifenesin
Triclabendazole
Rocuronium (Bromide)
Dapagliflozin ((2S)-1,2-
propanediol, hydrate)
Nitisinone
Trazodone (hydrochloride)
Hyodeoxycholic acid
Tannic acid
Fasudil (Hydrochloride)
Cefprozil (monohydrate)
Iopanoic acid
γ-Oryzanol
Etomidate
Doxapram (hydrochloride
hydrate)
Thiabendazole
Fluphenazine decanoate
Primaquine (Diphosphate)
Etretinate
Alfuzosin (hydrochloride)
Naftifine (hydrochloride)
Levomepromazine
Quetiapine (hemifumarate)
Heparin (sodium salt) (MW
15 kDa)
Gastrodenol
Tenofovir
Etomidate (hydrochloride)
L-Thyroxine
Vilazodone (Hydrochloride)
Glucosamine (hydrochloride)
Gadoxetate (Disodium)
Levoleucovorin (Calcium)
Gastrodin
Pantoprazole (sodium hydrate)
Acetophenazine (dimaleate)
Ropivacaine (mesylate)
Valganciclovir (hydrochloride)
Chlorprothixene
Isoniazid
Azelnidipine
Dabrafenib (Mesylate)
Elagolix sodium
Dimercaprol
Plicamycin
Angiotensin II human (acetate)
Prulifloxacin
Naloxegol (oxalate)
Sulfacarbamide
Lubiprostone
Indomethacin
Lorlatinib
Phenformin (hydrochloride)
Sulfacetamide
Ambrisentan
9-Aminoacridine
Lappaconitine (hydrobromide)
Tenoxicam
Fluocinonide
Methylprednisolone
Tafamidis meglumine
Hydrocortisone 17-butyrate
Epristeride
Choline Fenofibrate
Dicoumarol
Salmeterol
Gefarnate
Tivozanib
Ethylparaben
Daclatasvir
Artemether
Isosorbide mononitrate
Dexamethasone
Vinburnine
Sodium stibogluconate
Benzyl alcohol
Dasatinib
Enalapril (maleate)
Arterolane
Camptothecin
Daptomycin
Glasdegib
Iloperidone
Mirodenafil (dihydrochloride)
Sulbactam
Flumethasone
Tamibarotene
Sorafenib
Pramipexole (dihydrochloride
hydrate)
Sodium Picosulfate
Levosulpiride
Abacavir
Carmustine
Eugenol
Clofoctol
Urapidil
Afloqualone
Cyproheptadine (hydrochloride)
Diroximel fumarate
Nimesulide
Cloperastine fendizoate
Deracoxib
Octreotide (acetate)
Oxaliplatin
Sparfloxacin
Esomeprazole magnesium
Zoledronic acid (monohydrate)
Neomycin (sulfate)
Clevudine
Atovaquone
Nylidrin (hydrochloride)
Pimozide
Sodium diatrizoate
Diphenhydramine
Oxolamine (citrate)
Diquafosol (tetrasodium)
Dapsone
Carbetocin
Inosine
Bromfenac (sodium hydrate)
Trimipramine (maleate)
Tazobactam
Dofetilide
DL-Menthol
Cilostazol
Abacavir (sulfate)
Etofylline
Carbazochrome
Amenamevir
Risperidone
Vemurafenib
Fluoxetine (hydrochloride)
Ramelteon
Etodolac
Adenine
Bemegride
Sulfadimethoxine
Spectinomycin (dihydrochloride
pentahydrate)
Eptifibatide
Rufloxacin hydrochloride
Gemifloxacin (mesylate)
Pyrithioxin (dihydrochloride)
Donepezil (Hydrochloride)
Broxyquinoline
Neostigmine (Bromide)
Lefamulin (acetate)
Piperaquine (tetraphosphate
tetrahydrate)
Tipiracil (hydrochloride)
Estropipate
Oxantel (pamoate)
Mepivacaine (hydrochloride)
Toceranib (phosphate)
Morinidazole
Selpercatinib
Solriamfetol (hydrochloride)
Cobimetinib (racemate)
Bempedoic acid
Promazine (hydrochloride)
Protirelin (Acetate)
Apixaban
Doravirine
Clorprenaline hydrochloride
Ribociclib succinate hydrate
Carcainium (chloride)
Potassium guaiacolsulfonate
Desonide
Puerarin
Irinotecan (hydrochloride)
Cloxacillin (sodium
monohydrate)
Hydroxyfasudil (hydrochloride)
Thio-TEPA
Homatropine (Bromide)
Tolazamide
Sacubitril
Dipyridamole
Dienestrol
Brexpiprazole
Tiagabine (hydrochloride)
Mequitazine
Montelukast (sodium)
Hexythiazox
Mometasone furoate
Pentamidine (isethionate)
Roxadustat
Pantoprazole (sodium)
Tiopronin
Quetiapine
Chloroxine
Meloxicam
Crizotinib
Vitamin K4
Pergolide (mesylate)
Loxoprofen
Trapidil
Ingenol Mebutate
Glafenine
Cetylpyridinium (chloride
monohydrate)
Sultamicillin (tosylate)
Promestriene
Niacin
Ciclopirox (olamine)
Clomipramine (hydrochloride)
Mebendazole
Carprofen
Clemastine (fumarate)
Rivastigmine
Clemizole (hydrochloride)
Ribociclib
Betamipron
Fenofibric acid
Solifenacin (hydrochloride)
Ethacrynic acid
Fludrocortisone acetate
Clindamycin (phosphate)
Dydrogesterone
Benidipine (hydrochloride)
Risedronate (sodium)
Pramiracetam
Nitroprusside (disodium
dihydrate)
Buspirone (hydrochloride)
Prucalopride
Temsirolimus
Metyrapone
Valrubicin
Peficitinib
Oseltamivir acid
Aprepitant
Cinnarizine
Halcinonide
Dacomitinib
Fidarestat
Aliskiren (hemifumarate)
D-α-Tocopherol acetate
Vilazodone
Cyproheptadine (hydrochloride
sesquihydrate)
Glecaprevir
Lofexidine (hydrochloride)
pentahydrate)
Ertugliflozin
Dehydroandrographolide
succinate
Dyclonine (hydrochloride)
Oleic acid
Nifuroxazide
Brivudine
Cefaclor
Danofloxacin (mesylate)
Diethylstilbestrol
Mangafodipir (trisodium)
Adenine (hemisulfate)
Avibactam (sodium)
Ornidazole (Levo-)
Isosulfan blue
Tebipenem pivoxil
Bedaquiline
Cortisone acetate
Clevidipine
Troxerutin
Baclofen
Pranlukast (hemihydrate)
Niraparib (hydrochloride)
Allylestrenol
Delapril (hydrochloride)
Anamorelin
Gefitinib
Ilaprazole (sodium)
Loratadine
Emtricitabine
Betamethasone dipropionate
Diazoxide
Tacrolimus (monohydrate)
Loxapine
Cromolyn (sodium)
Brinzolamide
L-Cycloserine
Bumetanide
Rauwolscine (hydrochloride)
Trelagliptin
Vitamin B12
Quinagolide (hydrochloride)
Moxonidine
Gentamicin (sulfate)
Enasidenib (mesylate)
Sodium copper chlorophyllin A
Darolutamide
Clodronate (disodium
tetrahydrate)
Sugammadex (sodium)
Dibucaine
Loxapine (succinate)
Efavirenz
Decloxizine (dihydrochloride)
Bronopol
Ioversol
Toceranib
Allopurinol
Riociguat
Selexipag
Naproxen
Rosuvastatin (Calcium)
Sulbutiamine
Delavirdine (mesylate)
Phenothiazine
Udenafil
Dimenhydrinate
Heparin (Lithium salt)
Tofogliflozin (hydrate)
Nonivamide
Flibanserin
Copanlisib (dihydrochloride)
Ciprofloxacin
Lactulose
Gatifloxacin
Domperidone
Triclosan
Metergoline
Dithranol
Hydrocortisone hemisuccinate
Cetrorelix (Acetate)
Idebenone
Ethylenediaminetetraacetic acid
Capreomycin (sulfate)
Bergenin
Nicorandil
Naftopidil
Phenylbutazone
Mafenide (Acetate)
Methyl Salicylate
Eslicarbazepine acetate
Besifovir
Benztropine (mesylate)
Sivelestat
Ampiroxicam
Erdafitinib
Orotic acid
Medetomidine (hydrochloride)
Bedaquiline (fumarate)
Doxylamine (succinate)
Sonidegib
Prednisone
Talc
Ziprasidone
Flunisolide
Hydrocortisone
Sodium citrate (dihydrate)
Difluprednate
Prostaglandin E2
Ipragliflozin
Cyproterone acetate
Bosutinib
Tedizolid
Finasteride
Zalcitabine
Lumefantrine
Atenolol
Cinacalcet
Hydralazine (hydrochloride)
Trimethadione
Amisulpride
Alendronic acid
Ticlopidine (hydrochloride)
Etripamil
Dronedarone (Hydrochloride)
Netupitant
Chondroitin (sulfate)
Relebactam
Irbesartan
Prothionamide
Guacetisal
Asenapine (hydrochloride)
Vernakalant (Hydrochloride)
Metformin (hydrochloride)
Metipranolol hydrochloride
Cinacalcet (hydrochloride)
Isopropamide (iodide)
Choline (chloride)
Chloropyramine hydrochloride
Clofibric acid
Castor oil
Salsalate
Sulfadiazine
Prednisolone (hemisuccinate)
Clindamycin (hydrochloride)
Leuprolide (Acetate)
Ropivacaine (hydrochloride
monohydrate)
Desvenlafaxine
Xanthinol Nicotinate
Duloxetine (hydrochloride)
Methylene blue (trihydrate)
Beclometasone
Cefditoren (Pivoxil)
Dolutegravir (sodium)
Memantine (hydrochloride)
Ivosidenib
Larotrectinib
Tolperisone (hydrochloride)
Carbimazole
Cefpodoxime Proxetil
Ziprasidone (hydrochloride
monohydrate)
Omidenepag isopropyl
Deprodone propionate
Dolasetron
Lercanidipine (hydrochloride)
Ceftezole (sodium)
Atropine (sulfate monohydrate)
Otilonium (bromide)
Vardenafil (hydrochloride)
Hydroxychloroquine sulfate
Dehydrocholic acid
Buclizine (dihydrochloride)
Rosiglitazone (maleate)
L-Methionine
Lapatinib
Osimertinib
L-Asparagine
Citric acid (trilithium salt
tetrahydrate)
Icotinib
Talazoparib
Flunarizine (dihydrochloride)
Tobramycin
Levobupivacaine
Edrophonium (chloride)
Benzthiazide
Afatinib
Escin
Tucidinostat
Cholic acid
Mitoxantrone (dihydrochloride)
Hydrocortisone buteprate
Bleomycin (sulfate)
Fludarabine (phosphate)
Bambuterol hydrochloride
Faropenem sodium
Pravastatin (sodium)
Oxprenolol (hydrochloride)
Erdosteine
Vinpocetine
Oxytocin (acetate)
Telmisartan
Berberine (chloride)
L-Epinephrine (Bitartrate)
Decitabine
Disodium succinate
Enasidenib
Topiramate
Flupirtine (Maleate)
Salicylanilide
Fluticasone furoate
Alizapride hydrochloride
Sisomicin (sulfate)
Enfuvirtide (acetate)
Escitalopram (oxalate)
Cefoselis (sulfate)
Terfenadine
Propantheline (bromide)
Raltegravir (potassium salt)
Tofacitinib
Tedizolid (phosphate)
Balsalazide
Fingolimod (hydrochloride)
Acitretin
Nilotinib
Nifenazone
Oseltamivir (phosphate)
Desoxycorticosterone pivalate
Almonertinib (hydrochloride)
Latrepirdine (dihydrochloride)
Saralasin (TFA)
Drofenine (hydrochloride)
Bulleyaconitine A
Lactitol (monohydrate)
Haloperidol
Velpatasvir
Homosalate
Erlotinib (Hydrochloride)
Celecoxib
Betaxolol (hydrochloride)
Crizotinib (hydrochloride)
Lesinurad
Valdecoxib
Pemetrexed (disodium)
Lodenafil
Glafenine (hydrochloride)
Azasetron (hydrochloride)
Manidipine (dihydrochloride)
Ibudilast
L-Valine
Maraviroc
Piroctone olamine
Atomoxetine (hydrochloride)
Cetirizine (dihydrochloride)
Mozavaptan (hydrochloride)
Fosamprenavir (Calcium Salt)
Dabigatran etexilate
Clobetasone butyrate
Amiodarone (hydrochloride)
Tolfenamic Acid
Cidofovir
Paeonol
Tinoridine hydrochloride
Tegaserod (maleate)
L-Thyroxine (sodium salt
pentahydrate)
Clidinium (bromide)
Trichlormethiazide
L-Carnitine (hydrochloride)
Entrectinib
Cefuroxime axetil
Benzbromarone
Cinoxacin
Colchicine
Carbasalate calcium
Docetaxel
Selamectin
Pamabrom
Ketanserin
Clobetasol propionate
Trovafloxacin
Diethylcarbamazine (citrate)
Galanthamine (hydrobromide)
Riluzole hydrochloride
L-Thyroxine (sodium)
Ezetimibe
DL-Methionine
Emedastine
Cetylpyridinium (chloride)
Suprofen
Reserpine
Acetohydroxamic acid
Migalastat (hydrochloride)
Thiamine (hydrochloride)
Lincomycin (hydrochloride
monohydrate)
Ketoprofen
Tenapanor
Rimonabant (Hydrochloride)
Lafutidine
L-Histidine
Visomitin
Fenbufen
Yohimbine (Hydrochloride)
Grazoprevir
Trametinib
Nelarabine
Vilanterol (trifenatate)
Nintedanib
Carbocisteine
Spectinomycin
Vanillin
Omeprazole (sodium)
Bisacodyl
Pidotimod
Vilazodone carboxylic acid
Deferiprone
Bosentan (hydrate)
Temocapril (hydrochloride)
Cytisinicline
Gabapentin (hydrochloride)
Chenodeoxycholic Acid
Dexpramipexole
Oxaprozin
Betahistine (mesylate)
Gemcitabine
Toloxatone
Prednisolone Tebutate
Mildronate
Harringtonine
Belotecan (hydrochloride)
Levocarnitine propionate
Batilol
Carbenoxolone (disodium)
Ixabepilone
Halobetasol (propionate)
Indinavir (sulfate)
Chlorquinaldol
Dexchlorpheniramine (maleate)
Pemetrexed (disodium
hemipenta hydrate)
Laquinimod
Eprosartan (mesylate)
Canagliflozin
L-Arginine (hydrochloride)
Trifluridine
Galanthamine
Bezafibrate
Lanatoside C
Idarubicin (hydrochloride)
Sulfadoxine
Delamanid
Aclacinomycin A hydrochloride
Asunaprevir
Paroxetine (hydrochloride)
Benzamil (hydrochloride)
Phentolamine (mesylate)
Cabozantinib
Osalmid
Azaperone
Eravacycline (dihydrochloride)
Propafenone (hydrochloride)
Phenazine (methylsulfate)
Etoricoxib
Pazufloxacin (mesylate)
Tandospirone
DL-Arginine
Ouabain (Octahydrate)
Auranofin
Acamprosate (calcium)
Lenalidomide
Chlorpheniramine (maleate)
Olprinone (Hydrochloride)
Ipriflavone
Panobinostat
Lapatinib (ditosylate)
Lumateperone (tosylate)
Dasatinib (hydrochloride)
Propylthiouracil
Daunorubicin (Hydrochloride)
Demeclocycline (hydrochloride)
Telbivudine
Imatinib
Sulfasalazine
Saxagliptin
Eprazinone (dihydrochloride)
Felbinac
Merbromin
Lenvatinib (mesylate)
Butenafine (Hydrochloride)
Lecithin
Pentoxifylline
Epinastine
Pipemidic acid
Telithromycin
Emetine (dihydrochloride hydrate)
Citric acid
Ibutilide (fumarate)
Chlormadinone acetate
Ensulizole
Pramipexole (dihydrochloride)
Pemetrexed
Labetalol (hydrochloride)
Acetazolamide
Methotrexate
Sacubitril hemicalcium salt
Acefylline
Ganciclovir
Bortezomib
Sulindac
Cinobufotalin
Gemcitabine (hydrochloride)
Proglumide
Phenoxybenzamine
Zanubrutinib
Raltitrexed
Lidocaine (hydrochloride)
Ixazomib
Everolimus
Catechin
L-Glutamine
Capsaicin
Dolutegravir
Ambroxol (hydrochloride)
Tacrine hydrochloride hydrate
Sulpiride
Oxaceprol
Sulfamethizole
Acetylleucine
Flutamide
Varenicline (Tartrate)
Betaxolol
Moclobemide
Nebivolol (hydrochloride)
Anamorelin (hydrochloride)
Pericyazine
Anastrozole
Iopromide
Rucaparib (phosphate)
Meclofenoxate (hydrochloride)
Clebopride (malate)
Piperonyl butoxide
Chlorhexidine
Oxytetracycline (hydrochloride)
Fluspirilene
Bucladesine (calcium)
Dabrafenib
Hemin
Cyclosporin A
Glycerol
Homoharringtonine
Imidafenacin
Vecuronium (bromide)
Nimodipine
Etravirine
Racanisodamine
Pirenzepine (dihydrochloride)
Linagliptin
Ganciclovir (sodium)
Teriparatide
Triptolide
Retapamulin
Sulfogaiacol
Tropicamide
Carboxin
Estradiol valerianate
Pirarubicin (Hydrochloride)
L-Cysteine
Apalutamide
Berberine (chloride hydrate)
Tasimelteon
Sivelestat (sodium tetrahydrate)
Digitoxin
Sofosbuvir
Iodixanol
Rilmenidine (phosphate)
Benzyl benzoate
Pinaverium bromide
Sulfameter
Furazolidone
Triamcinolone
Aniracetam
Vigabatrin
Tetramisole (hydrochloride)
Chloroxylenol
Nefopam (hydrochloride)
Nomegestrol acetate
Deflazacort
Dasabuvir
Tanshinone I
Imipenem monohydrate
Elbasvir
Vincristine (sulfate)
Vismodegib
Gemcitabine (elaidate)
Opicapone
Fadrozole hydrochloride
Nepafenac
Neratinib
Azatadine (dimaleate)
Chlorhexidine (digluconate)
Deferasirox (Fe3+ chelate)
Cefoxitin (sodium)
Amsacrine
Lurasidone (Hydrochloride)
Liranaftate
Pramipexole
Succinylsulfathiazole
Fusidic acid (sodium salt)
Eltrombopag (Olamine)
Amifostine
Ferulic acid (sodium)
Pamidronic acid
Tezacaftor
Regorafenib (Hydrochloride)
Methotrexate (disodium)
Imrecoxib
Penfluridol
Tipranavir
Aprotinin
Sulfachloropyridazine
4-(Aminomethyl)benzoic acid
Cyclic somatostatin
Vorapaxar
Flubendazole
Dichlorphenamide
Succinic acid
Disopyramide
Pitavastatin (Calcium)
Citicoline (sodium)
Paritaprevir
Isocarboxazid
Podofilox
Pheniramine (Maleate)
Granisetron (Hydrochloride)
Paclitaxel
Tazarotene
Levobetaxolol (hydrochloride)
Safinamide
Vesnarinone
Menadione
Adefovir
Dapoxetine (hydrochloride)
Levomefolic acid
Fimasartan
Triamcinolone (acetonide)
Meropenem (trihydrate)
Puromycin (dihydrochloride)
Terazosin (hydrochloride
dihydrate)
Leflunomide
Coumarin
Amfenac (Sodium Hydrate)
Nestoron
Adefovir dipivoxil
Bismuth subgallate
Ceritinib
Methacholine (chloride)
Fluvoxamine (maleate)
Pregnenolone monosulfate
Tenofovir alafenamide fumarate
Gilteritinib
Fipronil
Blonanserin
Vincamine
Icotinib (Hydrochloride)
Pargyline (hydrochloride)
5-Azacytidine
Zinc Pyrithione
Diclofenac (potassium)
Travoprost
Furosemide (sodium)
Sofalcone
Meglumine
Gadopentetate (dimeglumine)
Dichlorisone acetate
Latanoprost
Doxifluridine
Cytarabine (hydrochloride)
Tolterodine (tartrate)
Stiripentol
Moguisteine
Encorafenib
Ozagrel (sodium)
Cobimetinib
Methenamine (hippurate)
Rotigotine
Cabazitaxel
Furagin
Quinidine hydrochloride
monohydrate
Clofazimine
Verapamil (hydrochloride)
Isocorydine
Domiphen (bromide)
Flopropione
Aminophylline
Vigabatrin (hydrochloride)
Palbociclib (isethionate)
Palmatine (chloride)
Ibrutinib (Racemate)
L-Ascorbic acid (sodium salt)
Perhexiline maleate
Ramipril
Rivastigmine (tartrate)
Nitrendipine
i-Inositol
Perospirone
Mitoxantrone
Milnacipran (hydrochloride)
Ponatinib
Floxuridine
Erlotinib
Naftidrofuryl (oxalate)
L-Ornithine (hydrochloride)
Indomethacin (sodium hydrate)
Pomalidomide
Torsemide
Tavaborole
Norepinephrine
Nintedanib esylate
Esaxerenone
Secnidazole
Ranolazine (dihydrochloride)
Levobunolol (hydrochloride)
Salicylamide
Ombitasvir
Sildenafil (citrate)
Methyclothiazide
Mirtazapine
Fludarabine
Diclofenac (diethylamine)
Clopidogrel
Triclocarban
Olsalazine (Disodium)
Naphazoline (hydrochloride)
Flavoxate (hydrochloride)
Degarelix
Revaprazan (hydrochloride)
Dimemorfan (phosphate)
Embelin
Dexmedetomidine (hydrochloride)
Sodium gualenate
Letermovir
Doxorubicin (hydrochloride)
Ondansetron
Triflusal
Rolapitant
Medroxyprogesterone acetate
6α-Methylprednisolone 21-
hemisuccinate (sodium salt)
Nilotinib (monohydrochloride
monohydrate)
Dirithromycin
Imipramine (hydrochloride)
4-Methylumbelliferone
Vancomycin (hydrochloride)
Fosamprenavir
Rizatriptan (benzoate)
Alibendol
Tigecycline (tetramesylate)
Cytarabine
Alprenolol (hydrochloride)
Sulfisoxazole
N-Acetylprocainamide
Diclazuril
Sotalol (hydrochloride)
Milnacipran ((1S-cis)
hydrochloride)
Tenofovir alafenamide
Tosufloxacin (tosylate hydrate)
Nitrofurantoin
Dicyclomine (hydrochloride)
Gefitinib (hydrochloride)
Cefsulodin (sodium)
Ruxolitinib
Tadalafil
Troglitazone
Benserazide (hydrochloride)
Mefloquine (hydrochloride)
Boceprevir
Cefathiamidine
5-Aminolevulinic acid
Osimertinib (dimesylate)
Vitamin D2
Dimethyl fumarate
L-5-Hydroxytryptophan
Bleomycin (hydrochloride)
Rimantadine (hydrochloride)
Nicotinamide
Dexamethasone acetate
DL-alpha-Tocopherol
Novobiocin (Sodium)
Biotin
Molindone (hydrochloride)
Lornoxicam
Disulfiram
Trioxsalen
Acyclovir
Hydroxyfasudil
Masitinib (mesylate)
Tacrine (hydrochloride)
Phenacetin
Sorafenib (Tosylate)
Phenytoin
Mycophenolate Mofetil
Levetiracetam
Estradiol (cypionate)
Azlocillin (sodium salt)
4-Aminosalicylic acid
Detomidine (hydrochloride)
Ticarcillin (disodium)
Ingenol
Iproniazid (phosphate)
Monobenzone
Topotecan (Hydrochloride)
Raltegravir
Erythromycin Ethylsuccinate
Simeprevir
Ivacaftor
Gabapentin
Acebutolol (hydrochloride)
L-Carnitine
Natamycin
Almitrine mesylate
Ciclesonide
L-SelenoMethionine
Tafenoquine (Succinate)
Tenofovir alafenamide
hemifumarate
Docetaxel (Trihydrate)
Taltirelin (acetate)
Acipimox
Benazepril (hydrochloride)
Zafirlukast
Bacampicillin (hydrochloride)
Cefmenoxime (hydrochloride)
Fulvestrant
Deoxycorticosterone acetate
Belinostat
Avibactam (sodium hydrate)
Cefotaxime
Creatine
Cefuroxime (sodium)
Azaphen (dihydrochloride
monohydrate)
Josamycin
Primidone
Rufinamide
Ceftaroline fosamil
Bilastine
Resveratrol
Peramivir (trihydrate)
Avatrombopag (hydrochloride)
Minoxidil sulfate
18β-Glycyrrhetinic acid
Davercin
Quinine
Alosetron (Hydrochloride)
Pralatrexate
EC5026
Acetohexamide
Ethacridine (lactate)
Mebhydrolin
Sulfaphenazole
Gabapentin enacarbil
Trifarotene
Telotristat etiprate
Ursodiol
17-Hydroxyprogesterone
Sildenafil
Trimetrexate
Mosapride (citrate)
Mianserin (hydrochloride)
Bifendate
Ozenoxacin
Fostamatinib (disodium
hexahydrate)
Linaclotide
Bexarotene
Eperisone (Hydrochloride)
Quetiapine sulfoxide
Selumetinib (sulfate)
Baricitinib (phosphate)
Saccharin
Efonidipine (hydrochloride
monoethanolate)
Cloperastine (hydrochloride)
Diosmin
Ritodrine (hydrochloride)
Tyloxapol
Dabigatran etexilate (mesylate)
Prasugrel
Avobenzone
Miglustat (hydrochloride)
D-Gluconic acid
Metronidazole Benzoate
Estriol
Choline theophyllinate
Faropenem daloxate
Mesna
Xylose
Rofecoxib
Metadoxine
Trametinib (DMSO solvate)
Vinblastine (sulfate)
Hydroxyzine (pamoate)
Gemfibrozil
Binimetinib
Osilodrostat
Salicylic acid
Octisalate
Olmutinib
Dihydroergocristine (mesylate)
Chloramphenicol succinate
Articaine (hydrochloride)
Benzoic acid
Venetoclax
Pemirolast (potassium)
Cisapride
Prednisolone acetate
Danazol
Cangrelor (tetrasodium)
Fostamatinib Disodium
Rasagiline (mesylate)
Sitagliptin
Irinotecan (hydrochloride
trihydrate)
Felypressin
Piracetam
Didanosine
Pralidoxime (iodide)
α-Lipoic Acid
L-Lysine hydrochloride
Ixazomib citrate
Polyvinylpyrrolidone
Fesoterodine (L-mandelate)
Roxatidine (Acetate
Hydrochloride)
Sotagliflozin
S-Adenosyl-L-methionine
Thiamphenicol
Lesinurad (sodium)
Methylergometrine (maleate)
Ozagrel (hydrochloride)
Indacaterol (maleate)
Terbinafine hydrochloride
Olopatadine (hydrochloride)
Pirmenol (hydrochloride)
Trifluridine/tipiracil
hydrochloride mixture
Terbinafine
Telotristat ethyl
Mexiletine (hydrochloride)
Mefenamic acid
Artesunate
Febuxostat
D-Sorbitol
Solifenacin (Succinate)
Selenomethionine
Levofloxacin (hydrate)
Omadacycline (hydrochloride)
Osimertinib mesylate
Anagliptin
Ethoxzolamide
Levosimendan
Ivabradine (hydrochloride)
Vildagliptin
Gadodiamide (hydrate)
Pixantrone (dimaleate)
Kanamycin (sulfate)
Nifedipine
Idramantone
Dacarbazine
Tricaprilin
Darifenacin (hydrobromide)
Prucalopride (succinate)
Povidone iodine
Azilsartan medoxomil
Antipyrine
Bivalirudin (TFA)
Aceclofenac
Tetrahydrozoline (hydrochloride)
Thioridazine (hydrochloride)
Masitinib
Saquinavir (Mesylate)
Cladribine
Rotigotine (Hydrochloride)
DL-Panthenol
Fluvastatin (sodium)
Nitroxoline
Obeticholic acid
Levamlodipine besylate
Panaxatriol
Cefazolin
Bicalutamide
Clonidine (hydrochloride)
Ceritinib dihydrochloride
Riboflavin (phosphate sodium)
N-Acetyl-L-tyrosine
Cinepazide (Maleate)
Telaprevir
Progesterone
Tropisetron (Hydrochloride)
Tirofiban (hydrochloride
monohydrate)
Perindopril (erbumine)
Clofibrate
Biapenem
Atazanavir (sulfate)
Hydroxyprogesterone caproate
Camphor
Pexidartinib (hydrochloride)
Mirabegron
Epirubicin (hydrochloride)
Glycyrrhizic acid
Toltrazuril
Fluticasone (propionate)
Latanoprostene bunod
Fingolimod
Kasugamycin (hydrochloride
hydrate)
Silodosin
Acetylspiramycin
Dicloxacillin (Sodium hydrate)
Amitriptyline (hydrochloride)
Nizatidine
Ibrutinib
Macitentan
Cysteamine hydrochloride
Liothyronine
Ethosuximide
Lenampicillin (hydrochloride)
Glutathione oxidized
Fruquintinib
Pyrazinamide
Epalrestat
Caffeic acid
Teprenone
Entacapone
Midostaurin
Trelagliptin (succinate)
Naproxen (sodium)
Florfenicol
6-Mercaptopurine
Thiamine monochloride
Arotinolol
Talaporfin (sodium)
Rivaroxaban
Isoprenaline (hydrochloride)
Itraconazole
Cefonicid (sodium)
Landiolol (hydrochloride)
Aclidinium (Bromide)
Phillyrin
Pentagastrin
Methimazole
Mizoribine
Eltrombopag
Lifitegrast
Benorilate
Oxethazaine
2-Ethoxybenzamide
Amiloride (hydrochloride)
Almonertinib
Clindamycin palmitate
Oclacitinib (maleate)
Darunavir
Cefotaxime (sodium salt)
Conivaptan (hydrochloride)
Roxithromycin
Revefenacin
Fudosteine
Alogliptin (Benzoate)
Trometamol
Lemborexant
Betamethasone
Imatinib (Mesylate)
Quinine (hydrochloride dihydrate)
Levodropropizine
Ranolazine
Efloxate
Bestatin (hydrochloride)
Empagliflozin
Clarithromycin
Terbutaline (sulfate)
Pimavanserin tartrate
Ramatroban
Prazosin (hydrochloride)
Hesperidin
Cortisone
Oxytocin
Hyperoside
Mizolastine
Hydrocortisone acetate
Rifaximin
Ethamsylate
Afatinib (dimaleate)
Laurocapram
Piperacetazine
Tamoxifen (Citrate)
Rebamipide
Polidocanol
Metolazone
Azilsartan
Octocrylene
Benfotiamine
Doripenem (monohydrate)
Ribociclib hydrochloride
Theophylline
Ambroxol
Lopinavir
Glibenclamide
Morinidazole (R enantiomer)
Artemotil
Cefmetazole (sodium)
Gatifloxacin (hydrochloride)
Esmolol (hydrochloride)
Nalfurafine (hydrochloride)
Bendazac L-Lysine
L-Ascorbic acid
Reboxetine (mesylate)
Ceftibuten (dihydrate)
Diltiazem (hydrochloride)
Clioquinol
Plerixafor
Sulfamethazine
Fosfomycin (sodium)
Fenitrothion
Temozolomide
Pamidronate (disodium
pentahydrate)
Alfuzosin
Idoxuridine
Sapropterin (dihydrochloride)
Griseofulvin
Lusutrombopag
Delafloxacin (meglumine)
Procyclidine (hydrochloride)
Xylitol
Menadione bisulfite (sodium)
Amiloride hydrochloride dihydrate
Bephenium (hydroxynaphthoate)
Cilazapril (monohydrate)
Bromisoval
Pefloxacin (mesylate)
Imiquimod (hydrochloride)
Monocrotaline
Bekanamycin
Prasugrel (hydrochloride)
Moroxydine (hydrochloride)
Spiramycin
Calcifediol
Danthron
L-Hyoscyamine
Phenprocoumon
Tafluprost
Moxisylyte (hydrochloride)
Aspartame
Sulbenicillin (disodium)
Ozanimod
6-Mercaptopurine hydrate
Sulfinpyrazone
Bupivacaine (hydrochloride)
Menthol
Paromomycin (sulfate)
Tetrandrine
Deoxycholic acid sodium salt
Lenvatinib
Miglitol
Garenoxacin (Mesylate hydrate)
Cefodizime
Nimustine (hydrochloride)
Carmofur
2-(Phosphonooxy)benzoic acid
Eliglustat (hemitartrate)
Aminohippurate (sodium)
Upadacitinib
Helicid
Hexylresorcinol
Penicillamine
Lanreotide (acetate)
Diacerein
Metixene hydrochloride hydrate
Omeprazole
Crotamiton
Desfesoterodine
Propyl gallate
Altretamine
Thalidomide
Sulfamethoxazole
Sitagliptin (phosphate
monohydrate)
Casanthranol
Butylphthalide
Chlorphenesin
Acetylcholine (iodide)
Phenindione
Foscarnet (sodium)
Cefotetan
Ketorolac (tromethamine salt)
Folic acid
Docusate (Sodium)
Brimonidine
Alcaftadine
Asenapine (maleate)
Azithromycin
Moxidectin
Isosorbide dinitrate
Tranylcypromine (hemisulfate)
Flurbiprofen
Pivmecillinam (hydrochloride)
Fluocinolone (Acetonide)
Ropivacaine
Dihydroergotamine (mesylate)
Ornidazole
Taurochenodeoxycholic acid
Amoxicillin (sodium)
Hexaminolevulinate
VAL-083
Azathioprine
Amantadine (hydrochloride)
Tinidazole
Ceftizoxime
Tolnaftate
L-Serine
Vidarabine
Dalbavancin (hydrochloride)
Tranilast
Estramustine (phosphate sodium)
Pimethixene maleate
L-Leucine
Fluorometholone
Cilnidipine
Proguanil
Chlorpropamide
Tamsulosin
Decamethonium (Bromide)
Acetylcholine (chloride)
Repaglinide
Treosulfan
Meclocycline (Sulfosalicylate Salt)
Streptomycin (sulfate)
Trimetazidine (dihydrochloride)
Ertugliflozin L-pyroglutamic acid
Nilvadipine
Pyrimethamine
Saquinavir
Amlodipine (besylate)
Bendamustine (hydrochloride)
Reldesemtiv
Atropine methyl bromide
Sonidegib (diphosphate)
D-Cycloserine
Zanamivir
Tizanidine (hydrochloride)
Evans Blue
Liothyronine (sodium)
Doxycycline (hyclate)
Pexidartinib
Sodium 4-phenylbutyrate
Chlorothiazide
Olmesartan
Irsogladine
Sulfabenzamide
Cytidine
Antazoline (hydrochloride)
Cyclopentolate (hydrochloride)
Fenspiride (Hydrochloride)
Dipotassium glycyrrhizinate
Ruxolitinib (phosphate)
Linezolid
Teniposide
Iloprost
Levofloxacin
Fenoprofen (Calcium hydrate)
Stavudine
L-Lactic acid
Metoprolol (Succinate)
Dihydroartemisinin
Betaine (hydrochloride)
Setiptiline
Eplerenone
Squalene
4-Phenylbutyric acid
Penicillin G benzathine
L-Phenylalanine
Rimegepant
Diphylline
Cephalothin (sodium)
Bucladesine (sodium)
Prednisolone
Tolbutamide
Benactyzine hydrochloride
Ethynyl Estradiol
Angiotensin III (TFA)
Entecavir (monohydrate)
Fluralaner
Serotonin hydrochloride
Alectinib (Hydrochloride)
Ropivacaine (hydrochloride)
Valsartan
Methazolamide
Bictegravir
Safinamide (mesylate)
Etoposide phosphate
Piribedil
Bromocriptine (mesylate)
Eflornithine (hydrochloride
hydrate)
Oxybutynin (chloride)
Cefodizime (sodium)
Bepotastine
L-Cysteine (hydrochloride)
Cobimetinib (hemifumarate)
Betahistine
Diethyltoluamide
Lumacaftor
Daidzin
Bentiromide
Baicalin
Pyridoxal phosphate
Nedaplatin
Thiamine nitrate
Varenicline (Hydrochloride)
Brigatinib
Sulfaguanidine
Glimepiride
Candesartan Cilexetil
Cefetamet pivoxil (hydrochloride)
Magnolol
Losartan (potassium)
Probucol
Sulfalene
Sodium nitroprusside
Methylthiouracil
Fosfomycin (calcium)
Guanidine (hydrochloride)
5-Aminosalicylic Acid
Fluorescein
Ligustrazine (hydrochloride)
Axitinib
Apronal
Colistin (sulfate)
Aspirin
Pimecrolimus
Erythromycin
Dienogest
Calcium dobesilate
Isoxsuprine hydrochloride
Crocin
Methylprednisolone succinate
Daphnetin
Oritavancin (diphosphate)
Ripasudil
Avanafil
Penbutolol (sulfate)
Chlorzoxazone
S-(+)-Ketoprofen
Uridine triacetate
Regorafenib
Droxidopa
Amrinone
Metaproterenol (hemisulfate)
Ecabet (sodium)
Tolcapone
Quizartinib
Guanabenz (Acetate)
Ofloxacin
Tranexamic acid
Furosemide
Etoposide
Succimer
Isoxicam
Azelastine (hydrochloride)
Asenapine
Edoxaban (tosylate monohydrate)
Trihexyphenidyl (hydrochloride)
Palbociclib (hydrochloride)
4-Deoxypyridoxine 5′-phosphate
Cefdinir
Zonisamide
Betahistine (dihydrochloride)
Glipizide
Heptaminol (hydrochloride)
Mitotane
Trandolapril
Naratriptan (hydrochloride)
Flufenamic acid
Cyclandelate
Eslicarbazepine
Fabomotizole (hydrochloride)
Treprostinil (sodium)
Sinomenine hydrochloride
Nimorazole
Flavin adenine dinucleotide
Valproic acid
Edoxaban
Rutin
Larotrectinib sulfate
D-Glucose
Mycophenolic acid
Clopidogrel (hydrogen sulfate)
Phensuximide
Chlorthalidone
Voriconazole
Tilorone (dihydrochloride)
Ampicillin (sodium)
Ketanserin (tartrate)
Tetrahydropalmatine
Santonin
Benfluorex (hydrochloride)
Voglibose
Polymyxin B (Sulfate)
Mirogabalin
Amifampridine
Thymol
Istradefylline
Fertirelin
Finafloxacin
Docosahexaenoic Acid
Icatibant (acetate)
[Sar1, Ile8]-Angiotensin II (TFA)
Dropropizine
Carbamazepine
D-Fructose
Tofacitinib (citrate)
Olanzapine
Candesartan
Lanolin
Cholic acid (sodium)
trans-Tranilast
Aripiprazole
Deserpidine
Pancuronium (dibromide)
Tolazoline (hydrochloride)
Nalidixic acid
Zileuton
Vorinostat
L-Tryptophan
Valproic acid (sodium salt)
D-Cysteine
5-Hydroxytryptophan
Cabergoline
Cefoperazone (sodium salt)
Carteolol hydrochloride
Ceftazidime
Tetrabenazine
Loperamide (hydrochloride)
Atrasentan (hydrochloride)
Racecadotril
Acetylcysteine
Fenofibrate
Phenolphthalein
Chlorobutanol
Reserpine (hydrochloride)
Guanethidine (sulfate)
Limaprost
Ribavirin
Favipiravir
Guaiazulene
Taltirelin
Argatroban (monohydrate)
Felodipine
Benzethonium chloride
D-Pantothenic acid (sodium)
Sodium Salicylate
Cefixime
ATP
Pentostatin
Pioglitazone (hydrochloride)
Felbamate
Tromantadine (hydrochloride)
Nifurtimox
Miltefosine
Probenecid
Inulin
Meprednisone
Albendazole
Goserelin (acetate)
Indapamide
Nafamostat (mesylate)
Acotiamide (monohydrochloride
trihydrate)
D-Panthenol
Parecoxib
Albendazole sulfoxide
Gabexate (mesylate)
Setiptiline (maleate)
Gadobutrol
Iodipamide
Talniflumate
Tocainide (hydrochloride)
Nortriptyline (hydrochloride)
Estradiol benzoate
Talipexole dihydrochloride
Inosine pranobex
Trilostane
Proglumide (sodium)
Pindolol
Lomitapide
Rifabutin
6-Acetamidohexanoic acid
Medrysone
Oxybenzone
Palonosetron (Hydrochloride)
Fenoldopam (mesylate)
Valemetostat (tosylate)
Prilocaine
Sulfadiazine (sodium)
Darunavir (Ethanolate)
β-Pinene
Amphotericin B
Baicalein
Aztreonam
Atracurium (besylate)
Deferasirox
Clinofibrate
Drospirenone
Mitiglinide (Calcium)
Lodoxamide
Ruxolitinib (S enantiomer)
Fedratinib (hydrochloride
hydrate)
Mezlocillin (sodium)
Levocetirizine (dihydrochloride)
Terpin (hydrate)
Proxyphylline
Droperidol
Rotundine
Glycine
Hyaluronidase
Metronidazole
Sulfamonomethoxine
Relugolix
Mestranol
Diclofenac
Fidaxomicin
Fumagillin
Lofexidine
Alvimopan (dihydrate)
Oxacillin (sodium monohydrate)
Imiquimod
Indirubin
Erythromycin estolate
Trimethoprim
Bestatin
Mephenytoin
Vonoprazan (Fumarate)
Solifenacin
Selumetinib
Hydroquinidine
Anagrelide (hydrochloride)
5-Fluorouracil
Dapiprazole (hydrochloride)
Sophoridine
Gliclazide
Cimetropium (Bromide)
Clonixin
Atropine
Fumaric acid
Dexrazoxane (hydrochloride)
Nifuratel
Doxofylline
Fesoterodine
Beclometasone dipropionate
Flucytosine
Pinacidil monohydrate
Vortioxetine (hydrobromide)
Medetomidine
Folinic acid
Chloroprocaine (hydrochloride)
Lactose
Triamterene
Ibandronate (Sodium
Monohydrate)
Oxymatrine
Rucaparib (Camsylate)
Sodium tauroglycocholate
Mozavaptan
Paliperidone
Frovatriptan (succinate hydrate)
Sodium 4-aminosalicylate
Tigecycline
Carboprost (tromethamine)
Metaxalone
Choline (bitartrate)
Tripelennamine (hydrochloride)
Quinidine
Hydroxyurea
Urea
Megestrol acetate
Talazoparib tosylate
Bromhexine (hydrochloride)
Uridine
Adenosine
Idelalisib
Rapacuronium bromide
Fondaparinux (sodium)
Oxiracetam
Sarpogrelate (hydrochloride)
Mifepristone
Mivacurium (dichloride)
Rapamycin
Cabozantinib (S-malate)
Maprotiline (hydrochloride)
L-Lysine
Demecarium Bromide
Lobeline (hydrochloride)
Testosterone propionate
Agomelatine
DL-Methionine methylsulfonium
Nadolol
Pralidoxime (chloride)
Valbenazine
Trometamol (hydrochloride)
Rifamycin (sodium)
Desloratadine
Lenalidomide (hemihydrate)
DHEA
Fexofenadine (hydrochloride)
Flucloxacillin sodium
Amlodipine (maleate)
Prednisone acetate
Camostat (mesylate)
Ledipasvir (D-tartrate)
Norfloxacin
Dorzolamide (hydrochloride)
Adiphenine (hydrochloride)
Benzocaine
Cefazolin (sodium)
Peretinoin
Penicillin G Procaine
Halofantrine hydrochloride
10-Undecenoic acid
Sumatriptan (succinate)
Chloroquine (phosphate)
Bicyclol
Olmesartan medoxomil
Regadenoson
Uracil
Sulfanilamide
Midodrine (hydrochloride)
Exemestane
Abiraterone acetate
Ritonavir
Lomerizine dihydrochloride
DL-Glutamine
Acrivastine
Tolterodine
Abemaciclib (methanesulfonate)
Ampicillin
Etamivan
β-Carotene
Malotilate
20(S)-Ginsenoside Rg3
Baricitinib
Megestrol
Sitafloxacin (hydrate)
Methacycline (hydrochloride)
Menaquinone-4
Estrone
Phthalylsulfacetamide
Ketotifen (fumarate)
Varenicline
10-Undecenoic acid (zinc salt)
Treprostinil
Tolmetin
Maltitol
Mebrofenin
Ethynodiol diacetate
Apraclonidine (hydrochloride)
Fluconazole
Pirfenidone
Suramin (sodium salt)
Dapagliflozin
Gliquidone
Gluconate (Calcium)
Permethrin
Pipobroman
Tenofovir (Disoproxil)
Levonorgestrel
Propofol
Chlormezanone
Rucaparib
Pyridoxine (hydrochloride)
Pranoprofen
Argipressin
Midecamycin
Cefoxitin
Doxazosin (mesylate)
Abemaciclib
Lamotrigine
Ferulic acid
Clonidine
Omarigliptin
Lidocaine
Solriamfetol
Gallamine Triethiodide
Taurochenodeoxycholic acid
Pretomanid
Duvelisib
Aristolochic acid A
Plerixafor (octahydrochloride)
Dantrolene (sodium
hemiheptahydrate)
Urapidil (hydrochloride)
Protriptyline (hydrochloride)
Siponimod
Bethanechol (chloride)
Cefozopran (hydrochloride)
Ioxilan
Sulfadimethoxine (sodium)
Tolmetin (sodium dihydrate)
Rifampicin
Ribostamycin (sulfate)
Niraparib (tosylate)
Dehydroandrographolide
sn-Glycero-3-phosphocholine
Sunitinib
Nelfinavir
Agomelatine (hydrochloride)
Cephradine
Sulfisomidin
Cephalexin
Ibuprofen
Azelaic acid
Tetrahydrobiopterin
Fostamatinib
Procainamide (hydrochloride)
Alectinib
Nelfinavir (Mesylate)
Irinotecan
Paliperidone palmitate
Trimethobenzamide hydrochloride
Famotidine
5-Acetylsalicylic acid
Tafamidis
Quinapril (hydrochloride)
Estradiol dipropionate
Moexipril (hydrochloride)
D-Pantothenic acid (hemicalcium
salt)
Voxelotor
Vortioxetine
Xylometazoline (hydrochloride)
Bepotastine (besilate)
Methoxsalen
Epinastine (hydrochloride)
Mupirocin
Chlortetracycline (hydrochloride)
Homatropine (methylbromide)
Mepyramine maleate
Fadrozole
Ipratropium (bromide)
Fedratinib
Troxipide
Mequinol
Brimonidine (tartrate)
Oxcarbazepine
Glycerol phenylbutyrate
Levamisole (hydrochloride)
Pyrantel (pamoate)
Triamcinolone hexacetonide
Bretylium (tosylate)
Umeclidinium (bromide)
Vonoprazan
Cimetidine
Ciprofibrate
Cilastatin
Ledipasvir (acetone)
Ethambutol (dihydrochloride)
Nabumetone
L-Glutamic acid monosodium salt
Silibinin
Eletriptan (hydrobromide)
Gluconate (sodium)
Methicillin (sodium salt)
Iopamidol
Piroxicam
Vitamin K1
Deferoxamine (mesylate)
Carbazochrome (sodium
sulfonate)
Dutasteride
Daclatasvir (dihydrochloride)
Flumazenil
Fipexide
Imidapril (hydrochloride)
Micafungin (sodium)
D-Tyrosine
Trospium (chloride)
Abiraterone
Famciclovir
Rilmenidine (hemifumarate)
Norvancomycin (hydrochloride)
Amsacrine (hydrochloride)
Taurodeoxycholic acid (sodium
hydrate)
Eliglustat
Deoxycholic acid
Ranitidine (hydrochloride)
Canagliflozin (hemihydrate)
Diclofenac (Sodium)
Teneligliptin (hydrobromide)
Norgestrel
Bevantolol (hydrochloride)
Pyridostigmine (bromide)
Lansoprazole
Methocarbamol
Nevirapine
Letrozole
Ibuprofen piconol
Chromocarb
Iguratimod
Nicardipine (hydrochloride)
Benznidazol
Crisaborole
Nilutamide
Lamivudine
Bimatoprost
Iotalamic acid
Gallic acid
Enzalutamide
Carvedilol
Ilaprazole
Losartan
Ledipasvir
Aliskiren
Rilpivirine
Pyrantel (tartrate)
Allantoin
Spironolactone
Pregnenolone
Atosiban (acetate)
Venlafaxine (hydrochloride)
Gilteritinib hemifumarate
Almotriptan (malate)
Praziquantel
Desvenlafaxine (succinate
hydrate)
Gestodene
Chlorphenoxamine
Rabeprazole (sodium)
Zaltoprofen
Meticrane
Amoxapine
Methylbenactyzium Bromide
Fosphenytoin (disodium)
Pioglitazone
Fursultiamine
Mepivacaine
Nicergoline
Salbutamol (hemisulfate)
Regorafenib (monohydrate)
Enalaprilat (dihydrate)
Butamben
α-Vitamin E
Clavulanate (lithium)
Zidovudine
Dinoprost (tromethamine salt)
Capecitabine
Bromfenac (sodium)
Tenofovir (Disoproxil Fumarate)
Desogestrel
Diphenmanil (methylsulfate)
Taurine
Citalopram (hydrobromide)
Budesonide
Triprolidine (hydrochloride
monohydrate)
Nedocromil
Ivermectin
Bremelanotide (Acetate)
Cholesterol
Desipramine hydrochloride
Itopride (hydrochloride)
Busulfan
Cephalexin (monohydrate)
Betrixaban
Minoxidil
Ospemifene
Lysipressin
Nitrofurazone
L-Proline
Amodiaquine (dihydrochloride)
Niflumic acid
Roflumilast
Dimetridazole
Lomefloxacin (hydrochloride)
Norethindrone acetate
Acemetacin
Tolvaptan
Carbidopa
Cefamandole (sodium)
Teriflunomide
Nefazodone (hydrochloride)
Artemisinin
Ornipressin
Glucosamine
Oxyphenbutazone
DL-Norepinephrine
Iohexol
Nadifloxacin
Sulfamerazine
Clodronic acid (disodium salt)
Sulfathiazole (sodium)
Guaiacol
Gimeracil
Oxytetracycline
Lacidipine
L-(−)-α-Methyldopa (hydrate)
Anethole (trithione)
Etofenamate
Fructose
Bithionol
Sucrose
Methylcobalamin
Moxalactam (sodium salt)
Acenocoumarol
Metformin
Andrographolide
Suplatast (Tosilate)
Chlorprothixene
Angiotensin II 5-valine
Diatrizoic acid
Anidulafungin
Afoxolaner
Glycopyrrolate
Stearic acid
Piperacillin (sodium)
Parecoxib (Sodium)
Chloroquine
Phenylephrine (hydrochloride)
Cephapirin (sodium)
Tiotropium (Bromide)
L-Isoleucine
Propyphenazone
A series of experiments were designed to assess the effect of cholesterol depletion and statin treatment on the anti-cancer effect of drugs identified in the FDA drug screens. Cancer cells were grown in media containing cholesterol and cholesterol-free media in the presence or absence of simvastatin. The effect of the drug identified in the FDA drug screens on cancer cell growth was measured.
On Day 1, cells were seeded at a density of around 7500 cells/well in a Corning 96-well flat bottom culture plate in complete media containing 10% FBS. On Day 2, the plates were washed with PBS then fed with three different media types, supplemented with increasing concentrations of the validation drug in 3-fold increasing concentration range (e.g., toremifene, from 13 nM to 30 μM. A ‘vehicle-only’ control condition and a ‘no-drug & no-vehicle’ control condition were also used. Medium 1 was ‘complete medium’ containing all essential nutrients, including cholesterol. Medium 2 was cholesterol-free medium. Medium 3 was cholesterol-free medium supplemented with 40 nM of simvastatin.
On Day 5, spent media was discarded, and wells were stained with a crystal violet staining solution, washed and dried. 100 μL of 10% acetic acid was added to each well to release the crystal violet taken up by the cells. Plates were read using a Biotek Powerwave plate reader to determine the absorbance of the crystal violet released as an indicator of cell growth at a wavelength of 595 nm.
Growth curves showing absorbance of crystal violet at 595 nm were plotted from test wells against the logarithmic concentration of the validation drug.
On Day 1, cells were seeded at a density of around 7500 cells/well in a Corning 96-well flat bottom culture plate in complete media containing 10% FBS. On Day 2, the plates were washed with PBS then fed with four different media types, supplemented with increasing concentrations of the validation drug in 3-fold increasing concentration range (e.g. toremifene, from 13 nM to 30 μM. A ‘vehicle-only’ control condition and a ‘no-drug & no-vehicle’ control condition were also used. Medium 1 was ‘complete medium’ containing all essential nutrients, including cholesterol. Medium 2 was cholesterol-free medium. Medium 3 was cholesterol-free medium supplemented with simvastatin 40 nM. Medium 4 was ‘complete medium’ containing all essential nutrients, including cholesterol, supplemented with simvastatin at the IC30 concentration for each cell line.
On Day 5, cell growth was measured by absorbance or fluorescence. For absorbance growth measurements, spent media was discarded, and wells were stained with a crystal violet staining solution, washed, and dried. 100 μL of 10% acetic acid was added to each well to release the crystal violet taken up by the cells. Plates were read using a Biotek Powerwave plate reader to determine the absorbance of the crystal violet released as an indicator of cell growth at a wavelength of 595 nm. For fluorescence growth measurements, 100 μL of a resazurin solution was added to each well and the plate incubated at 37° C. for four hours. Plates were read using a Biotek Powerwave plate reader to determine the fluorescence of reosurfin as an indicator of cell growth at a wavelength of 590 nm.
Growth curves showing absorbance of crystal violet at 595 nm or fluorescene of reosurfin at 590 nm were plotted from test wells against the logarithmic concentration of the validation drug.
The anti-proliferative effect of neticonazole was strongly enhanced by the lack of cholesterol and presence of statin as indicated by the observed ‘left-shift’ in the dose-response curve when cells are grown in the cholesterol-free medium+simvastatin condition compared to the other media conditions in H292, PC9, and PSN1 cells (
A series of in vivo experiments were designed to assess the effect of cholesterol depletion on cancer cell growth. The added role of statin treatment and additional therapeutic agents was studied by dosing mice and assessing tumor growth over a defined time period.
Immunodeficient BALB/c nude mice were subcutaneously injected with human mucoepidermoid lung cancer NCI-H292 cells to initiate tumor development and randomly assigned into one of three experimental groups (n=6 per group): normal cholesterol diet “Normal Chol Diet” containing 0.2% dietary cholesterol without atorvastatin; low cholesterol diet “Low Chol Diet” containing less than 0.05% dietary cholesterol without atorvastatin; or Low Chol Diet treated with atorvastatin at 30 mg/kg by oral gavage. Once the tumor volume reached ˜150 mm3, experimental diets were commenced. Atorvastatin or vehicle treatment was initiated four days after the diet change and continued daily until the tumor volume exceeded 2000 mm3 or the time end-point of three weeks after diet commencement was reached. Throughout the course of the study, tumor volume was measured twice per week.
Immunodeficient M-NSG (NOD-Prkdcscid Il2rgem1Smoc) mice were subcutaneously injected with human colorectal cancer SW480 cells and matrigel to initiate tumor development and randomly assigned into one of four experimental groups (n=6 per group): normal cholesterol diet “Normal Chol Diet” containing 0.2% dietary cholesterol and vehicle, low cholesterol diet “Low Chol Diet” containing less than 0.05% dietary cholesterol and vehicle, Low Chol Diet treated with atorvastatin at 15 mg/kg, or Low Chol Diet treated with toremifene at 2 mg/kg. Once the tumor volume reached ˜150 mm3, experimental diets were commenced. Atorvastatin, vehicle, or toremifene treatment by oral gavage was initiated four days after the diet change and continued daily until the tumor volume exceeded 2000 mm3 or the time end-point of three weeks after treatment initiation was reached. Throughout the course of the study, tumor volume was measured twice per week.
Evaluation of the Anti-Tumour Activity of Combining Simvastatin and Toremifene with a Low Cholesterol Diet in PC9 Bearing C.B-17 SCID Mice.
Immunodeficient C.B-17 SCID (C.B-Igh-1b/IcrTac-Prkdcscid) mice were subcutaneously injected with human lung cancer PC9 cells to initiate tumor development and randomly assigned into one of three experimental groups (n=6 per group): “Low Chol Diet” containing less than 0.05% dietary cholesterol and vehicle, Low Chol Diet and simvastatin 20 mg/kg, and Low Chol Diet and simvastatin 10 mg/kg in combination with toremifene 2 mg/kg. Once the tumor volume reached ˜200 mm3, treatment was commenced with vehicle, simvastatin, and toremifene administered daily by oral gavage. Treatment continued for 28 days or until the tumor volume exceeded 2000 mm3. Throughout the course of the study, tumor volume was measured twice per week.
A patient described herein can be administered any of the following diets to reduce dietary fat, dietary cholesterol intake, or both. An example diet can contain little to no animal or animal-derived products. Such diets are expected to contain little to no cholesterol, e.g., no more than 30 g/day total fat, no more than 10 g/day saturated fat, or no more than 200 mg/day cholesterol. Example diets can also be vegan and contain no animal or animal-derived products. Such diets are expected to be devoid of cholesterol.
Diet 1: 1) Breakfast: oatmeal made with non-dairy milk or skim milk, almond nut butter, chia seeds, flax seeds, and blueberries; 2) Lunch: large salad with many different types of plants, crispy chickpeas as a crouton-alternative, and an olive oil-based salad dressing; 3) Dinner: oven-baked salmon over a bed of ½ cup barley, side of green beans steamed with olive oil, lemon and garlic side salad with olive oil-based dressing; 4) Snack: bowl of edamame beans.
Diet 2: 1) Breakfast: oatmeal made with non-dairy milk or skim milk, almond nut butter, chia seeds, flax seeds, and blueberries; 2) Lunch: large salad with many different types of plants, crispy chickpeas as a crouton-alternative, and an olive oil-based salad dressing; 3) Dinner: oven-baked eggplant over a bed of ½ cup barley, side of green beans steamed with olive oil, lemon and garlic side salad with olive oil-based dressing; 4) Snack: bowl of edamame beans.
Diet 3: 1) Breakfast: cinnamon+banana oatmeal bowl, almond milk, flax seeds, and dried blueberries; 2) Lunch: Indian-spiced vegetables, brussel sprouts, green lentils, butternut squash, cremini mushrooms, and tahini sauce; 3) Dinner: baked gigante bean and artichokes, asparagus, cauliflower, basil; 4) Snacks: frozen dessert, cashew nuts, pistachio nuts, hazelnuts, vanilla bean and maple; and raspberry and fig bites, almond, coconut, dried cranberries.
Diet 4: 1) Breakfast: strawberry-almond smoothie, almond milk, lemon; and chia seed pudding, coconut yogurt, strawberry preserves; 2) Lunch: chopped salad, romaine, avocado, walnuts, blueberries, pickled peppers, chickpeas, vegan green-goddess dressing; 3) Dinner: vegan lasagna, whole wheat noodles, almonds, tomato-garlic sauce, butternut squash, kale; 4) Snacks: honey-roasted mixed nuts; and vegan chocolate chip cookies.
Embodiment 1. A method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an inhibitor of a mevalonate pathway; and b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids.
Embodiment 2. A method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an inhibitor of a mevalonate pathway; and b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol.
Embodiment 3. A method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an HMG-CoA reductase inhibitor; and b) administering to the subject a diet, wherein the diet comprises less than about 40 g/day of lipids.
Embodiment 4. A method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of an HMG-CoA reductase inhibitor; and b) administering to the subject a diet, wherein the diet comprises less than about 200 mg/day of cholesterol.
Embodiment 5. The method of any one of embodiments 1-4, wherein the subject is a human.
Embodiment 6. The method of any one of embodiments 1-5, wherein the condition is a cancer.
Embodiment 7. The method of embodiment 6, wherein the cancer is lung cancer.
Embodiment 8. The method of embodiment 6, wherein the cancer is pancreatic cancer.
Embodiment 9. The method of embodiment 6, wherein the cancer is head and neck cancer.
Embodiment 10. The method of embodiment 6, wherein the cancer is colorectal cancer.
Embodiment 11. The method of embodiment 6, wherein the cancer is renal cancer.
Embodiment 12. The method of embodiment 6, wherein the cancer is breast cancer.
Embodiment 13. The method of embodiment 6, wherein the cancer is a blood cancer.
Embodiment 14. The method of embodiment 6, wherein the cancer is liver cancer.
Embodiment 15. The method of embodiment 6, wherein the cancer is a cholesterol-dependent cancer.
Embodiment 16. The method of any one of embodiments 1, 2, and 5-15, wherein the inhibitor of the mevalonate pathway is a statin.
Embodiment 17. The method of any one of embodiments 3-15, wherein the HMG-CoA reductase inhibitor is a statin.
Embodiment 18. The method of embodiment 16 or 17, wherein the statin is atorvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 19. The method of embodiment 18, wherein the statin is atorvastatin calcium.
Embodiment 20. The method of embodiment 18, wherein the therapeutically effective amount of the atorvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day.
Embodiment 21. The method of embodiment 16 or 17, wherein the statin is fluvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 22. The method of embodiment 21, wherein the statin is fluvastatin sodium.
Embodiment 23. The method of embodiment 21, wherein the therapeutically effective amount of the fluvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day.
Embodiment 24. The method of embodiment 16 or 17, wherein the statin is pravastatin or a pharmaceutically acceptable salt thereof.
Embodiment 25. The method of embodiment 24, wherein the statin is pravastatin sodium.
Embodiment 26. The method of embodiment 24, wherein the therapeutically effective amount of the pravastatin or the pharmaceutically acceptable salt is from about 20 mg/day to about 60 mg/day.
Embodiment 27. The method of embodiment 16 or 17, wherein the statin is rosuvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 28. The method of embodiment 27, wherein the statin is rosuvastatin calcium.
Embodiment 29. The method of embodiment 27, wherein the therapeutically effective amount of the rosuvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day.
Embodiment 30. The method of embodiment 16 or 17, wherein the statin is simvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 31. The method of embodiment 30, wherein the statin is simvastatin sodium.
Embodiment 32. The method of embodiment 30, wherein the therapeutically effective amount of the simvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day.
Embodiment 33. The method of embodiment 16 or 17, wherein the statin is pitavastatin or a pharmaceutically acceptable salt thereof.
Embodiment 34. The method of embodiment 33, wherein the statin is pitavastatin calcium.
Embodiment 35. The method of embodiment 33, wherein the statin is pitavastatin magnesium.
Embodiment 36. The method of embodiment 33, wherein the therapeutically effective amount of the pitavastatin or the pharmaceutically acceptable salt is from about 1.5 mg/day to about 4.5 mg/day.
Embodiment 37. The method of embodiment 16 or 17, wherein the statin is lovastatin or a pharmaceutically acceptable salt thereof.
Embodiment 38. The method of embodiment 37, wherein the statin is lovastatin sodium.
Embodiment 39. The method of embodiment 37, wherein the therapeutically effective amount of the lovastatin or the pharmaceutically acceptable salt is from about 1 mg/day to about 5 mg/day.
Embodiment 40. The method of any one of embodiments 1-39, further comprising administering a therapeutically-effective amount of a cholesterol absorption inhibitor.
Embodiment 41. The method of embodiment 40, wherein the cholesterol absorption inhibitor is ezetimibe.
Embodiment 42. The method of embodiment 40, wherein the therapeutically effective amount of the cholesterol absorption inhibitor is from about 5 mg/day to about 20 mg/day.
Embodiment 43. The method of any one of embodiments 16-42, wherein the administering the statin is oral.
Embodiment 44. The method of any one of embodiments 1-43, further comprising administering a cancer therapy.
Embodiment 45. The method of embodiment 44, wherein the cancer therapy is a chemotherapeutic agent.
Embodiment 46. The method of embodiment 44, wherein the cancer therapy is radiotherapy.
Embodiment 47. The method of embodiment 44, wherein the cancer therapy is an immunotherapy.
Embodiment 48. The method of any one of embodiments 1-47, wherein the diet is a vegan diet.
Embodiment 49. The method of any one of embodiments 1-47, wherein the diet is a vegetarian diet.
Embodiment 50. The method of any one of embodiments 1-47, wherein the diet is plant-based.
Embodiment 51. The method of any one of embodiments 1-47, wherein the diet is substantially devoid of animal fats.
Embodiment 52. The method of any one of embodiments 1-51, wherein the subject consumes a 2000 kcal/day diet.
Embodiment 53. A method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of a cholesterol lowering agent; and b) administering to the subject a diet, wherein the diet is formulated to reduce a level of fat in the subject.
Embodiment 54. A method of treating a condition in a subject in need thereof, the method comprising: a) administering to the subject a therapeutically effective amount of a cholesterol lowering agent; and b) administering to the subject a diet, wherein the diet is formulated to reduce a level of cholesterol in the subject.
Embodiment 55. The method of embodiment 53 or 54, wherein the subject is a human.
Embodiment 56. The method of any one of embodiments 53-55, wherein the condition is a cancer.
Embodiment 57. The method of embodiment 56, wherein the cancer is lung cancer.
Embodiment 58. The method of embodiment 56, wherein the cancer is pancreatic cancer.
Embodiment 59. The method of embodiment 56, wherein the cancer is head and neck cancer.
Embodiment 60. The method of embodiment 56, wherein the cancer is colorectal cancer.
Embodiment 61. The method of embodiment 56, wherein the cancer is renal cancer.
Embodiment 62. The method of embodiment 56, wherein the cancer is breast cancer.
Embodiment 63. The method of embodiment 56, wherein the cancer is a blood cancer. Embodiment 64. The method of embodiment 56, wherein the cancer is liver cancer.
Embodiment 65. Embodiment 3. The method of embodiment 56, wherein the cancer is a cholesterol-dependent cancer.
Embodiment 66. The method of any one of embodiments 53-65, wherein the cholesterol lowering agent is an inhibitor of the mevalonate pathway.
Embodiment 67. The method of embodiment 66, wherein the inhibitor of the mevalonate pathway inhibits HMG-CoA reductase.
Embodiment 68. The method of embodiment 67, wherein the HMG-CoA reductase inhibitor is a statin.
Embodiment 69. The method of embodiment 68, wherein the statin is atorvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 70. The method of embodiment 69, wherein the statin is atorvastatin calcium.
Embodiment 71. The method of embodiment 69, wherein the therapeutically effective amount of the atorvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day.
Embodiment 72. The method of embodiment 68, wherein the statin is fluvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 73. The method of embodiment 72, wherein the statin is fluvastatin sodium. Embodiment 74. The method of embodiment 72, wherein the therapeutically effective amount of the fluvastatin or the pharmaceutically acceptable salt is from about 10 mg/day to about 80 mg/day.
Embodiment 75. The method of embodiment 68, wherein the statin is pravastatin or a pharmaceutically acceptable salt thereof.
Embodiment 76. The method of embodiment 75, wherein the statin is pravastatin sodium.
Embodiment 77. The method of embodiment 75, wherein the therapeutically effective amount of the pravastatin or the pharmaceutically acceptable salt is from about 20 mg/day to about 60 mg/day.
Embodiment 78. The method of embodiment 68, wherein the statin is rosuvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 79. The method of embodiment 78, wherein the statin is rosuvastatin calcium.
Embodiment 80. The method of embodiment 78, wherein the therapeutically effective amount of the rosuvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day.
Embodiment 81. The method of embodiment 68, wherein the statin is simvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 82. The method of embodiment 81, wherein the statin is simvastatin sodium.
Embodiment 83. The method of embodiment 81, wherein the therapeutically effective amount of the simvastatin or the pharmaceutically acceptable salt is from about 5 mg/day to about 40 mg/day.
Embodiment 84. The method of embodiment 68, wherein the statin is pitavastatin or a pharmaceutically acceptable salt thereof.
Embodiment 85. The method of embodiment 84, wherein the statin is pitavastatin calcium.
Embodiment 86. The method of embodiment 84, wherein the statin is pitavastatin magnesium.
Embodiment 87. The method of embodiment 84, wherein the therapeutically effective amount of the pitavastatin or the pharmaceutically acceptable salt is from about 1.5 mg/day to about 4.5 mg/day.
Embodiment 88. The method of embodiment 68, wherein the statin is lovastatin or a pharmaceutically acceptable salt thereof.
Embodiment 89. The method of embodiment 88, wherein the statin is lovastatin sodium.
Embodiment 90. The method of embodiment 88, wherein the therapeutically effective amount of the lovastatin or the pharmaceutically acceptable salt is from about 1 mg/day to about 5 mg/day.
Embodiment 91. The method of any one of embodiments 68-90, wherein the administering the statin is oral.
Embodiment 92. The method of any one of embodiments 53-65, wherein the cholesterol lowering agent is a cholesteryl ester transfer protein (CETP) inhibitor.
Embodiment 93. The method of any one of embodiments 53-65, wherein the cholesterol lowering agent is a lecithin-cholesterol acyltransferase (LCAT) inhibitor.
Embodiment 94. The method of any one of embodiments 53-65, wherein the cholesterol lowering agent is a bile acid sequestrant.
Embodiment 95. The method of any one of embodiments 53-65, wherein the cholesterol lowering agent is a cholesterol absorption inhibitor.
Embodiment 96. The method of any one of embodiments 91-95, wherein the administering the cholesterol lowering agent is oral.
Embodiment 97. The method of any one of embodiments 53-96, further comprising administering to the subject a cancer therapy.
Embodiment 98. The method of embodiment 97, wherein the cancer therapy is a chemotherapeutic agent.
Embodiment 99. The method of embodiment 97, wherein the cancer therapy is radiotherapy.
Embodiment 100. The method of embodiment 97, wherein the cancer therapy is an immunotherapy.
Embodiment 101. The method of any one of embodiments 53-100, wherein the diet is a vegan diet.
Embodiment 102. The method of any one of embodiments 53-100, wherein the diet is a vegetarian diet.
Embodiment 103. The method of any one of embodiments 53-100, wherein the diet is plant-based.
Embodiment 104. The method of any one of embodiments 53-100, wherein the diet is devoid of animal fats.
Embodiment 105. The method of any one of embodiments 53-104, wherein the diet is formulated to reduce a blood level of fat in the subject.
Embodiment 106. The method of any one of embodiments 53-105, wherein the diet is formulated to reduce a blood level of cholesterol in the subject.
Embodiment 107. The method of any one of embodiments 53-106, wherein the diet reduces a level of fat in the subject.
Embodiment 108. The method of any one of embodiments 53-107, wherein the diet reduces a level of cholesterol in the subject.
Embodiment 109. The method of any one of embodiments 53-108, wherein the diet reduces a blood level of fat in the subject.
Embodiment 110. The method of any one of embodiments 53-109, wherein the diet reduces a blood level of cholesterol in the subject.
Embodiment 111. The method of any one of embodiments 53-110, wherein the diet comprises less than 70% of a daily recommended cholesterol intake value.
Embodiment 112. The method of embodiment 111, wherein the daily recommended cholesterol intake value is according to a dietary guideline published by the United States Departments of Agriculture and Health and Human Services.
Embodiment 113. The method of embodiment 111, wherein a daily recommended cholesterol intake value is 300 mg/day.
Embodiment 114. The method of any one of embodiments 53-113, wherein the diet comprises less than 1% of the subject's average daily cholesterol intake prior to administering the diet.
Embodiment 115. The method of any one of embodiments 53-114, wherein the diet does not comprise cholesterol.
Embodiment 116. The method of any one of embodiments 53-115, wherein the diet comprises less than 50% of a daily recommended fat intake value.
Embodiment 117. The method of claim 116, wherein a daily recommended fat intake value is according to a dietary guideline published by the United States Departments of Agriculture and Health and Human Services.
Embodiment 118. The method of embodiment 116, wherein a daily recommended fat intake value is about 78 g/day.
Embodiment 119. The method of any one of embodiments 53-118, wherein the diet comprises less than 1% of the subject's average daily fat intake prior to administering the diet.
Embodiment 120. The method of any one of embodiments 53-119, wherein the diet does not comprise fat.
Embodiment 121. The method of any one of embodiments 53-120, wherein the diet comprises less than about 200 mg/day of cholesterol.
Embodiment 122. The method of any one of embodiments 53-121, wherein the diet comprises less than about 40 g/day of lipids.
Embodiment 123. The method of any one of embodiments 53-122, wherein the diet comprises less than 15% of total kcal/day in saturated fats.
Embodiment 124. The method of any one of embodiments 53-123, wherein the diet comprises less than 5% of total kcal/day in trans fats.
Embodiment 125. The method of any one of embodiments 53-124, wherein the diet comprises less than 15% of total kcal/day in polyunsaturated fats.
Embodiment 126. The method of any one of embodiments 53-125, wherein the diet comprises less than 5% of total kcal/day in monounsaturated fats.
Embodiment 127. The method of any one of embodiments 53-126, wherein the diet comprises less than a daily recommended intake value of saturated fat.
Embodiment 128. The method of embodiment 127, wherein a daily recommended saturated fat intake value is 20 g/day.
Embodiment 129. The method of any one of embodiments 53-128, wherein the subject consumes a 2000 kcal/day diet.
Embodiment 130. A composition comprising: a) a cholesterol lowering agent; and b) a dietary product, wherein the dietary product is formulated to reduce a level of fat, a level of cholesterol, or both in a subject.
Embodiment 131. The composition of embodiment 130, wherein the subject is a human.
Embodiment 132. The composition of embodiment 130 or 131, wherein the cholesterol lowering agent is an inhibitor of the mevalonate pathway.
Embodiment 133. The composition of embodiment 132, wherein the inhibitor of the mevalonate pathway inhibits HMG-CoA reductase.
Embodiment 134. The composition of embodiment 133, wherein the HMG-CoA reductase inhibitor is a statin.
Embodiment 135. The composition of embodiment 134, wherein the statin is atorvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 136. The composition of embodiment 134, wherein the statin is fluvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 137. The composition of embodiment 134, wherein the statin is pravastatin or a pharmaceutically acceptable salt thereof.
Embodiment 138. The composition of embodiment 134, wherein the statin is rosuvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 139. The composition of embodiment 134, wherein the statin is simvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 140. The composition of embodiment 134, wherein the statin is pitavastatin or a pharmaceutically acceptable salt thereof.
Embodiment 141. The composition of embodiment 134, wherein the statin is lovastatin or a pharmaceutically acceptable salt thereof.
Embodiment 142. The composition of embodiment 130 or 131, wherein the cholesterol lowering agent is a cholesteryl ester transfer protein (CETP) inhibitor.
Embodiment 143. The composition of embodiment 130 or 131, wherein the cholesterol lowering agent is a lecithin-cholesterol acyltransferase (LCAT) inhibitor.
Embodiment 144. The composition of embodiment 130 or 131, wherein the cholesterol lowering agent is a bile acid sequestrant.
Embodiment 145. The composition of embodiment 130 or 131, wherein the cholesterol lowering agent is a cholesterol absorption inhibitor.
Embodiment 146. The composition of any one of embodiments 130-145, wherein the cholesterol lowering agent is formulated for oral administration.
Embodiment 147. The composition of any one of embodiments 130-146, wherein the dietary product is formulated for oral administration.
Embodiment 148. The composition of any one of embodiments 130-147, wherein the dietary product is formulated as a solid.
Embodiment 149. The composition of any one of embodiments 130-147, wherein the dietary product is formulated as a liquid.
Embodiment 150. The composition of any one of embodiments 130-149, wherein the dietary product is a vegan.
Embodiment 151. The composition of any one of embodiments 130-149, wherein the dietary product is a vegetarian.
Embodiment 152. The composition of any one of embodiments 130-149, wherein the dietary product is plant-based.
Embodiment 153. The composition of any one of embodiments 130-149, wherein the dietary product is devoid of animal fats.
Embodiment 154. The composition of any one of embodiments 130-153, wherein the dietary product is formulated to reduce a blood level of fat in the subject.
Embodiment 155. The composition of any one of embodiments 130-154, wherein the dietary product is formulated to reduce a blood level of cholesterol in the subject.
Embodiment 156. The composition of any one of embodiments 130-155, wherein the dietary product reduces a level of fat in the subject.
Embodiment 157. The composition of any one of embodiments 130-156, wherein the dietary product reduces a level of cholesterol in the subject.
Embodiment 158. The composition of any one of embodiments 130-157, wherein the dietary product reduces a blood level of fat in the subject.
Embodiment 159. The composition of any one of embodiments 130-158, wherein the dietary product reduces a blood level of cholesterol in the subject.
Embodiment 160. The composition of any one of embodiments 130-159, wherein the dietary product comprises less than 70% of a daily recommended cholesterol intake value.
Embodiment 161. The composition of embodiment 160, wherein the daily recommended cholesterol intake value is according to a dietary guideline published by the United States Departments of Agriculture and Health and Human Services.
Embodiment 162. The composition of embodiment 160, wherein a daily recommended cholesterol intake value is 300 mg/day.
Embodiment 163. The composition of any one of embodiments 130-162, wherein the dietary product comprises less than 1% of the subject's average daily cholesterol intake.
Embodiment 164. The composition of any one of embodiments 130-163, wherein the dietary product does not comprise cholesterol.
Embodiment 165. The composition of any one of embodiments 130-164, wherein the dietary product comprises less than 50% of a daily recommended fat intake value.
Embodiment 166. The composition of claim 165, wherein a daily recommended fat intake value is according to a dietary productary guideline published by the United States Departments of Agriculture and Health and Human Services.
Embodiment 167. The composition of embodiment 165, wherein a daily recommended fat intake value is about 78 g/day.
Embodiment 168. The composition of any one of embodiments 130-167, wherein the dietary product comprises less than 1% of the subject's average daily fat intake.
Embodiment 169. The composition of any one of embodiments 130-168, wherein the dietary product does not comprise fat.
Embodiment 170. The composition of any one of embodiments 130-169, wherein the dietary product comprises less than about 200 mg/day of cholesterol.
Embodiment 171. The composition of any one of embodiments 130-170, wherein the dietary product comprises less than about 40 g/day of lipids.
Embodiment 172. The composition of any one of embodiments 130-171, wherein the dietary product comprises less than 15% of total kcal/day in saturated fats.
Embodiment 173. The composition of any one of embodiments 130-172, wherein the dietary product comprises less than 5% of total kcal/day in trans fats.
Embodiment 174. The composition of any one of embodiments 130-173, wherein the dietary product comprises less than 15% of total kcal/day in polyunsaturated fats.
Embodiment 175. The composition of any one of embodiments 130-174, wherein the dietary product comprises less than 5% of total kcal/day in monounsaturated fats.
Embodiment 176. The composition of any one of embodiments 130-175, wherein the dietary product comprises less than a daily recommended intake value of saturated fat.
Embodiment 177. The composition of embodiment 176, wherein a daily recommended saturated fat intake value is 20 g/day.
Embodiment 178. A kit comprising: a) an effective amount of a cholesterol lowering agent; b) an effective amount of a dietary product, wherein the dietary product is formulated to reduce a level of fat, a level of cholesterol, or both in a subject; and optionally, c) written instructions for use of the kit.
Embodiment 179. The kit of embodiment 178, wherein the subject is a human.
Embodiment 180. The kit of embodiment 178 or 179, wherein the cholesterol lowering agent is an inhibitor of the mevalonate pathway.
Embodiment 181. The kit of embodiment 180, wherein the inhibitor of the mevalonate pathway inhibits HMG-CoA reductase.
Embodiment 182. The kit of embodiment 181, wherein the HMG-CoA reductase inhibitor is a statin.
Embodiment 183. The kit of embodiment 182, wherein the statin is atorvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 184. The kit of embodiment 182, wherein the statin is fluvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 185. The kit of embodiment 182, wherein the statin is pravastatin or a pharmaceutically acceptable salt thereof.
Embodiment 186. The kit of embodiment 182, wherein the statin is rosuvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 187. The kit of embodiment 182, wherein the statin is simvastatin or a pharmaceutically acceptable salt thereof.
Embodiment 188. The kit of embodiment 182, wherein the statin is pitavastatin or a pharmaceutically acceptable salt thereof.
Embodiment 189. The kit of embodiment 182, wherein the statin is lovastatin or a pharmaceutically acceptable salt thereof.
Embodiment 190. The kit of embodiment 178 or 179, wherein the cholesterol lowering agent is a cholesteryl ester transfer protein (CETP) inhibitor.
Embodiment 191. The kit of embodiment 178 or 179, wherein the cholesterol lowering agent is a lecithin-cholesterol acyltransferase (LCAT) inhibitor.
Embodiment 192. The kit of embodiment 178 or 179, wherein the cholesterol lowering agent is a bile acid sequestrant.
Embodiment 193. The kit of embodiment 178 or 179, wherein the cholesterol lowering agent is a cholesterol absorption inhibitor.
Embodiment 194. The kit of any one of embodiments 178-193, wherein the cholesterol lowering agent is formulated for oral administration.
Embodiment 195. The kit of any one of embodiments 178-194, wherein the dietary product is formulated for oral administration.
Embodiment 196. The kit of any one of embodiments 178-195, wherein the dietary product is formulated as a solid.
Embodiment 197. The kit of any one of embodiments 178-195, wherein the dietary product is formulated as a liquid.
Embodiment 198. The kit of any one of embodiments 178-197, wherein the dietary product is a vegan.
Embodiment 199. The kit of any one of embodiments 178-197, wherein the dietary product is a vegetarian.
Embodiment 200. The kit of any one of embodiments 178-197, wherein the dietary product is plant-based.
Embodiment 201. The kit of any one of embodiments 178-197, wherein the dietary product is devoid of animal fats.
Embodiment 202. The kit of any one of embodiments 178-201, wherein the dietary product is formulated to reduce a blood level of fat in the subject.
Embodiment 203. The kit of any one of embodiments 178-202, wherein the dietary product is formulated to reduce a blood level of cholesterol in the subject.
Embodiment 204. The kit of any one of embodiments 178-203, wherein the dietary product reduces a level of fat in the subject.
Embodiment 205. The kit of any one of embodiments 178-204, wherein the dietary product reduces a level of cholesterol in the subject.
Embodiment 206. The kit of any one of embodiments 178-205, wherein the dietary product reduces a blood level of fat in the subject.
Embodiment 207. The kit of any one of embodiments 178-206, wherein the dietary product reduces a blood level of cholesterol in the subject.
Embodiment 208. The kit of any one of embodiments 178-207, wherein the dietary product comprises less than 70% of a daily recommended cholesterol intake value.
Embodiment 209. The kit of embodiment 208, wherein the daily recommended cholesterol intake value is according to a dietary guideline published by the United States Departments of Agriculture and Health and Human Services.
Embodiment 210. The kit of embodiment 280, wherein a daily recommended cholesterol intake value is 300 mg/day.
Embodiment 211. The kit of any one of embodiments 178-210, wherein the dietary product comprises less than 1% of the subject's average daily cholesterol intake.
Embodiment 212. The kit of any one of embodiments 178-211, wherein the dietary product does not comprise cholesterol.
Embodiment 213. The kit of any one of embodiments 178-212, wherein the dietary product comprises less than 50% of a daily recommended fat intake value.
Embodiment 214. The kit of claim 213, wherein a daily recommended fat intake value is according to a dietary productary guideline published by the United States Departments of Agriculture and Health and Human Services.
Embodiment 215. The kit of embodiment 213, wherein a daily recommended fat intake value is about 78 g/day.
Embodiment 216. The kit of any one of embodiments 178-215, wherein the dietary product comprises less than 1% of the subject's average daily fat intake.
Embodiment 217. The kit of any one of embodiments 178-216, wherein the dietary product does not comprise fat.
Embodiment 218. The kit of any one of embodiments 178-217, wherein the dietary product comprises less than about 200 mg/day of cholesterol.
Embodiment 219. The kit of any one of embodiments 178-218, wherein the dietary product comprises less than about 40 g/day of lipids.
Embodiment 220. The kit of any one of embodiments 178-219, wherein the dietary product comprises less than 15% of total kcal/day in saturated fats.
Embodiment 221. The kit of any one of embodiments 178-220, wherein the dietary product comprises less than 5% of total kcal/day in trans fats.
Embodiment 222. The kit of any one of embodiments 178-221, wherein the dietary product comprises less than 15% of total kcal/day in polyunsaturated fats.
Embodiment 223. The kit of any one of embodiments 178-222, wherein the dietary product comprises less than 5% of total kcal/day in monounsaturated fats.
Embodiment 224. The kit of any one of embodiments 178-223, wherein the dietary product comprises less than a daily recommended intake value of saturated fat.
Embodiment 225. The kit of embodiment 224, wherein a daily recommended saturated fat intake value is 20 g/day.
This application is a continuation of International Application No. PCT/US2022/081307, filed Dec. 9, 2022, which claims the benefit of U.S. Provisional Application No. 63/288,062, filed on Dec. 10, 2021, which is incorporated herein by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 63288062 | Dec 2021 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2022/081307 | Dec 2022 | WO |
| Child | 18676700 | US |